WO1995006659A1 - Amine-derivatized nucleosides and oligonucleosides - Google Patents

Amine-derivatized nucleosides and oligonucleosides Download PDF

Info

Publication number
WO1995006659A1
WO1995006659A1 PCT/US1994/010131 US9410131W WO9506659A1 WO 1995006659 A1 WO1995006659 A1 WO 1995006659A1 US 9410131 W US9410131 W US 9410131W WO 9506659 A1 WO9506659 A1 WO 9506659A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
mmol
uridine
dimethoxytrityl
oligomer
Prior art date
Application number
PCT/US1994/010131
Other languages
French (fr)
Inventor
Phillip Dan Cook
Muthiah Manoharan
Charles J. Guinosso
Original Assignee
Isis Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/117,363 external-priority patent/US6783931B1/en
Application filed by Isis Pharmaceuticals, Inc. filed Critical Isis Pharmaceuticals, Inc.
Priority to EP94928048A priority Critical patent/EP0728139B1/en
Priority to CA002170869A priority patent/CA2170869C/en
Priority to JP50832695A priority patent/JP3484197B2/en
Priority to DE69433036T priority patent/DE69433036T2/en
Priority to AU77233/94A priority patent/AU679566B2/en
Priority to AT94928048T priority patent/ATE247128T1/en
Priority to US08/602,862 priority patent/US7037646B1/en
Publication of WO1995006659A1 publication Critical patent/WO1995006659A1/en
Priority to US09/435,806 priority patent/US6653458B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1133—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against herpetoviridae, e.g. HSV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3527—Other alkyl chain

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Nucleosides and oligonucleosides functionalized to include alkylamino functionality, and derivatives thereof. In certain embodiments, the compounds of the invention further include steroids, reporter molecules, reporter enzymes, lipophilic molecules, peptides or proteins attached to the nucleosides through the alkylamino group.

Description

AMINE-DERIVATIZED NUCLEOSIDES AND OLIGONUCLEOSIDES
CROSS REFERENCE TO RELATED APPLICATIONS
This application is a continuation-in-part of United States Application Serial No. 08/117,363, filed September 3, 1994 and of Application PCT/US91/00243, filed January 11, 1991 (now United States Application Serial No. 07/854,634, filed July 1, 1992). Application Serial No. 08/117,363, in turn, is a continuation-in-part of Application PCT/US92/09196, filed October 23, 1992, which is a continuation-in-part of United States Application Serial No. 07/782,374, filed October 24, 1991. Application Serial No. 07/782,374 and Application PCT/US91/00243 are both continuations-in-part of United States Application Serial Nos. 07/463,358, filed January 11, 1990, and 07/566,977, filed August 13, 1990. The entire disclosures of each of these applications, which are assigned to the assignee of this application, are incorporated herein by reference.
FIELD OF THE INVENTION
This application is directed to nucleosides, oligonucleotides and oligonucleosides functionalized to include alkylamino functionality, and derivatives thereof. In certain embodiments, the compounds of the invention further include steroids, reporter molecules, reporter enzymes, lipophilic molecules, peptides or proteins attached to the nucleosides through the alkylamino group. BACKGROUND OF THE INVENTION
Messenger RNA (mRNA) directs protein synthesis. Antisense methodology is the complementary hybridization of relatively short oligonucleotides to mRNA or DNA such that the normal, essential functions of these intracellular nucleic acids are disrupted. Hybridization is the sequence-specific hydrogen bonding via Watson-Crick base pairs of oligonucleo- tides to RNA or single-stranded DNA. Such base pairs are said to be complementary to one another.
The naturally occurring events that provide the disruption of the nucleic acid function, discussed by Cohen in Oligonucleotides : Antisense Inhibi tors of Gene Expression, CRC Press, Inc., Boca Raton, Florida (1989) are thought to be of two types. The first, hybridization arrest, denotes the terminating event in which the oligonucleotide inhibitor binds to the target nucleic acid and thus prevents, by simple steric hindrance, the binding of essential proteins, most often ribosomes, to the nucleic acid. Methyl phosphonate oligonucleotides (Miller, et al., Anti-Cancer Drug Design 1987, 2, 117) and α-anomer oligonucleotides are the two most extensively studied antisense agents which are thought to disrupt nucleic acid function by hybridization arrest.
The second type of terminating event for antisense oligonucleotides involves the enzymatic cleavage of the targeted RNA by intracellular RNase H. A 2' -deoxyribofuranosyl oligonucleotide or oligonucleotide analog hybridizes with the targeted RNA and this duplex activates the RNase H enzyme to cleave the RNA strand, thus destroying the normal function of the RNA. Phosphorothioate oligonucleotides are the most prominent example of an antisense agent that operates by this type of antisense terminating event.
Considerable research is being directed to the application of oligonucleotides and oligonucleotide analogs as antisense agents for diagnostics, research reagents and potential therapeutic purposes. At least for therapeutic purposes, the antisense oligonucleotides and oligonucleotide analogs must be transported across cell membranes or taken up by cells to express activity. One method for increasing membrane or cellular transport is by the attachment of a pendant lipophilic group. Ramirez, et al . , J. Am . Chem. Soc . 1982, 104 , 5483, introduced the phospholipid group 5'-O-(1,2-di-O-myristoyl-sn-glycero-3-phosphoryl) into the dimer TpT independently at the 3' and 5' positions. Subsequently Shea, et al . , Nuc. Acids Res . 1990, 18, 3777, disclosed oligonucleotides having a 1,2- di-O-hexyldecyl-rac-glycerol group linked to a 5' -phosphate on the 5'-terminus of the oligonucleotide. Certain of the Shea, et. al . authors also disclosed these and other compounds in patent application PCT/US90/01002. A further glucosyl phospholipid was disclosed by Guerra, et al . , Tetrahedron Letters 1987, 28, 3581.
In other work, a cholesteryl group was attached to the inter-nucleotide linkage between the first and second nucleotides (from the 3' terminus) of an oligonucleotide. This work is disclosed in United States patent 4,958,013 and further by Letsinger, et al . , Proc. Natl . Acad. Sci . USA 1989, 86, 6553. The aromatic intercalating agent anthraquinone was attached to the 2' position of a sugar fragment of an oligonucleotide as reported by Yamana, et al . , Bioconjugate Chem . 1990, 1 , 319. The same researchers placed pyrene-1-methyl at the 2' position of a sugar (Yamana et. al . , Tetrahedron Lett . 1991, 32, 6347).
Lemairte, et al . , Proc . Natl . Acad. Sci . USA 1986, 84 , 648; and Leonetti, et al ., Bioconjugate Chem. 1990, 1 , 149. The 3' terminus of the oligonucleotides each include a 3'- terminal ribose sugar moiety. The poly (L-lysine) was linked to the oligonucleotide via periodate oxidation of this terminal ribose followed by reduction and coupling through a N- morpholine ring. Oligonucleotide-poly (L-lysine) conjugates are described in European Patent application 87109348.0. In this instance the lysine residue was coupled to a 5' or 3' phosphate of the 5' or 3' terminal nucleotide of the oligonucleotide. A disulfide linkage has also been utilized at the 3' terminus of an oligonucleotide to link a peptide to the oligonucleotide as is described by Corey, et al . , Science 1987, 238, 1401; Zuckermann, et al . , J. Am. Chem. Soc . 1988, 110, 1614; and Corey, et al . , J. Am. Chem. Soc . 1989, 111 , 8524. Nelson, et al . , Nuc. Acids Res . 1989, 17, 7187 describe a linking reagent for attaching biotin to the 3 '-terminus of an oligonucleotide. This reagent, N-Fmoc-O-DMT-3-amino-l, 2- propanediol is now commercially available from Clontech Laboratories (Palo Alto, CA) under the name 3'-Amine on. It is also commercially available under the name 3'-Amino-Modifier reagent from Glen Research Corporation (Sterling, VA). This reagent was also utilized to link a peptide to an oligonucleotide as reported by Judy, et al., Tetrahedron Letters 1991, 32, 879. A similar commercial reagent (actually, a series of such linkers having various lengths of polymethylene connectors) for linking to the 5'-terminus of an oligonucleotide is 5'-Amino-Modifier C6. These reagents are available from Glen Research Corporation (Sterling, VA). These compounds or similar ones were utilized by Krieg, et al . , Antisense Research and Development 1991, 1, 161 to link fluorescein to the 5'-terminus of an oligonucleotide. Other compounds of interest have also been linked to the 3' -terminus of an oligonucleotide. Asseline, et al . , Proc. Natl . Acad. Sci . USA 1984 , 81 , 3297 described linking acridine on the 3 ' -terminal phosphate group of an poly (Tp) oligonucleotide via a polymethylene linkage. Haralambidis, et al . , Tetrahedron Letters 1987, 28, 5199 report building a peptide on a solid state support and then linking an oligonucleotide to that peptide via the 3' hydroxyl group of the 3' terminal nucleotide of the oligonucleotide. Chollet, Nucleosides & Nucleotides 1990, 9, 957 attached an Aminolink 2 (Applied Biosystems, Foster City, CA) to the 5' terminal phosphate of an oligonucleotide. They then used the bifunctional linking group SMPB (Pierce Chemical Co., Rockford, II) to link an interleukin protein to the oligonucleotide.
An EDTA iron complex has been linked to the 5 position of a pyrimidine nucleoside as reported by Dreyer, et al . , Proc . Natl . Acad. Sci . USA 1985, 82, 968. Fluorescein has been linked to an oligonucleotide in the same manner as reported by Haralambidis, et al . , Nucleic Acid Research 1987, 15, 4857 and biotin in the same manner as described in PCT application PCT/US/02198. Fluorescein, biotin and pyrene were also linked in the same manner as reported by Telser, et al . , J. Am . Chem . Soc . 1989, 111 , 6966. A commercial reagent, Amino-Modifier-dT, from Glen Research Corporation (Sterling, VA) can be utilized to introduce pyrimidine nucleotides bearing similar linking groups into oligonucleotides.
Cholic acid linked to EDTA for use in radioscintigraphic imaging studies was reported by Betebenner, et.al.,
Bioconjugate Chem. 1991, 2, 117; however, it is not known to link cholic acid to nucleosides, nucleotides or oligonucleotides.
OBJECTS OF THE INVENTION
It is one object of this invention to provide nucleosides, oligonucleotides and oligonucleosides that include alkylamino chemical functionality.
It is a further object of the invention to provide compounds having improved transfer across cellular membranes .
It is another object to provide compounds that include intercalators, nucleic acid cleaving agents, cell surface phospholipids, and/or diagnostic agents.
It is yet another object to provide improvements in research and diagnostic methods and materials for assaying bodily states in animals, especially disease states.
It is an additional object of this invention to provide therapeutic and research materials having improved transfer and uptake properties for the treatment of diseases through modulation of the activity of DNA or RNA. BRIEF DESCRIPTION OF THE INVENTION
These and other objects are satisfied by the present invention, which provides compounds containing alkylamino chemical functionality. In one aspect, the invention provides nucleosides having base portions and ribofuranosyl sugar portions. Such nucleosides bear at a 2'-O-position, a 3'-O-position, or a 5'-O-position a substituent having formula:
-RA-N(R1a) (R1b) where:
RA is alkyl having from 1 to about 10 carbon atoms or RA is (CH2-CH2-Q-)x;
R1a and R1b, independently, are H, R2, or an amine protecting group, have formula C(X)-R2, C(X)-RA-R2, C(X)-Q-RA-R2,
C(X)-Q-R2, or, together, complete a cycloalkyl or cycloaryl moiety having two to six carbon atoms and one or two nitrogen atoms ;
R2 includes a steroid molecule, a reporter molecule, a lipophilic molecule, a reporter enzyme, a peptide, a protein, or has formula -Q-(CH2CH2-Q-)x-R3;
X is O or S;
each Q is, independently, is NH, O, or S;
x is 1 to about 200;
R3 is H, RA, C(O)OH, C(O)ORA, C(O)R4, RA-N3, RA-NH2, or RA-SH; and
R4 is Cl, Br, I, SO2Rs or has structure:
Figure imgf000008_0001
;
m is 2 to 7; and
R5 is alkyl having 1 to about 10 carbon atoms.
In another aspect, the invention provides oligonucleotides and oligonucleosides comprising a plurality of linked nucleosides, wherein each nucleoside includes a ribofuranosyl sugar portion and a base portion and at least one (preferably more than one) of the nucleosides bears at a 2'-O-position, a
3' -O-position, or a 5'-O-position a substituent having formula -RA-N(R1a)(R1b).
In another aspect the invention provides methods for preparing oligonucleotides and oligonucleosides comprising the steps of contacting nucleosides according to the invention for a time and under reaction conditions effective to form a covalent bond therebetween. In preferred embodiments, at least one of the nucleosides bears a phosphoramidate group at its 2'-O-position or at its 3'-O-position.
In other embodiments, compounds according to the invention are prepared by contacting a nucleoside, oligonucleotide or oligonucleoside with derivatizing reagents. For example, a nucleoside, oligonucleotide or oligonucleoside bearing a 2'-hydroxy group, a 3'-hydroxy group, or a 5'-hydroxy group under basic conditions with a compound having formula L1-RA-N(R1a)(R1b) wherein L1 is a leaving group such as a halogen and at least one of R1a and R1b is an amine protecting group.
The present invention also provides methods for inhibiting the expression of particular genes in the cells of an organism, comprising administering to said organism a compound according to the invention. Also provided are methods for inhibiting transcription and/or replication of particular genes or for inducing degradation of particular regions of double stranded DNA in cells of an organism by administering to said organism a compound of the invention. Further provided are methods for killing cells or virus by contacting said cells or virus with a compound of the invention. The compound can be included in a composition that further includes an inert carrier for the compound.
DETAILED DESCRIPTION OF THE INVENTION
This invention provides nucleosides, oligonucleotides and oligonucleosides containing alkylamino chemical functionality. The nucleoside subunits can be "natural" or "synthetic" moieties. Each nucleoside is formed from a naturally occurring or synthetic base and a naturally occurring or synthetic pentofuranosyl sugar group.
The term "oligonucleotide" refers to a polynucleotide formed from a plurality of linked nucleotide units. The nucleotides units each include a nucleoside unit. In the context of this invention, the term "oligonucleoside" refers to a plurality of nucleoside units that are linked together. In a generic sense, since each nucleotide unit of an oligonucleotide includes a nucleoside therein, the term "oligonucleoside" can be considered to be inclusive of oligonucleotides (i.e., nucleosides linked together via phosphate linking groups). In a further sense, the term "oligonucleoside" also refers to a plurality of nucleosides that are linked together via linkages other than phosphate linkages. The term "oligonucleoside" thus effectively includes naturally occurring species or synthetic species formed from naturally occurring subunits. For brevity, the term "oligonucleoside" will be used as encompassing both phosphate linked (oligonucleotides) and non-phosphate linked polynucleoside species.
Oligonucleosides according to the invention also can include modified subunits. Representative modifications include modification of a heterocyclic base portion of a nucleoside or a sugar portion of a nucleoside. Exemplary modifications are disclosed in the following United States Patent Applications: Serial No. 463,358, filed January 11, 1990, entitled Compositions And Methods For Detecting And Modulating RNA Activity; Serial No. 566,977, filed August 13, 1990, entitled Sugar Modified Oligonucleotides That Detect And Modulate Gene Expression; Serial No. 558,663, filed July 27, 1990, entitled Novel Polyamine Conjugated Oligonucleotides; Serial No. 558,806, filed July 27, 1991, entitled Nuclease Resistant Pyrimidine Modified Oligonucleotides That Detect And Modulate Gene Expression and Serial No. PCT/US91/00243, filed January 11, 1991, entitled Compositions and Methods For Detecting And Modulating RNA Activity. Each of these patent applications are assigned to the assignee of this invention. The disclosure of each is incorporated herein by reference.
The term oligonucleoside thus refers to structures that include modified portions, be they modified sugar moieties or modified base moieties, that function similarly to natural bases and natural sugars. Representative modified bases include deaza or aza purines and pyrimidines used in place of natural purine and pyrimidine bases; pyrimidines having substituent groups at the 5 or 6 position; and purines having altered or replacement substituent groups at the 2, 6 or 8 positions. Representative modified sugars include carbocyclic or acyclic sugars, sugars having substituent groups at their 2' position, and sugars having substituents in place of one or more hydrogen atoms of the sugar. Other altered base moieties and altered sugar moieties are disclosed in United States Patent 3,687,808 and PCT application PCT/US89/02323.
Altered base moieties or altered sugar moieties also include other modifications consistent with the spirit of this invention. Such oligonucleosides are best described as being structurally distinguishable from yet functionally interchangeable with naturally occurring or synthetic wild type oligonucleotides. All such oligonucleosides are comprehended by this invention so long as they function effectively to mimic the structure of a desired RNA or DNA strand.
For use in antisense methodology, the oligonucleosides of the invention preferably comprise from about 10 to about 30 subunits. It is more preferred that such oligonucleosides comprise from about 15 to about 25 subunits. As will be appreciated, a subunit is a base and sugar combination suitably bound to adjacent subunits through, for example, a phosphorous- containing { e . g. , phosphodiester) linkage or some other linking moiety. The nucleosides need not be linked in any particular manner, so long as they are covalently bound. Exemplary linkages are those between the 3'- and 5' -positions or 2'- and 5' -positions of adjacent nucleosides. Exemplary linking moieties are disclosed in the following references: Beaucage, et al . , Tetrahedron 1992, 48, 2223 and references cited therein; and United States Patent Applications: Serial No. 703,619, filed May 21, 1991; Serial No. 903,160, filed June 24, 1992; Serial No. 039,979, filed March 20, 1993; Serial No. 039,846, filed March 30, 1993; and Serial No. 040,933, filed March 31, 1993. Each of the foregoing patent applications are assigned to the assignee of this invention. The disclosure of each is incorporated herein by reference.
It is preferred that the RNA or DNA portion which is to be modulated using oligonucleosides of the invention be preselected to comprise that portion of DNA or RNA which codes for the protein whose formation or activity is to be modulated. The targeting portion of the composition to be employed is, thus, selected to be complementary to the preselected portion of DNA or RNA, that is, to be an antisense oligonucleoside for that portion.
In accordance with one preferred embodiment of this invention, the compounds of the invention hybridize to HIV mRNA encoding the tat protein, or to the TAR region of HIV mRNA. In another preferred embodiment, the compounds mimic the secondary structure of the TAR region of HIV mRNA, and by doing so bind the tat protein. Other preferred compounds are complementary to sequences for herpes, papilloma and other viruses.
The nucleosides and oligonucleosides of the invention can be used in diagnostics, therapeutics and as research reagents and kits. They can be used in pharmaceutical compositions by including a suitable pharmaceutically acceptable diluent or carrier. They further can be used for treating organisms having a disease characterized by the undesired production of a protein. The organism should be contacted with an oligonucleotide having a sequence that is capable of specifically hybridizing with a strand of nucleic acid coding for the undesirable protein. Treatments of this type can be practiced on a variety of organisms ranging from unicellular prokaryotic and eukaryotic organisms to multicellular eukaryotic organisms. Any organism that utilizes DNA-RNA transcription or RNA-protein translation as a fundamental part of its hereditary, metabolic or cellular control is susceptible to therapeutic and/or prophylactic treatment in accordance with the invention. Seemingly diverse organisms such as bacteria, yeast, protozoa, algae, all plants and all higher animal forms, including warm-blooded animals, can be treated. Further, since each cell of multicellular eukaryotes can be treated since they include both DNA-RNA transcription and RNA-protein translation as integral parts of their cellular activity. Many of the organelles ( e . g. , mitochondria and chloroplasts) of eukaryotic cells also include transcription and translation mechanisms. Thus, single cells, cellular populations or organelles can also be included within the definition of organisms that can be treated with therapeutic or diagnostic oligonucleotides . As used herein, therapeutics is meant to include the eradication of a disease state, by killing an organism or by control of erratic or harmful cellular growth or expression.
In one aspect, the present invention is directed to nucleosides and oligonucleosides that bear at least one amine- containing substituent at a position. Such substituents preferably have formula -RA-N(R1a) (R1b) and are appended at 2'-O-, 3'-O-, and/or 5'-O-positions.
Each RA according to the invention is an alkyl moiety independently selected to having 1 to about 10 carbon atoms or RA is a polyether, a polythioether or polyalkylamine . The term
"alkyl" is intended to include straight chain and branched hydrocarbons. The preferred length of these hydrocarbons is 1 to about 7 carbon atoms, more preferably 3 or 4 carbon atoms.
R1a and R1b according to the invention are H, R2, an amine protecting group, have formula C(X)-R2, C(X)-RA-R2, C(X)-Q-RA-R2, C(X)-Q-R2, or, together, complete a cycloalkyl or cycloaryl moiety having two to six carbon atoms and one or two nitrogen atoms such as an imidazole moiety. R1a and R1b according to the invention are H, RA, R2, an amine protecting group, or have formula C(X)-R2, C(X)-RA-R2, C(X)-Q-RA-R2, C(X)-Q-R2. Protecting groups are known per se as chemical functional groups that can be selectively appended to and removed from functionalities, such as amine groups. These groups are present in a chemical compound to render such functionality inert to chemical reaction conditions to which the compound is exposed. See, e . g. , Greene and Wuts, Protective Groups in Organic Synthesis, 2d edition, John Wiley & Sons, New York, 1991. Numerous amine protecting groups are known in the art, including, but not limited to: phthalimide (PHTH), trifluoroacetate (triflate), allyloxycarbonyl (Alloc), benzyloxycarbonyl (CBz), chlorobenzyloxycarbonyl, t-butyloxycarbonyl (Boc), fluorenylmethoxycarbonyl (Fmoc), and isonicotinyloxycarbonyl (i-Noc) groups, ( see, e. g. , Veber and Hirschmann, et al . , J. Org. Chem. 1977, 42, 3286 and Atherton, et al . , The Peptides, Gross and Meienhofer, Eds, Academic Press; New York, 1983; Vol. 9 pp. 1-38). R2 can include a steroid molecule, a reporter molecule, a lipophilic molecule, a reporter enzyme, a peptide, a protein (i.e., a substituent consisting essentially of same), or a molecule having formula -Q-(CH2CH2-Q-)x-R3. For the purposes of this invention the terms "reporter molecule" and "reporter enzyme" are inclusive of those molecules or enzymes that have physical or chemical properties that allow them to be identified in gels, fluids, whole cellular systems, broken cellular systems and the like utilizing physical properties such as spectroscopy, radioactivity, colorimetric assays, fluorescence, and specific binding. Steroids include those chemical compounds that contain a perhydro-1,2-cyclop-ntanophenanthrene ring system. Proteins and peptides are utilized in their usual sense as polymers of amino acids. Normally peptides comprise such polymers that contain a smaller number of amino acids per unit molecule than do the proteins. Lipophilic molecules include naturally-occurring and synthetic aromatic and non-aromatic moieties such as fatty acids, esters, alcohols and other lipid molecules, substituted aromatic groups such as dinitrophenyl groups, cage structures such as adamantane and buckminsterfullerenes, and aromatic hydrocarbons such as benzene, perylene, phenanthrene, anthracene , naphthalene , pyrene , chrysene , and naphthacene .
Particularly useful as steroid molecules are the bile acids including cholic acid, deoxycholic acid and dehydrocholic acid; steroids including cortisone, digoxigenin, testosterone and cholesterol and even cationic steroids such as cortisone having a trimethylaminomethyl hydrazide group attached via a double bond at the 3 position of the cortisone rings. Particularly useful as reporter molecules are biotin, dinitrophenyl, and fluorescein dyes. Particularly useful as lipophilic molecules are alicyclic hydrocarbons, saturated and unsaturated fatty acids, waxes, terpenes and polyalicyclic hydrocarbons including adamantane and buckminsterfullerenes . Particularly useful as reporter enzymes are alkaline phosphatase and horseradish peroxidase. Particularly useful as peptides and proteins are sequence-specific peptides and proteins including phosphodiesterase, peroxidase, phosphatase and nuclease proteins. Such peptides and proteins include SV40 peptide, RNaseA, RNase H and Staphylococcal nuclease. Particularly useful as terpenoids are vitamin A, retinoic acid, retinal and dehydroretinol.
R2 also can have formula -Q-(CH2CH2-Q-)x-R3, where Q is 0, S, or NH. Subscript x can be 1 to about 200, preferably about 20 to about 150, more preferably about 10 to about 50. Preferably, Q are selected to be O, such that R2 constitutes a poly (ethyleneglycol) (PEG) group (i.e., R3 = H) or a functionalized derivative thereof ( e . g. , R3 = C(O)Cl). R3 can be H, RA, C(O)OH, C(O)ORA, C(O)R4, RA-N3, RA-NH2 or RA-SH where R4 is F, Cl, Br, I, SO2R5 or a small thio-containing heterocycle having structure
Figure imgf000015_0001
where m is 2 to 7. Representative PEG-containing R2 groups are disclosed by Ouchi, et al . , Drug Design and Discovery 1992, 9, 93, Ravasio, et al., J. Org. Chem. 1991, 56, 4329, and Delgardo et. al . , Cri tical Reviews in Therapeutic Drug Carrier Systems 1992, 9, 249.
Oligonucleosides according to the invention can be assembled in solution or through solid-phase reactions, for example, on a suitable DNA synthesizer utilizing nucleosides according to the invention and/or standard nucleotide precursors. The nucleosides and nucleotide precursors can already bear alkylamino groups or can be later modified to bear such groups.
In the former case, compounds according to the invention are prepared by, for example, reacting nucleosides bearing at least one free 2'-, 3'-, or 5 '-hydroxyl group under basic conditions with a compound having formula L1-(CH2)n-N(R1a) (R1b) where L2 is a leaving group and at least one of R1a and R1b is an amine protecting group. Displacement of the leaving group through nucleophilic attack of an oxygen anion produces the desired amine derivative. Leaving groups according to the invention include but are not limited to halogen, alkyl sulfonyl, substituted alkylsulfonyl, arylsulfonyl, substituted arylsulfonyl, hetercyclcosulfonyl or trichloroacetimidate. A more preferred group includes chloro, fluoro, bromo, iodo, p- (2,4-dinitroanilino)benzenesulfonyl, benzenesulfonyl, methylsulfonyl (mesylate), p-methylbenzenesulfonyl (tosylate), p-bromobenzenesulfonyl, trifluoromethylsulfonyl (triflate), trichloroacetimidate, acyloxy, 2,2,2-trifluoroethanesulfonyl, imidazoleysulfonyl, and 2,4,6-trichlorophenyl, with bromo being preferred.
Suitably protected nucleosides can be assembled into an oligonucleosides according to known techniques. See, e . g. , Beaucage, et al . , Tetrahedron 1992, 48, 2223.
Oligonucleosides according to the invention also can be prepared by assembling an oligonucleoside and appending alkyl- amino functionality thereto. For example, oligonucleosides having free hydroxyl groups can be assembled according to known techniques and then reacted with a reagent having formula L1- (CH2)n-N(R1a) (R1b). As will be recognized, however, greater selectivity can be achieved in terms of placement of alkylamino functionality within an oligonucleoside by introducing such functionality, as discussed above, on selected nucleosides and then using both the selected nucleosides and other nucleosides to construct an oligonucleoside.
Once assembled, an oligonucleoside bearing one or more groups having formula -RA-N(R1a)(R1b) wherein at least one of R1a and R1b is a protecting group is treated with reagents effective to remove the protecting group. Once deprotected, the oligonucleoside can be contacted with electrophillic moieties such as, for example, succinimidyl esters and other activated carboxylic acids including C(=O)-O-succinimide and C(=O)-O-pentafluorophenyl, isothiocyanates, sulfonyl chlorides, halacetamides, phospholipid carbocyclic acid active esters, o-phenanthroline-5-iodoacetamide, fluorescein isothiocyanate, 1-pyrene butyric acid-N-hydroxy succinimide ester and carboxylic acid derivatives of PNA (carboxylic acid derivatives of peptide nucleic acids). Preferred electrophillic moieties include cholesteryl-3-hemisuccinate-N-hydroxy succinimide ester, pyrene-1-butyric acid-N-hydroxy succinimide ester and polyethylene glycol-propionic acid-N-hydroxy succimide ester.
Thus, the invention first builds the desired linked nucleoside sequence in the normal manner on the DNA synthesizer. One or more (preferably two or more) of the linked nucleosides are then functionalized or derivatized with the lipophilic steroid, reporter molecule, lipophilic molecule, reporter enzyme, peptide or protein.
Additional objects, advantages, and novel features of this invention will become apparent to those skilled in the art upon examination of the following examples, which are not intended to be limiting. All oligonucleotide sequences are listed in a standard 5' to 3' order from left to right.
EXAMPLE 1
Oligonucleotides Having 2 '-Protected-Amine Terminating Linking Group
A. Preparation of 5'-Dimethoxytrityl-2'-(O-Pentyl-N-phthalimido)-2'-Deoxyadenosine Phosphoramidite.
To introduce a functionalization at the 2' position of nucleotides within desired oligonucleotide sequences, 5'-dimethoxytrityl-2'-(O-pentyl-N-phthalimido)-2'-deoxyadenosine phosphoramidite was utilized to provide a linking group attached to the 2' position of nucleotide components of an oligonucleotide. This compound was synthesized generally in accordance with the procedures of patent application serial numbers US91/00243 and 463,358, identified above, starting from adenosine. Briefly, this procedure treats adenosine with NaH in dimethylformamide (DMF) followed by treatment with N-(5-bromopentyl)phthalimide. Further treatment with (CH3)3SiCl, Ph-C(O)-Cl and NH4OH yields N6-benzyl protected 2'-pentyl-N-phthalimido functionalized adenosine. Treatment with DIPA and CH2Cl2 adds a DMT blocking group at the 5' position. Finally phosphitylation gives the desired phosphoramidite compound. This compound was utilized in the DNA synthesizer as a 0.09M solution in anhydrous CH3CN. Oligonucleotide synthesis was carried out in either an ABI 390B or an ABI 394 synthesizer employing the standard synthesis cycles with an extended coupling time of 10 minutes during coupling of Compound 2 into the oligonucleotide sequence. Coupling efficiency of greater than 98% was observed.
B. 2 '-Protected-Amine Linking Group Containing Phosphodiester Oligonucleotides
The following oligonucleotides having phosphodiester inter-nucleotide linkages were synthesized:
Oligomer 9: 5' TA*G 3';
Oligomer 10: 5' CCA* G 3' ;
Oligomer 11 (SEQ ID NO:1) : 5' GGC TGA* CTG CG 3 ' ;
Oligomer 12 (SEQ ID NO: 2) : CTG TCT CCA* TCC TCT TCA CT;
Oligomer 13: CTG TCT CCA* TCC TCT TCA* CT
wherein A* represents a nucleotide functionalized to incorporate a pentyl-N-phthalimido functionality. Oligomers 12 and 13 are antisense compounds to the E2 region of the bovine papilloma virus-1 (BPV-1). Oligomers 12 and 13 have the same sequence as Oligomer 3 in Application Serial Number 782,374, except for the 2' modification. The oligonucleotides were synthesized in either a 10 μmol scale or a 3 × 1 μmol scale in the "Trityl-On" mode. Standard deprotection conditions (30%
NH4OH, 55°C, 24 hours) were employed. The oligonucleotides were purified by reverse phase HPLC (Waters Delta-Pak C4 15 μm, 300A, 25×100 mm column equipped with a guard column of the same material). They were detritylated and further purified by size exclusion using a Sephadex G-25 column. NMR analyses by both proton and phosphorus NMR confirmed the expected structure for the Oligomers 9 and 10.
C. 2' -Protected-Amine Linking Group Containing
Phosphorothioate Oligonucleotides
The following oligonucleotides having phosphorothioate inter-nucleotide linkages were synthesized:
Oligomer 14 (SEQ ID NO: 3) :
TsTsGs CsTsTs CsCsA*s TsCsTs TsCsCs TsCsGs TsC;
Oligomer 15 (SEQ ID NO:4) :
TsGsGs GsAsGs CsCsAs TsAsGs CsGsA*s GsGsC ; and Oligomer 16 :
TsGsGs GsA*sGs CsCsA*s TsA*sGs CsGsA*s GsGsC
wherein A* represents a nucleotide functionalized to incorporate a pentyl-N-phthalimido functionality and the subscript "s" represents a phosphorothioate inter-nucleotide backbone linkage. Oligomer 14 is an antisense compound directed to the E2 region of the bovine papilloma virus-1 (BPV-1). Oligomers 15 and 16 are antisense compounds to ICAM. Oligomer 14 has the same sequence as Oligomer 3 in Application Serial Number 782,374, except for the 2' modification whereas Oligomers 15 and 16 have the same sequence as Oligomer 4 in Application Serial Number 782,374 except for the 2' modification. These oligonucleotides were synthesized as per the method of Example 1(B) except during the synthesis, for oxidation of the phosphite moieties, the Beaucage reagent
(i.e., 3H-1,2-benzodithioate-3-one 1,1-dioxide, see,
Radhakrishnan, et al . , J. Am. Chem. Soc . 1990, 112, 1253) was used as a 0.24 M solution in anhydrous CH3CN solvent. The oligonucleotides were synthesized in the "Trityl-On" mode and purified by reverse phase HPLC utilizing the purification procedure of Example 1(B).
D. 2'-O-Methyl Derivatized, 2'-Protected-Amine Linking Group Containing RNA Oligonucleotides
The following oligonucleotides having 2'-O-methyl groups on each nucleotide not functionalized with a 2' -protected amine functionalization were synthesized:
Oligomer 17 (SEQ ID NO: 24) : CCA A*GC CUC AGA; and Oligomer 18 (SEQ ID NO: 25) : CCA GGC UCA GA*T
wherein A* represents a nucleotide functionalized to incorporate a pentyl-N-phthalimido functionality and where the remaining nucleotides except the 3 '-terminus nucleotide are each 2'-O-methyl derivatized nucleotides. The 3 '-terminus nucleotide in both Oligomers 17 and 18 is a 2'-deoxy nucleotide. Both Oligomers 17 and 18 are antisense compounds to the HIV-1 TAR region. The oligonucleotides were synthesized as per the method of Example 6 in Application Serial Number 782,374 (utilizing Compound 2 thereof) for introduction of the nucleotides containing the pentyl-N-phthalimido functionality and appropriate 2-O-methyl phosphoramidite nucleotides from Chemgenes Inc. (Needham, MA) for the remaining RNA nucleotides. The 3 '-terminus terminal 2'-deoxy nucleotides were standard phosphoamidites utilized for the DNA synthesizer. The oligonucleotides were deprotected and purified as per the method of Example 1(B).
EXAMPLE 2
Functionalization Of Oligonucleotides At the 2' Position
A. Functionalization with Biotin
1. Single Site Modification
About 10 O.D. units (A260) of Oligomer 12 (see, Example 1) (approximately 60 nmols based on the calculated extinction coefficient of 1.6756 × 105) was dried in a microfuge tube. The oligonucleotide was dissolved in 200 μl of 0.2 M NaHCO3 buffer and D-biotin-N-hydroxysuccinimide ester (2.5 mg, 7.3 μmols) (Sigma, St. Louis, MO) was added followed by 40 μl DMF. The solution was let stand overnight. The solution was applied to a Sephadex G-25 column (0.7 × 15 cm) and the oligonucleotide fractions were combined. Analytical HPLC showed nearly 85% conversion to the product. The product was purified by HPLC
(Waters 600E with 991 detector, Hamilton PRP-1 column 0.7 × 15 cm; solvent A: 50 mM TEAA pH 7.0; B: 45 mM TEAA with 80% acetonitrile: 1.5 ml flow rate: Gradient: 5% B for first 5 minutes, linear (1%) increase in B every minute thereafter) and further desalted on Sephadex G-25 to give the oligonucleotide:
Oligomer 19 (SEQ ID NO: 5) : CTG TCT CCA* TCC TCT TCA CT wherein A* represents a nucleotide functionalized to incorporate a biotin functionality linked via a 2'-O-pentylamino linking group to the 2' position of the designated nucleotide. HPLC retention times are shown in Table 1 below.
2. Multiple Site Modification
About 10 O.D. units (A260) of Oligomer 13 (see, Example 1, approximately 60 nmols) was treated utilizing the method of Example 8(A) (1) in Application Serial Number 782,374 with D-biotin-N-hydroxysuccinimide ester (5 mg) in 300 μl of 0.2 M NaHCO3 buffer/ 50 μl DMF. Analytical HPLC showed 65% of double labeled oligonucleotide product and 30% of single labeled products (from the two available reactive sites). HPLC and Sephadex G-25 purification gave the oligonucleotide:
Oligomer 20: CTG TCT CCA* TCC TCT TCA* CT
wherein A* represents nucleotides functionalized to incorporate a biotin functionality linked via a 2 ' -O-pentyl-amino linking group to the 2' position of the designated nucleotide. HPLC retention times for this product (and its accompanying singly labeled products) are shown in Table 1 below.
B. Functionalization with Fluorescein
1. Single Site Modification
A 1M Na2CO3/1M NaHCO3 buffer (pH 9.0) was prepared by adding 1M NaHCO3 to 1 M Na2CO3. A 200 μl portion of this buffer was added to 10 O.D. units of Oligomer 12 (see, Example 1) in a microfuge tube. A 10 mg portion of fluorescein-isocyanate in 500 μl DMF was added to give a 0.05 M solution. A 100 μl portion of the fluorescein solution was added to the oligonucleotide solution in the microfuge tube. The tube was covered with aluminum foil and let stand overnight. The reaction mixture was applied to a Sephadex G-25 column (0.7 × 20 cm) that had been equilibrated with 25% (v/v) ethyl alcohol in water. The column was eluted with the same solvent. Product migration could be seen as a yellow band well separated from dark yellow band of the excess fluorescein reagent. The fractions showing absorption at 260 nm and 485 nm were combined and purified by HPLC as per the purification procedure of Example 2(A)(1). Analytical HPLC indicated 81% of the desired doubly functionalized oligonucleotide. The product was lyophilized and desalted on Sephadex to give the oligonucleotide :
Oligomer 21 [(SEQ ID NO: 9)]: CTG TCT CCA* TCC TCT TCA CT wherein A* represents a nucleotide functionalized to incorporate a fluorescein functionality linked via a 2'-O-pentyl-amino linking group to the 2' position of the designated nucleotide. HPLC retention times are shown in Table 1 below. 2. Multiple Site Modification
A 10 O.D. unit (A260) portion of Oligomer 13 (from Example 1) was dissolved in 300 μl of the 1M Na2HCO3/ 1M Na2CO2 buffer of Example 2(B) (1) and 200 μl of the fluorescein-isothiocyanate stock solution of Example 2(B) (1) was added. The resulting solution was treated as per Example 2 (B) (1). Analytical HPLC indicated 61% of doubly labeled product and 38% of singly labeled products. Work up of the reaction gave the oligonucleotide :
Oligomer 22: CTG TCT CCA* TCC TCT TCA* CT
wherein A* represents nucleotides functionalized to incorporate a fluorescein functionality linked via a 2'-O-pentyl-amino linking group to the 2' position of the designated nucleotide. HPLC retention times are shown in Table 1 below.
C. Functionalization with Cholic Acid
1. Single Site Modification
A 10 O.D. unit (A260) portion of Oligomer 12 (see, Example 1) was treated with cholic acid-NHS ester (Compound 1 in Application Serial Number 782,374, 5 mg, 9.9 μmols) in 200 μl of 0.2 M NaHCO3 buffer/ 40 μl DMF. The reaction mixture was heated for 16 hours at 45°C. The product was isolated as per the method of Example 2(B) (1). Analytical HPLC indicated greater than 85% product formation. Work up of the reaction gave the oligonucleotide:
Oligomer 23: CTG TCT CCA* TCC TCT TCA CT
wherein A* represents a nucleotide functionalized to incorporate a cholic acid functionality linked via a 2'-O-pentyl-amino linking group to the 2' position of the designated nucleotide. HPLC retention times are shown in Table 1 below.
2. Multiple Site Modification
A 10 O.D. unit (A260) portion of Oligomer 13 (see, Example 1) was treated with cholic acid-NHS ester (Compound 1 in Application Serial Number 782,374, 10 mg, 19.8 μmols) in 300 μl of 0.2 M NaHCO3 buffer/ 50 μl DMF. The reaction mixture was heated for 16 hours at 45°C. The product was isolated as per the method of Example 2(A)(1). Analytical HPLC revealed 58% doubly labeled product, 17% of a first singly labeled product and 24% of a second singly labeled product. Work up as per Example 2(A) (1) gave the oligonucleotide:
Oligomer 24 : CTG TCT CCA* TCC TCT TCA* CT
wherein A* represents nucleotides functionalized to incorporate a cholic acid functionality linked via a 2'-O-pentyl-amino linking group to the 2' position of the designated nucleotide. HPLC retention times are shown in Table 1 below.
D. Functionalization with Digoxigenin
1. Single Site Modification
A 10 O.D. unit (A260) portion of Oligomer 12 (see, Example 1) was treated with digoxigenin-3-O-methylcarbonyl-∊-aminocaproic N-hydroxy succinimide ester (Boehringer Mannheim Corporation, Indianapolis, IN) in 200 μl of 0.1 M borate pH 8.3 buffer/ 40 μl DMF. The reaction mixture was let stand overnight. The product was isolated as per the method of Example 2(A) (1). Work up of the reaction gave the oligonucleotide:
Oligomer 25: CTG TCT CCA* TCC TCT TCA CT
wherein A* represents a nucleotide functionalized to incorporate a digoxigenin functionality linked via a 2'-O-pentyl-amino linking group to the 2' position of the designated nucleotide. HPLC retention times are shown in Table 1 below.
2. Multiple Site Modification
A 10 O.D. units (A260) portion of Oligomer 13 (see, Example 1) was treated with digoxigenin-3-O-methylcarbonyl-∊-aminocaproic N-hydroxy succinimide ester (Boehringer Mannheim Corporation, Indianapolis, IN) in 300 μl of 0.1 M borate pH 8.3 buffer/50 μl DMF. The reaction mixture was let stand overnight. The product was isolated as per the method of Example 2(A)(1). Work up as per Example 2(A) (1) gave the oligonucleotide:
Oligomer 26: CTG TCT CCA* TCC TCT TCA* CT
wherein A* represents nucleotides functionalized to incorporate a cholic acid functionality linked via a 2'-O-pentyl-amino linking group to the 2' position of the designated nucleotide. HPLC retention times are shown in Table 1 below. TABLE 1
HPLC Retention Times Of Oligonucleotides Functionalized
At 2' Position
Retention Time Minutes
Oligomer Mono Substitution Multiple Substitution
Oligomer 121 21.78
Oligomer 131 22.50
Oligomer 192 23.58
Oligomer 202 24.16a 25.19b
Oligomer 213 26.65
Oligomer 223 26.99a 29.33b
27.55a
Oligomer 234 30.10
Oligomer 244 30.38a 37.00b
32.22a
Oligomer 255 28.06
Oligomer 265 28.14a 33.32b
29.24a
a Mono conjugated minor product;
b Doubly conjugated major product;
1 Parent Oligonucleotide - no 2' functionalization;
2 2' Biotin functionalization;
3 2' Fluorescein functionalization;
4 2' Cholic Acid functionalization; and
5 2' Digoxigenin functionalization.
The conditions employed were as follows: Waters 600E with 991 detector, Hamilton PRP-1 column 0.7 × 15 cm; solvent A: 50 mM TEAA pH 7.0; B: 45 mM TEAA with 80% acetonitrile:
1.5 ml flow rate: Gradient: 5% B for first 5 minutes, linear
(1%) increase in B every minute thereafter.
PROCEDURE A
Confirmation of Structure of Functionalized Oligonucleotides Containing A Tethered 2'-Amino Moiety
Oligonucleotides of the invention were digested with snake venom phosphodiesterase and calf-intestine alkaline phosphatase to their individual nucleosides. After digestion, the nucleoside composition was analyzed by HPLC. The HPLC analysis established that functionalized nucleotide compounds having the tethered 2'-amino moiety thereon were correctly incorporated into the oligonucleotide. Snake venom phosphodiesterase [Boehringer-Mannheim cat . #108260, 1 mg (1.5 units) /0.5 ml] and alkaline phosphatase from calf intestine (1 unit/microliter, Boehringer-Mannheim cat. # 713023) in Tris-HCl buffer (pH 7.2, 50 mM) were used to digest the oligonucleotides to their component nucleosides. To 0.5 O.D. units of oligonucleotide in 50 μl buffer (nearly 40 μM final concentration for a 20 mer) was added 5 μl of snake venom phosphodiesterase (nearly 0.3 units/mL, final concentration) and 10 μl of alkaline phosphatase (app. 150 units/mL, final concentration). The reaction mixture was incubated at 37°C for 3 hours. Following incubation, the reaction mixture was analyzed by HPLC using a reverse phase analytical column (app. 30 × 2.5 cm); solvent A: 50 mM TEAA pH 7; solvent B: acetonitrile; gradient 100% for 10 minutes, then 5% B for 15 minutes, then 10% B and then wash. The results of these digestion are shown in Table 2 for representative oligonucleotides.
TABLE 2
OLIGONUCLEOTIDE ANALYSIS VIA ENZYMATIC DIGESTION
Observed Ratios**
Oligomer Abs. max. 267 252 267 260
C G T A* A
Oligomer 10 2 1 1
Oligomer 11 3 5 2 1
Oligomer 12 9 1 8 1 1 Oligomer 13 9 1 8 2 * Nucleoside having 2'-O-linker attached thereto; and ** Corrected to whole numbers.
As is evident from Table 2, the correct nucleoside ratios are observed for the component nucleotides of the test oligonucleotides. PROCEDURE B
Determination of Melting Temperatures (Tm's) of Cholic Acid
Oligonucleotide Conjugates
The relative ability of oligonucleotides to bind to their complementary strand is compared by determining the melting temperature of the hybridization complex of the oligonucleotide and its complementary strand. The melting temperature (Tm), a characteristic physical property of double helices, denotes the temperature in degrees centigrade at which 50% helical versus coil (un-hybridized) forms are present. Tm is measured by using the UV spectrum to determine the formation and breakdown (melting) of hybridization. Base stacking, which occurs during hybridization, is accompanied by a reduction in UV absorption (hypochromicity). Consequently a reduction in UV absorption indicates a higher Tm. The higher the Tm, the greater the strength of the binding of the strands. Non-Watson-Crick base pairing has a strong destabilizing effect on the Tm. Consequently, absolute fidelity of base pairing is necessary to have optimal binding of an antisense oligonucleotide to its targeted RNA.
1. Terminal End Conjugates
a. Synthesis
A series of oligonucleotides were synthesized utilizing standard synthetic procedures (for un-functionalized oligonucleotides) or the procedure of Example 3 (A) in Application Serial Number 782,374 for oligonucleotides having a 5' -terminus amino linker bearing oligonucleotide or the procedure of Example 3(B) in Application Serial Number 782,374 for 5' -terminus cholic acid-bearing oligonucleotides. Each of the oligonucleotides had the following 5-LO antisense sequence: 5' TCC AGG TGT CCG CAT C 3' (SEQ ID NO: 6). The nucleotides were synthesized on a 1.0 μmol scale. Oligomer 32 was the parent compound having normal phosphodiester internucleotide linkages. Oligomer 33 incorporated phosphorothioate inter-nucleotide linkages in the basic oligonucleotide sequence. Oligomer 34 is a an intermediate oligonucleotide having a 5'-aminolink at the 5'-terminus of the basic oligonucleotide sequence and Oligomer 35 was a similar 5'-aminolink compound incorporating phosphorothioate inter-nucleotide linkages. Oligomer 36 is a 5'-terminus cholic acid conjugate of the basic phosphodiester oligonucleotide sequence while Oligomer 37 is a similar 5'-cholic acid conjugate incorporating phosphorothioate inter-nucleotide linkages. Oligomers 32 and 33 were synthesized in a "TritylOn" mode and were purified by HPLC. Oligomers 34 and 35 were synthesized as per Example 30(A) in Application Serial Number 782,374 without or with Beaucage reagent treatment, to yield phosphodiester or phosphorothioate inter-nucleotide linkages, respectively. Oligomers 36 and 37 were prepared from samples of Oligomers 34 and 35, respectively, utilizing a solution of cholic acid N-hydroxysuccinimide ester (Compound 1) 1 dissolved in DMF as per Example 3 (B) in Application Serial Number 782,374. Oligomers 36 and 37 were purified by HPLC. The products were concentrated and desalted in a Sephadex G-25 column. Gel electrophoresis analyses also confirmed a pure product with the pure conjugate moving slower than the parent oligonucleotide or 5' -amino functionalized oligonucleotide.
b. Melting Analysis
The test oligonucleotides [either the phosphodiester, phosphorothioate, cholic acid conjugated phosphodiester, cholic acid conjugated phosphorothioate or 5'-aminolink intermediate phosphodiester or phosphorothioate oligonucleotides of the invention or otherwise] and either the complementary DNA or RNA oligonucleotides were incubated at a standard concentration of 4 μM for each oligonucleotide in buffer (100 mM NaCl, 10 mM Na-phosphate, pH 7.0, 0.1 mM EDTA). Samples were heated to 90 degrees C and the initial absorbance taken using a Guilford Response II spectrophotometer (Corning). Samples were then slowly cooled to 15 degrees C and then the change in absorbance at 260 nm was monitored during the heat denaturation procedure. The temperature was elevated 1 degree/absorbance reading and the denaturation profile analyzed by taking the 1st derivative of the melting curve. Data was also analyzed using a two-state linear regression analysis to determine the Tm's. The results of these tests are shown in Table 3 as are the HPLC retention times of certain of the test compounds.
TABLE 3
Melting Temperature Of The Hybridization Complex Of The Oligonucleotide And Its Complementary Strand
Oligomer Tm** HPLC Ret. Time*
DNA RNA minutes
32 62.6 62.0
33 55.4 54.9
34 ND ND 13.6
35 ND ND 17.0
36 63.4 62.4 22.0
37 56.3 55.8 22.5
* HPLC conditions: Walters Delta Pak C-18 RP 2.5u column; at 0 min 100% 0.1 TEAA; at 30 min 50% TEAA and 50% Acetonitrile: Flow rate 1.0 ml/min.
** Tm at 4μM each strand from fit of duplicate melting curves to 2-state model with linear sloping base line. Conditions: 100 mM NaCl, 10 mM Phosphate, 0.1 mM EDTA, pH 7.0.
ND = not determined
As is evident from Table 2, conjugates of cholic acid at the end of the oligonucleotide do not affect the Tm of the oligonucleotides.
2. Strands Incorporating 2 '-O-Pentylamino Linker
a. Synthesis
An oligonucleotide of the sequence:
Oligomer 38 (SEQ ID NO: 7) : GGA* CCG GA*A* GGT A*CG A*G wherein A* represents a nucleotide functionalized to incorporate a pentylamino functionality at its 2' -position was synthesized in a one micromole scale utilizing the method of Example 1 (B). The oligonucleotide was purified by reverse phase HPLC, detritylated and desalted on Sephadex G-25. PAGE gel analysis showed a single band. A further oligonucleotide, Oligomer 39, having the same sequence but without any 2'-O-amino linker was synthesis in a standard manner. A complementary DNA oligonucleotide of the sequence: Oligomer 40 (SEQ ID NO: 8) : CCT GGC CTT CCA TGC TC was also synthesized in a standard manner as was a complementary RNA oligonucleotide of the sequence:
Oligomer 41 (SEQ ID NO: 9) : CCU GGC CUU CCA UGC UC. b. Melting Analysis
Melting analysis was conducted as per the method of Procedure B(1) (b). The results are shown in Table 4.
TABLE 4
Melting Temperature Of The Hybridization Complex Of
The Oligonucleotide And Its Complementary Strand
Oligomer Tm*
DNA1 RNA2
38 54.5 58.0
39 60.6 56.9
* Tm at 4μM each strand from fit of duplicate melting curves to 2-state model with linear sloping base line. Conditions: 100 mM NaCl, 10 mM Phosphate, 0.1 mM EDTA, pH 7.0.
1 Against DNA complementary strand, Oligomer 40.
2 Against RNA complementary strand, Oligomer 41
As is evident from Table 4 against the RNA complementary strand the change in Tm's between the strand having 2 '-amino linkers thereon and the unmodified strand is 1.1 degrees (0.22 change per modification). Against the DNA strand, the change is -6.1 degrees (-1.2 change per modification). When compared to the parent unmodified oligonucleotide the 2'-amino linker- containing strand has a stabilizing effect upon hybridization with RNA and a destabilizing effect upon hybridization with DNA.
Compounds of the invention were tested for their ability to increase cellular uptake. This was determined by judging either their ability to inhibit the expression of bovine papilloma virus-1 (BPV-1) or an assay involving luciferase production (for HIV-1). PROCEDURE C
Determination of Cellular Uptake Judged By The Inhibition Of Expression of Bovine Papilloma Virus-1 (bpv-1) As Measured By an E2 Transactivation Assay
For this test, a phosphorothioate oligonucleotide analog of the sequence:
Oligomer 42 : CTG TCT CCA TCC TCT TCA CT
was used as the basic sequence. This sequence is designed to be complementary to the translation initiation region of the E2 gene of bovine papilloma virus type 1 (BPV-1). Oligomer 42 served as the positive control and standard for the assay. Oligomer 3 (from Example 4 in Application Serial Number 782,374) served as a second test compound. It has the same basic sequence except it is a phosphorothioate oligonucleotide and further it has a cholic acid moiety conjugated at the 3'-end of the oligonucleotide. Oligomer 2 (from Example 2 in Application Serial Number 782,374) served as a third test compound. Again it is of the same sequence, it is a phosphorothioate oligonucleotide and it has a cholic acid moiety conjugated at the 5'-end. Oligomer 5 (from Example 5 in Application Serial Number 782,374) served as a fourth test compound. Once again it has the same sequence, is a phosphorothioate oligonucleotide and it has a cholic acid moiety conjugated at both the 3 '-end and 5' -end. A fifth test compound was a phosphorothioate oligonucleotide with no significant sequence homology with BPV-1. A sixth test compound was a further phosphorothioate oligonucleotide with no significant sequence homology with BPV-1. The last test compound, the seventh test compound, was a phosphorothioate oligonucleotide with cholic acid conjugated to the 3 '-end but having no significant sequence homology with BPV-1. Compounds five, six and seven served as negative controls for the assay.
For each test 1-38 cells were plated at 5×104 cells per cm2 in 60 mm petri dishes. Eight hours after plating, medium was aspirated and replaced with medium containing the test oligonucleotide and incubated overnight. Following incubation, medium was aspirated and replaced with fresh medium without oligonucleotide and incubated for one hour. Cells were then transfected by the CaPO4 method with 2 μg of pE2RE-l-CAT. After a four hour incubation period cells were glycerol shocked (15% glycerol) for 1 minute followed by washing 2 times with PBS. Medium was replaced with DMEM containing oligonucleotide at the original concentration. Cells were incubated for 48 hours and harvested. Cell lysates were analyzed for chloramphenicol acetyl transferase by standard procedures. Acetylated and nonacetylated 14C-chloramphenicol were separated by thin layer chromatography and quantitated by liquid scintillation. The results are expressed as percent acetylation.
Two lots of the positive control compound were found to acetylate at a level of 29% and 30%. The negative controls, test compounds five, six and seven, were found to acetylate at 59%, 58% and 47%, respectively. The 3'-cholic acid conjugate test compound, Oligomer 3, was found to acetylate to 23%, the 5' -cholic acid conjugate test compound, Oligomer 2, was found to acetylate to 36% and the test compound conjugated at both the 3 '-end and the 5'-end, Oligomer 5, was found to acetylate to 27%.
The results of this test suggests that placement of a cholic acid moiety at the 3 '-terminus of an oligonucleotide increase the activity. This in turn suggests that the increased activity was the result of increased cellular membrane transport.
PROCEDURE D
Determination of Cellular Uptake Judged By Inhibition of pHIVluc With Cholic Acid Linked 2'-O-Methyl Substituted Oligonucleotides
For this test the absence of an oligonucleotide in a test well served as the control. All oligonucleotides were tested as 2'-O-methyl analogs. For this test an oligonucleotide of the sequence:
Oligomer 43 (SEQ ID NO: 10) : CCC AGG CUC AGA where each of the nucleotides of the oligonucleotide includes a 2'-O-methyl substituent group served as the basic test compound. The second test compound of the sequence:
Oligomer 44: 5'-CHA CCC AGG CUC AGA
wherein CHA represents cholic acid and where each of the nucleotides of the oligonucleotide includes a 2'-O-methyl substituent group, was also of the same sequence as the first test compound. This second test compound included cholic acid conjugated to its 5' -end and was prepared as per the method of Example 3 in Application Serial Number 782,374 utilizing 2'-O-methyl phosphoramidite intermediates as identified in Example 1(C). The third test compound of the sequence:
Oligomer 45: CCC AGG CUC AGA 3' -CHA
wherein CHA represents cholic acid and where each of the nucleotides of the oligonucleotide includes a 2'-O-methyl substituent group was also of the same sequence as the first test compound. The third test compound included cholic acid conjugated to its 3 '-end and was prepared as per the method of Example 4 in Application Serial Number 782,374 utilizing 2'-O-methyl phosphoramidite intermediates as identified in Example 1(C). The fourth test compound was a 2'-O-Me oligonucleotide of a second sequence:
Oligomer 46 (SEQ ID NO: 11): GAG CUC CCA GGC
where each of the nucleotides of the oligonucleotide includes a 2'-O-methyl substituent group. The fifth test compound was of sequence:
Oligomer 47: 5' -CHA GAG CUC CCA GGC
wherein CHA represents cholic acid and where each of the nucleotides of the oligonucleotide includes a 2'-O-methyl substituent group. It was of the same sequence as the fifth test compound. This test compound included cholic acid conjugated to its 5'-end and was prepared as per the method of Example 3 in Application Serial Number 782,374 utilizing 2'-O-methyl phosphoramidite intermediates as identified in Example 1(C).
A sixth test compound was a randomized oligonucleotide of the sequence: Oligomer 48 (SEQ ID NO: 12): CAU GCU GCA GCC.
HeLa cells were seeded at 4×105 cells per well in 6-well culture dishes. Test oligonucleotides were added to triplicate wells at 1 μM and allowed to incubate at 37°C for 20 hours. Medium and oligonucleotide were then removed, cells washed with PBS and the cells were CaPO4 transfected. Briefly, 5μg of pHIVluc, a plasmid expressing the luciferase cDNA under the transcriptional control of the HIV LTR constructed by ligating the Kpnl/Hindlll restriction fragments of the plasmids pT3/T71uc and pHIVpap (NAR 19(12)) containing the luciferase cDNA and the HIV LTR respectively, and 6 μg of pcDEBtat, a plasmid expressing the HIV tat protein under the control of the SV40 promoter, were added to 500 μl of 250 mM CaCl2, then 500 μl of 2x HBS was added followed by vortexing. After 30 minutes, the CaPO4 precipitate was divided evenly between the six wells of the plate, which was then incubated for 4 hours. The media and precipitate were then removed, the cells washed with PBS, and fresh oligonucleotide and media were added. Incubation was continued overnight. Luciferase activity was determined for each well the following morning. Media was removed, then the cells washed 2X with PBS. The cells were then lysed on the plate with 200 μl of LB (1% Trit X-100, 25 mM Glycylglycine pH 7.8, 15 mM MgSO4, 4 mM EGTA, ImM DTT). A 75 μl aliquot from each well was then added to a well of a 96 well plate along with 75 μl of assay buffer (25 mM
Glycylglycine pH 7.8, 15 mM MgSO4, 4 mM EGTA, 15 mM KPO4, 1 mM
DTT, 2.5 mM ATP). The plate was then read in a Dynatec multiwell luminometer that injected 75 μl of Luciferin buffer
(25 mM Glycylglycine pH 7.8, 15 mM MgSO4, 4 mM EGTA, 4 mM DTT, 1 mM luciferin) into each well, immediately reading the light emitted (light units).
The random sequence compound (Oligomer 48) and the other non-cholic acid-conjugated test compounds (Oligomers 43 and 46) had comparable activity. The 5'-conjugate of the first sequence (Oligomer 44) also had activity comparable to the non-conjugated compounds. The 5'-conjugate of the second sequence (Oligomer 47) showed a three-fold increase in activity compared to the non-conjugated compounds and the 3'- conjugate of the first sequence (Oligomer 45) showed a further 3-fold increase in activity compared to Oligomer 47.
All the test cholic acid-bearing oligonucleotides showed significant inhibition of luciferase production compared to non-cholic acid- bearing oligonucleotides. This suggests that the increased activity was the result of increased cellular membrane transport of the cholic acid-bearing test oligonucleotides. EXAMPLE 3
Preparation of 5'-O-[Dimethoxytrityl]-2 '-O-[hexyl-(Ω-N-phthalimido)amino]uridine and 5'-O-[dimethoxytrityl]-3'-O- [hexyl(Q-N-phthalimidoamino)uridine.
2',3'-O-Dibutyl stannylene-uridine was synthesized according to the procedure of Wagner et. al . , J. Org. Chem. , 1974, 39, 24. This compound was dried over P2O5 under vacuum for 12 hours. To a solution of this compound (29 g, 42.1 mmols) in 200 ml of anhydrous DMF were added (16.8 g, 55 mmols) of 6-bromohexyl phthalimide and 4.5 g of sodium iodide and the mixture was heated at 130°C for 16 hours under argon. The reaction mixture was evaporated, co-evaporated once with toluene and the gummy tar residue was applied on a silica column (500 g). The column was washed with 2L of ethyl acetate (EtOAc) followed by eluting with 10% methanol (MeOH) :90% EtOAc. The product, 2'- and 3'-isomers of O-hexyl-Ω-N-phthalimido uridine, eluted as an inseparable mixture (Rf=0.64 in 10% MeOH in EtOAc). By 13C NMR, the isomeric ration was about 55% of the 2 ' isomer and about 45% of the 3 ' isomer . The combined yield was 9.2 g (46.2%). This mixture was dried under vacuum and re-evaporated twice with pyridine. It was dissolved in 150 mL anhydrous pyridine and treated with 7.5 g of dimethyocytrityl chloride (22.13 mmols) and 500 mg of dimethylaminopyridine (DMAP). After 2 hour, thin layer chromatography (TLC; 6:4 EtOAc:Hexane) indicated complete disappearance of the starting material and a good separation between 2' and 3' isomers (Rf=0.29 for the 2' isomer and 0.12 for the 3' isomer) . The reaction mixture was quenched by the addition of 5mL of CH3OH and evaporated under reduced pressure. The residue was dissolved in 300mL CH2Cl2, washed successively with saturated NaHCO3 followed by saturated NaCl solution. It was dried over Mg2SO4 and evaporated to give 15 g of a brown foam which was purified on a silica gel (500 g) to give 6.5 g of the 2' -isomer and 3.5 g of the 3' isomer.
EXAMPLE 4
Preparation of 5'-O-Dimethoxytrityl-2'-O-[hexyl-(Ω-N-phthalimido)-amino]uridine-3'-O-(2-cyanoethyl-N,N-diisopropyl)-phosphoramidite.
The 5'-dimethoxytrityl-2'-[0-hexyl-(Ω-N-phthalimido)-amino]uridine (4 g, 5.2 mmole) was dissolved in 40 mL of anhydrous CH2Cl2. To this solution diisopropylaminetetra- zolide (0.5 g, 2.9 mmol) was added and stirred overnight. TLC
(1:1 EtoAC/hexane) showed complete disappearance of starting material. The reaction mixture was transferred with CH2Cl2 and washed with saturated NaHCO3 (100 mL) followed by saturated NaCl solution. The organic layer was dried over anhydrous Na2SO4 and evaporated to yield 6.4 g of a crude product which was purified in a silica column (200 g) using 1:1 hexane/EtOAc to give 4.6 g (4.7 mmol, 90%) of the desired phosphoramidite.
EXAMPLE 5
Preparation of 5'-O-(Dimethoxytrityl)-3'-O-[hexyl-(Ω-N-phthalimido)amino]uridine-2'-O-succinyl-aminopropyl controlled pore glass.
Succinylated and capped aminopropyl controlled pore glass (CPG; 500A pore diameter, aminopropyl CPG, 1.0 grams prepared according to Damha et. al . , Nucl . Acids Res . 1990, 18, 3813.) was added to 12 ml anhydrous pyridine in a 100 ml round-bottom flask. 1-(3-Dimethylaminopropyl)-3-ethyl-carbodiimide (DEC; 0.38 grams, 2.0 mmol)], triethylamine (TEA; 100 μl, distilled over CaH2), dimethylaminopyridine (DMAP; 0.012 grams, 0.1 mmol) and nucleoside 5'-O-dimethoxytrityl-3'-O- [hexyl-(Ω-N-phthalimidoamino)]uridine (0.6 grams, 0.77 mmol) were added under argon and the mixture shaken mechanically for 2 hours. More nucleoside (0.20 grams) was added and the mixture shaken an additional 24 hours. CPG was filtered off and washed successively with dichloromethane, triethylamine, and dichloromethane. The CPG was then dried under vacuum, suspended in 10 ml piperidine and shaken 15 minutes. The CPG was filtered off, washed thoroughly with dichloromethane and again dried under vacuum. The extent of loading (determined by spectrophotometric assay of dimethoxytrityl cation in 0.3 M p-toluenesulfonic acid at 498 nm) was approximately 28 μmol/g. The 5'-O-(dimethoxytrityl)-3'-O-[hexyl-(Ω-N-phthalimidoamino]uridine-2'-O-succinyl-aminopropyl controlled pore glass was used to synthesize the oligomers 5'-GACU*-3' and 5'- GCC TTT CGC GAC CCA ACA CU*-3' (SEQ ID NO: 13) (where the * indicated the derivatized nucleotide) in an ABI 380B DNA synthesizer using phosphoramidite chemistry standard conditions. 45 and 200 O.D.'s of the 4-mer and 20-mer, respectively, were obtained from two and three 1 μmol syntheses after purification by RP-HPLC and desalting.
The oligomer 5'-GACU*-3' was used to confirm the structure of 3 ' -O-hexylamine tether introduced into the oligonucleotide by NMR. As expected a multiplet signal was observed between 1.0-1.8 ppm in 1H NMR. The oligomer 5' -GCC TTT CGC GAC CCA ACA CU*- 3' belongs to a HCV sequence and it was used to show the nuclease resistance properties of the 3'-O-amino tether [see example 39].
EXAMPLE 6
Preparation of 5'-O-(Dimethoxytrityl)-2 '-O-[hexyl-(Ω-N-phthalimido)amino] 3'-O-succinyl-aminopropyl controlled pore glass..
The procedure of Example 5 was repeated, except that 5'-O-(Dimethoxytrityl)-2'-O-[hexyl-(Ω-N-phthalimidoamido)-amino]uridine was used in the loading process. EXAMPLE 7
Preparation of 5'-O-(Dimethoxytrityl)-2'-O-(hexylamino)-uridine.
5'-O-(dimethoxytrityl)-2'-O-[hexyl-(Ω-N-phthalimidoamino)]uridine (4.5 grams, 5.8 mmol) was dissolved in 200 ml methanol in a 500 ml flask. Hydrazine (1 ml, 31 mmol) was added to the stirring reaction mixture. The mixture was heated to 60-65° in an oil bath and refluxed 14 hours. Solvent was evaporated in vacuo . The residue was dissolved in dichloromethane (250 ml) and extracted twice with an equal volume NH4OH. The organic layer was evaporated to yield 4.36 grams of crude product, and NMR indicated that the product was not completely pure. Rf=0 in 100% ethyl acetate. The product was used in subsequent reactions without further purification. EXAMPLE 8
Preparation of 5'-O-(dimethoxytrityl)-3'-O-[hexylamino]uridine.
The procedure of Example 7 was repeated, except that 5'-O-(dimethoxytrityl)-3'-O-[hexyl-(Ω-N-phthalimido-amino)]uridine was used as the starting material.
EXAMPLE 9
Preparationof 5'-O-(dimethoxytrityl)-2 '-O-[hexyl-N-(1-pyrene propyl carbonyl)amino]uridine
5'-O-Dimethoxytrityl-2'-O-(hexylamino)uridine (0.5g, 0.78 mmol) was dissolved in anhydrous DMF (15 mL). 1-Hydroxybenzotriazole (0.16 grams, 1.17 mmol) and 1-pyrenebutyric acid pentafluorophenyl ester (0.53 grams, 1.17 mmol) were added to the reaction mixture. The mixture was stirred under argon at room temperature for 2 hours, after which it was concentrated in vacuo. Residual DMF was coevaporated with toluene. The residue was dissolved in dichloromethane (50 mL) and washed with an equal volume saturated NaHCO3. The aqueous layer was washed with dichloromethane and the combined organic extracts washed with an equal volume saturated NaCl. The aqueous layer was washed with dichloromethane and the combined organic layers dried over MgSO4 and concentrated. The residue was chromatographed on a silica gel column, eluting with a gradient of 50% ethyl acetate in hexanes to 100% ethyl acetate. The desired product (0.83 grams, 58%) eluted with 100% ethyl acetate (Rf 0.46 by thin-layer chromatography (TLC)).
EXAMPLE 10
Preparation of 5'-O-[Dimethoxytrityl]-2'-O-[hexyl-N-(1-pyrene propyl carbonyl)amino]uridine-3'-O-(2-cyanoethyl-N, N-diisopropyl)phosphoramidite
5'-O-[Dimethoxytrityl]-2'-O-[hexyl-N-(1-pyrene propyl carbonyl) amino] uridine (0.80 grams, 0.87 mmol) was dissolved in 20 mL dry dichloromethane. 2-Cyanoethyl N, N, N' , N'-tetraisopropylphosphorodiamidite (purchased from Sigma Chemical Co; 800 μL, 2.4 mmol) and diisopropylamine tetrazolide (0.090 grams, 0.52 mmol) were added to the mixture, which was stirred under argon for 20 hours The reaction mixture was then concentrated in vacuo and the residue dissolved in dichloromethane (75 mL). The solution was washed with an equal volume of saturated NaHCO3. The aqueous layer was washed with dichloromethane (20 mL) and the combined organic layers washed with an equal volume of saturated NaCl. The aqueous layer was washed with dichloromethane (20 mL) and the combined organic layers dried over MgSO4 and concentrated. The residue was chromatographed on a silica gel column, eluting with a gradient of 50% ethyl acetate in hexanes to 100% ethyl acetate. The desired product (750 mg, 78% yield, Rf 0.54 by TLC in 100% ethyl acetate) eluted with 100% ethyl acetate. EXAMPLE 11
Preparation of 2'-O-[hexyl-N-(1-pyrene-propyl-carbonyl) amino] uridine.
5'-O-dimethoxytrityl-2'-O-[hexyl-N-(1-pyrene-propylcarbonyl)amino]uridine (1.0 g) was dissolved in 20 mL CH2Cl2 and kept in ice-bath for 10 minutes. To the cold solution, 5 mL of 80% acetic acid in water was added and the solution was left to stand for 30 minutes. It was then evaporated to dryness and loaded into a silica column and eluted with 10% methanol in methylene chloride to give 2'-O-[hexyl-N-(1-pyrene-propyl-carbonyl)amino]uridine.
EXAMPLE 12
Preparationof 5'-O-(dimethoxytrityl)-2'-O-[hexyl-N-(1-pyrenepropylcarbonyl)amino]uridine-3'-O-[succinylaminopropyl]-controlled pore glass.
Succinylated/capped aminopropyl controlled pore glass was dried under vacuum for 3 hours immediately before use.
A portion (0.3 g) was added to 3 ml anhydrous pyridine in a
50 ml round-bottom flask. DEC (0.12 grams, 0.63 mmol), TEA
(25 μl, distilled over CaH2), DMAP (0.005 grams, mmol) and 5'-O-(dimethoxytrityl)-3'-O-[hexyl-N-(1-pyrene propyl carbonyl] amino]uridine (0.21 grams, 0.22 mmol) were added under argon and the mixture shaken mechanically for 19 hours. More nucleoside (0.025 grams) was added and the mixture shaken an additional 5.5 hours. Pentachlorophenol (0.045 grams, mmol) was added and the mixture shaken 18 hours. CPG was filtered off and washed successively with dichloromethane, triethylamine, and dichloromethane. The resulting CPG was then dried under vacuum, suspended in 15 ml piperidine and shaken 30 minutes. CPG was filtered off, washed thoroughly with dichloromethane and again dried under vacuum. The extent of loading (determined by spectrophotometric assay of dimethoxytrityl cation in 0.3 M p-toluenesulfonic acid at 498 nm) was approximately 27 μmol/g. The product solid support was subsequently used to synthesize the oligomers. EXAMPLE 13
Preparation of 5'-O-dimethoxytrityl-3'-O-[hexyl-N-(1-pyrene propyl carbonyl] amino] uridine-2'-O-(succinyl amino propyl) controlled pore glass.
The procedure of Example 12 is repeated, except that 5'-O-dimethoxytrityl-3'-O-[hexyl-N-(1-pyrene propyl carbonyl] amino] uridine is used.
EXAMPLE 14
Preparation of 5'-O-(dimethoxytrityl)-2'-O-[hexyl-N-(5-thiocarbonyl-3,6-dipivolyl-fluorescein)amino]uridine.
Fluorescein isothiocyanate (Isomer I, available from Cal Biochem, La Jolla, CA) was treated with 12 equivalents of pivaloyl chloride in Et3N/THF to give di-O-pivaloyl fluorescein isothiocyanate. This compound was purified in silica gel column using 3:1 hexane:ethyl acetate. Nucleoside 5'-O-(dimethoxytrityl)-2'-O-(hexylamino)uridine was then condensed with dipivolyl fluorescein isothiocyanate in CH2Cl2/pyrimidine. The resultant compound 5'-O- (dimethoxytrityl)-2'-O-[hexyl-N-(5-thiocarbonyl-3,6-dipivolylfluorescein)amino]uridine is then purified by using 100% ethyl acetate, in a silica column.
EXAMPLE 15
Preparation of 5'-O-dimethoxytrityl-2'-O-[hexyl-N-(5-thiocarbonyl-3,6-di-pivaloyl fluorescein) amino] uridine-3'-O- (2-cyanoethyl, N-N-diisopropyl phosphoramidite.
5'-O-(dimethoxytrityl)-2'-O-[hexyl-N-(5-thiocarbonyl-3,6-dipivolyl fluorescein)amino]uridine (0.75 grams, 0.672 mmol) was dissolved in dry dichloromethane (20 mL). 2-Cyanoethyl N, N,N' ,N' -tetraisopropylphosphorodiamidite (700 μL, 2.2 mmol) and diisopropylamine tetrazolide were added to the mixture, which was stirred under argon for 16 hours. The reaction mixture was then concentrated in vacuo and the residue dissolved in dichloromethane (75 mL) followed by washing with an equal volume of saturated ΝaHCO3. The aqueous layer was washed with dichloromethane (50 mL) and the combined organic layers washed with an equal volume of saturated NaCl . The aqueous layer was washed with dichloromethane (50 mL) and the combined organic layers dried over MgSO4 and concentrated. The residue was chromatographed on a silica gel column, eluting with a gradient of 25% ethyl acetate in hexanes to 100% ethyl acetate. The desired product (670 mg, 77% yield, Rf 0.79 by TLC) eluted with 100% ethyl acetate.
EXAMPLE 16
Preparation of 5'-O-(dimethoxytrityl)-2'-O-[hexyl-N-(5-thiocarbonyl-3,6-di-pivaloyl fluorescein)amino]uridine-3'-O- (succinylaminopropyl) controlled pore glass.
Succinylated and capped aminopropyl controlled pore glass (CPG) is dried under vacuum for 3 hours immediately before use. CPG (0.3 grams) is added to 3 ml anhydrous pyridine in a 50 ml round-bottom flask. DEC (0.12 grams, 0.63 mmol), TEA (25 μl, distilled over CaH2, DMAP (dimethyl amino pyridine) (0.005 grams, 0.04 mmol) and 5'-O-dimethoxytrityl-2'-O-[hexyl-N-(5-thiocarbonyl-3,6-di-pivaloyl fluorescein)amino] uridine (0.21 grams, 0.19 mmol) are added under argon and the mixture shaken mechanically for 19 hours. More nucleoside (0.025 grams) is added and the mixture shaken an additional 5.5 hours. Pentachlorophenol (0.045 grams, 0.17 mmol) is added and the mixture shaken 18 hours. CPG is filtered off and washed successively with dichloromethane, triethylamine, and dichloromethane. CPG then is dried under vacuum, suspended in 15 mL piperidine and shaken 30 minutes. CPG is filtered off, washed thoroughly with dichloromethane, and again dried under vacuum. The extent of loading is then determined by spectrophotometric assay of dimethoxytrityl cation in 0.3 M p-toluenesulfonic acid at 498 nm.
EXAMPLE 17
Preparation of 5'-O-(dimethoxytrityl)-2 '-O-[hexyl-N-(3-oxycarbonyl-cholesteryl)amino]uridine.
Nucleoside 5'-O-(dimethoxytrityl)-2'-O-[hexylamino]-uridine (3.85 g, 6.0 mmol) was dissolved in anhydrous pyridine/dichloromethane 50/50 (v/v) (20 mL). Cholesteryl chloroformate (Fluka, 3.0 g, 6.68 mmol) was dissolved in anhydrous dichloromethane (20 ml) and added slowly under argon with a syringe to the stirring reaction mixture. The mixture was stirred under argon at room temperature for 2 h after which it was concentrated in vacuo . Residual DMF was coevaporated with toluene. The residue was dissolved in dichloromethane (50 mL) and washed with an equal volume saturated NaHCO3. The aqueous layer was washed with dichloromethane and the combined organic extracts washed with an equal volume saturated NaCl. The aqueous layer was washed with dichloromethane and the combined organic layers dried over MgSO4 and concentrated. The residue was chromatographed on a silica gel column with a gradient of 25% ethyl acetate in hexanes to 100% ethyl acetate. The desired product (3.78 g, 60%) eluted with 100% ethyl acetate (Rf 0.41 by TLC).
EXAMPLE 18
Preparation of 5'-O-(dimethoxytrityl)-2'-O-[hexyl-N-(3-oxy¬carbonyl-cholesteryl)amino]uridine-3'-O-[2-cyanoethyl-N,N-di-isopropyl]phosphoramidite
Nucleoside 5'-O-(dimethoxytrityl)-2'-O-[hexyl-N-(3-oxycarbonyl-cholesteryl)amino]uridine (3.44 g, 3.3 mmol) was dissolved in dry dichloromethane (75 mL). 2-cyanoethyl N, N, N'N' -tetraisopropylphosphorodiamidite (Sigma, 2.1ml, 6.6 mmol) and diisopropylamine tetrazolide (0.29 g, 1.7 mmol) were added to the mixture, which was stirred under argon for 16 H. Dichloromethane (75 mL) was added to the solution, which was washed with an equal volume of saturated ΝaHCO3. The aqueous layer was washed with an equal volume of dichloromethane. The aqueous layer was washed with dichloromethane (30 ml) and the combined organic layers washed with an equal volume of saturated NaCl. The aqueous layer was washed with dichloromethane (30 mL) and the combined organic layers dried over Mg2SO4 and concentrated in vacuo. The residue was chromatographed on a silica gel column with a gradient of 25% ethyl acetate in hexanes to 70% ethyl acetate. The desired product (3.35 g, 82% yield, Rf=0.71 by TLC in 50% ethyl acetate in hexanes) eluted with 50% ethyl acetate.
EXAMPLE 19
Preparation of 5'-O-(dimethoxytrityl)-2 '-O-[hexyl-N-(3-oxycarbonyl-cholesteryl)amino]uridine-3'-O-(succinyl aminopropyl)-controlled pore glass.
Succinylated and capped controlled pore glass (0.3 grams) is added to 2.5 ml anhydrous pyridine in a 15 ml pear- shaped flask. DEC (0.07 grams, 0.36 mmol), TEA (100 μl, distilled over CaH2), DMAP (0.002 grams, 0.016 mmol) and 5'-O- (dimethoxytrityl)-2'-O-[hexyl-N-(3-oxycarbonyl-cholesteryl)-amino]uridine (0.25 grams, 0.23 mmol) are added under argon and the mixture shaken mechanically for 16 hours. More nucleoside (0.20 grams) is added and the mixture shaken an additional 18 hours. Pentachlorophenol (0.03 grams, 0.11 mmol) is added and the mixture shaken 9 hours. CPG is filtered off and washed successively with dichloromethane, triethylamine, and dichloromethane. CPG is then dried under vacuum, suspended in 10 ml piperidine and shaken 15 minutes. CPG is filtered off, washed thoroughly with dichloromethane and again dried under vacuum. The extent of loading is determined by spectrophotometric assay of dimethoxytrityl cation in 0.3 M p-toluenesulfonic acid at 498 nm as approximately 39 μmol/g. EXAMPLE 20
Preparation of 5'-O-(dimethoxytrityl)-2 '-O-[hexyl-N-(2,4-dinitrophenyl)amino]uridine.
5'-O-(dimethoxytrityl)-2'-O-(hexylamino)uridine (0.88 grams, 1.37 mmol) was dissolved in methanol (20 mL). 2,4-Dinitrofluorobenzene (DNFB, 0.25 grams, 1.37 mmol) was added and the mixture shaken on a mechanical shaker. The reaction was monitored by TLC. After 90 min, another 0.25 grams of DNFB was added and the reaction mixture shaken an additional 30 min, followed by addition of another 0.25 grams of DNFB. After shaking 2.5 hours, the mixture was concentrated in vacuo and chromatographed on a silica gel column, eluting with a gradient of 25% ethyl acetate in hexanes to 100% ethyl acetate. The desired product (0.51 grams, 46%) eluted with 100% ethyl acetate (Rf 0.85 by TLC). EXAMPLE 21
Preparation of 5' -O- (dimethoxytrityl) -2 ' -O- [hexyl-N- (2 , 4-dini trophenyl ) amino] uridine - 3 ' - O - ( 2 - cyanoethyl -N, N-diisopropyl)phosphoramidite .
5'-O-(dimethoxytrityl)-2'-O-[hexyl-N-(2,4-dinitrophenyl)amino]uridine (0.45 grams, 0.55 mmol) was dissolved in dry dichloromethane (12 mL). 2-Cyanoethyl N, N, N' ,N' -tetraisopropylphosphorodiamidite (380 μL, 1.2 mmol) and diisopropylamine tetrazolide (0.041 grams, 0.024 mmol) were added to the mixture, which was stirred under argon for 16 hours. The reaction mixture was then concentrated in vacuo and the residue dissolved in dichloromethane (75 mL) followed by washing with an equal volume of saturated ΝaHCO3. The aqueous layer was washed with dichloromethane (25 mL) and the combined organic layers washed with an equal volume of saturated NaCl. The aqueous layer was washed with dichloromethane (25 mL) and the combined organic layers dried over MgSO4 and concentrated. The residue was chromatographed on a silica gel column, eluting with a gradient of 20% ethyl acetate in hexanes to 100% ethyl acetate. The desired product (510 mg foam, 93% yield, Rf 0.70 by TLC) eluted with 100% ethyl acetate. 31PNMR (CDCl3) : 150.56 and 150.82 ppm.
EXAMPLE 22
Preparation of 5'-O-(dimethoxytrityl)-2 '-O-[hexyl-N-(2,4-dinitrophenyl)amino]uridine-3'-O-(succinyl aminopropyl) controlled pore glass.
Succinylated and capped controlled pore glass (0.3 grams) is added to 3 ml anhydrous pyridine in a 50 ml round-bottom flask. DEC (0.12 grams, mmol), TEA (25 μl, distilled over CaH2), DMAP (0.005 grams, 0.041 mmol) and 5'-O-(di-methoxytrityl)-2'-O-[hexyl-N-(2,4-dinitrophenyl)amino]uridine (0.21 grams, 0.26 mmol) are added under argon and the mixture shaken mechanically for 19 hours. More nucleoside (0.025 grams) is added and the mixture shaken an additional 5.5 hours. Pentachlorophenol (0.045 grams, 0.16 mmol) is added and the mixture shaken 18 hours. CPG is filtered off and washed successively with dichloromethane, triethylamine, and dichloromethane. CPG then is dried under vacuum, suspended in 15 ml piperidine and shaken for 15 minutes. CPG is filtered off, washed thoroughly with dichloromethane, and again dried under vacuum. The extent of loading is determined by spectrophotometric assay of dimethoxytrityl cation in 0.3 M p-toluenesulfonic acid at 498 nm, as approximately 29 μmol/gm.
EXAMPLE 23
Preparation of 5'-O-(dimethoxytrityl)-2 '-O-[hexyl-N-(Nα-Nimid-Di-FMOC-L-Histidyl)amino]uridine.
Nucleoside 5'-O-(dimethoxytrityl)-2'-O-(hexylamino)-uridine (0.97 g, 1.51 mmol) was dissolved in dichloromethane
(25 mL) and cooled to 0°C in an ice bath. Nα,Nimid-Di-FMOC-L-histine pentafluorophenyl ester (2.4 g, 3.1 mmol, purchased from Sigma) and 1-hydroxybenzotriazole (0.32 g, 0.24 mmol, purchased from Fluka) were added to the stirred reaction mixture stirred under argon. After 15 minutes, the ice bath was removed and the mixture stirred under argon at room temperature for 72 h. The mixture was concentrated in vacuo and chromatographed on a silica gel column, eluting with a gradient of 50% ethyl acetate in hexanes to 70% ethyl acetate in hexanes. The desired product (0.53 g, 28%) eluted with 70% ethyl acetate (Rf 0.53 by TLC in 100% ethyl acetate). EXAMPLE 24
Preparation of 5'-O-(dimethoxytrityl)-2'-O-[hexyl-N-(Nα-Nimid-Di-FMOC-L-histidyl)-amino]-uridine-3'-O-[2-cyanoethyl-N,N-diisopropyl]phosphoramidite.
5'-O-Dimethoxytrityl-2'-O-[hexyl-N-(Nc.-Nimid-Di-FMOC-L-histidyl)amino]uridine (1.9 g, 1.6 mmol) is dissolved in dry dichloromethane (20mL). 2-Cyanoethyl N, N, N' , N' -tetraisopropylphosphorodiamidite (800 μL, 2.4 mmol) and diisopropylamine tetrazolide (0.090 grams, 0.52 mmol) are added to the mixture, which is stirred under argon for 20 hours. The reaction mixture then is concentrated in vacuo and the residue dissolved in dichloromethane (75 mL). The solution is washed with an equal volume of saturated ΝaHCO3. The aqueous layer is washed with dichloromethane (20 mL) and the combined organic layers washed with an equal volume of saturated NaCl. The aqueous layer is washed with dichloromethane (20 mL) and the combined organic layers dried over MgSO4 and concentrated. The residue is chromatographed on a silica gel column, eluting with a gradient of 50% ethyl acetate in hexanes to 100% ethyl acetate. The desired product elutes with 100% ethyl acetate. EXAMPLE 25
Preparation of 5'-O-(dimethoxytrityl)-2'-O-[hexyl-N-(Nα-Nimid-Di-FMOC)-L-histidyl)amino]uridine-3'-O-[succinylaminopropyl] controlled pore glass.
Succinylated and capped controlled pore glass (dried under vacuum for 3 hours immediately before use; 0.3 grams) is added to 3 ml anhydrous pyridine in a 50 ml round-bottom flask. DEC (0.12 grams, 0.63 mmol), TEA (25 μl, distilled over CaH2), DMAP (0.005 grams, 0.04 mmol) and 5'-O-(dimethoxytrityl)-2'-O-[hexyl-N-(Nα!-Nimid-Di-FMOC)-L-histidyl)amino]-uridine (0.21 grams, 0.17 mmol) are added under argon and the mixture shaken mechanically for 19 hours. More nucleoside
(0.025 grams) is added and the mixture shaken an additional
5.5 hours. Pentachlorophenol (0.045 grams, 0.17 mmol) is added and the mixture shaken 18 hours. CPG is filtered off and washed successively with dichloromethane, triethylamine, and dichloromethane. CPG then is dried under vacuum, suspended in 15 ml piperidine and shaken 15 minutes. CPG is filtered off, washed thoroughly with dichloromethane and again dried under vacuum. The extent of loading is determined by spectrophotometric assay of dimethoxytrityl cation in.0.3 M p-toluenesulfonic acid at 498 nm. to be approximately 27 μmol/g.
EXAMPLE 26
Preparation of 5'-O-(dimethoxytrityl)-2'-O-[hexyl-N-(Ω-methylpolyethylene glycol-propionoyl)amino]uridine.
Nucleoside 5'-O-(dimethoxytrityl)-2'-O-[hexylamino]-uridine, (1 g, 1.55 mmol) is dissolved in anhydrous DMF (15 mL). 1-Hydroxybenzotriazole (0.24 g, 1.75 mmol) and polyethylene glycol-propionic acid-NHS-ester (1.23 g, 1.75 mmol) are added to the reaction mixture. The mixture is stirred under argon at room temperature for 2 hours after which it is concentrated in vacuo . Residual DMF is coevaporated with toluene. The residue is dissolved in dichloromethane (50 mL) and then washed with an equal volume saturated NaHCO3. The aqueous layer is washed with dichloromethane and the combined organic extracts washed with an equal volume saturated NaCl. The aqueous layer is washed with dichloromethane and the combined organic layers dried over MgSO4 and concentrated. The residue is chromatographed on a silica gel column, eluting with a gradient of 50% ethyl acetate in hexanes to 100% ethyl acetate. The desired product (1.08 g, 58%) eluted with 100% ethyl acetate.
EXAMPLE 27
Preparation of 5'-O-(dimethoxytrityl)-2'-O-[hexyl-N-(Ω-methylpolyethylene glycol-propionoyl)amino]uridine-3'-O-(2-cyanoethoxy-N,N-diisopropyl)phosphoramidite.
5'-O- (Dimethoxytrityl)-2'-O- [hexyl-N-(Ω-methylpolyethylene glycol-propionoyl) amino] uridine (1.04 grams, 0.87 mmol) is dissolved in dry dichloromethane (20mL). 2-Cyanoethyl N, N, N' , N' -tetraisopropylphosphorodiamidite (800 μL, 2.4 mmol) and diisopropylamine tetrazolide (0.090 grams, 0.52 mmol) are added to the mixture, which is stirred under argon for 20 hours. The reaction mixture then is concentrated in vacuo and the residue dissolved in dichloromethane (75 mL). The solution is washed with an equal volume of saturated NaHCO3. The aqueous layer is washed with dichloromethane (20 mL) and the combined organic layers washed with an equal volume of saturated NaCl. The aqueous layer is washed with dichloromethane (20 mL) and the combined organic layers dried over MgSO4 and concentrated. The residue is chromatographed on a silica gel column, eluting with a gradient of 50% ethyl acetate in hexanes to 100% ethyl acetate. The desired product elutes with 100% ethyl acetate.
EXAMPLE 28
Preparation of 5'-O-(dimethoxytrityl)-2 '-O-[hexyl-N-(Ω-methylpolyethylene glycol-propionoyl)ammo]uridine-3'-O-(succinylaminopropyl) controlled pore glass.
Succinylated and capped controlled pore glass (CPG) is dried under vacuum for 3 hours immediately before use. Controlled pore glass (0.3 grams) is added to 3 ml anhydrous pyridine in a 50 ml round-bottom flask. DEC (0.12 grams, 0.67 mmol), TEA (25 μl, distilled over CaH2), DMAP (0.005 grams, mmol) and 5'-O-(dimethoxytrityl)-2'-O-[hexyl-N-(w-methylpolyethylene glycol-propionoyl) amino] uridine (0.21 grams, 0.175 mmol) are added under argon and the mixture shaken mechanically for 19 hours. More nucleoside (0.025 grams) is added and the mixture shaken an additional 5.5 hours. Pentachlorophenol (0.045 grams, 0.17 mmol) is added and the mixture shaken 18 hours. CPG is filtered off and washed successively with dichloromethane, triethylamine, and dichloromethane. CPG then is dried under vacuum, suspended in 15 ml piperidine, and shaken 15 minutes. CPG is filtered off, washed thoroughly with dichloromethane, and again dried under vacuum. The extent of loading is determined by spectrophotometric assay of dimethoxytrityl cation in 0.3 M p-toluenesulfonic acid at 498 nm. to be approximately 18 μmol/g. EXAMPLE 29
Preparation of Macrocycle derivatized nucleoside
5'-O-(dimethoxytrityl)-2'-O-(hexylamine)uridine is treated as per the procedure of Example 3 with the macrocycle 4-{1,4,8,11-tetraza-[tri-(trifluoroacetyl)cyclotetradec-1-yl]}methyl benzoic acid-N-hydroxy succinimide ester (prepared according to Simon Jones, et. al . , Bioconjugate Chem. 1991, 2, 416) to yield the product.
EXAMPLE 30
Preparation of macrocycle derivatized uridine phosphoramidite
The nucleoside product of Example 29 is treated as per the procedure of Example 4 to yield the product.
EXAMPLE 31
Preparation of CPG derivatized with macrocycle derivatized nucleoside
The nucleoside product of Example 29 is treated as per the procedure of Example 5 to yield the product.
EXAMPLE 32
Preparation of 5'-O-(dimethoxyltrityl)-2'-O-(hexyl-N-(folate)-amino)uridine
5'-O-(Oimethoxytrityl)-2'-O-(hexylamine)uridine is treated as per the procedure of Example 3 with folic acid pentafluorophenyl ester (protected with an isobutyryl protecting group) to yield the product. EXAMPLE 33
Preparation of 5'-O-(dimethoxyltrityl)-2 '-O-[hexyl-N-(folate)-amino]uridine-3'-O-(2-cyanoethoxy-N,N-diisopropyl)phosphoramidite
The nucleoside product of Example 29 is treated as per the procedure of Example 4 to yield the product. EXAMPLE 34
Preparation of CPG derivatized with 5'-O-(dimethoxyltrityl)- 2 '-O-(hexyl-N-(folate)amino)uridine nucleoside
The nucleoside product of Example 32 is treated as per the procedure of Example 5 to yield the product.
EXAMPLE 35
Preparation of 5'-O-(dimethoxytrityl)-2'-O-{hexyl-N-[2-methoxy-6-chloro-9(Ω-amino-caproyl)acridine]amino}uridine.
6,9-Dichloro-2-methoxyacridine (Aldrich, 10 g, 36 mmol) and phenol (2.5 g) were placed together on a round-bottom flask with a stirring bar and to this 6-amino-hexanoic acid (9.3 g, 71 mmol) was added and the flask was heated to 100° (oil bath) for 2 hours. TLC (10% methanol in methylene chloride) showed complete disappearance of starting material. The reaction mixture was cooled and poured into 200 mL of methanol. The product isolates out as a yellow solid (about 10 g). This compound was then converted into its pentafluorophenyl ester.
5'-O-(Dimethoxytrityl)-2'-(hexylamino)uridine (0.5g, 0.78 mmol) is dissolved in anhydrous DMF (15 mL). 1-Hydroxybenzotriazole (0.16 grams, 1.17 mmol) and 2-methoxy-6-chloro-9-(Ω-caproyl-amino) acridine pentafluorophenyl ester (0.53 grams, 1.17 mmol) are added to the reaction mixture. The mixture is stirred under argon at room temperature for 2 h, after which it is concentrated in vacuo . Residual DMF is coevaporated with toluene. The residue is dissolved in dichloromethane (50 mL) and washed with an equal volume saturated NaHCO3. The aqueous layer is washed with dichloromethane and the combined organic extracts washed with an equal volume saturated NaCl. The aqueous layer is washed with dichloromethane and the combined organic layers dried over MgSO4 and concentrated. The residue is chromatographed on a silica gel column, eluting with a gradient of 50% ethyl acetate in hexanes to 100% ethyl acetate. The desired product elutes with 100% ethyl acetate. EXAMPLE 36
Preparation of 5'-O-(dimethoxytrityl)-2 '-O-{hexyl-N-[2-methoxy-6-chloro-9-(Ω-amino-caproyl)acridine]amino}uridine-3'-O-(2-σyanoethyl-N-N-diisopropyl) phosphoramidite.
5'-O-Dimethoxytrityl-2'-O-{hexyl-N-[2-methoxy-6-chloro-9-(w-amino-caproyl)acridine]amino}uridine (0.80 grams, 0.77 mmol) is dissolved in dry dichloromethane (20mL). 2-Cyanoethyl N ,N, N' , N' -tetraisopropylphosphorodiamidite (800 μL, 2.4 mmol) and diisopropylamine tetrazolide (0.090 grams, 0.52 mmol) are added to the mixture, which is stirred under argon for 20 hours. The reaction mixture is then concentrated in vacuo and the residue dissolved in dichloromethane (75 mL) . The solution is washed with an equal volume of saturated ΝaHCO3. The aqueous layer is washed with dichloromethane (20 mL) and the combined organic layers washed with an equal volume of saturated NaCl. The aqueous layer is washed with dichloromethane (20 mL) and the combined organic layers dried over MgSO4 and concentrated. The residue is chromatographed on a silica gel column, eluting with a gradient of 50% ethyl acetate in hexanes to 92% ethyl acetate. The desired product elutes with 100% ethyl acetate.
EXAMPLE 37
Preparation of 5'-O-(dimethoxytrityl)-2 ' -O-{hexyl-N-[2-methoxy-6-chloro-9-(Ω-aminocaproyl)acridine]amino}uridine-3'-O-(succinyl aminopropyl) controlled pore glass.
Succinylated and capped controlled pore glass (0.3 grams) is added to 3 ml anhydrous pyridine in a 50 ml round- bottom flask. DEC (0.12 grams, 0.67 mmol), TEA (25 μl, distilled over CaH2), DMAP (0.005 grams, 0.04 mmol) and 5'-O-dimethoxytrityl-2'-O-{hexyl-N-[2-methoxy-6-chloro-9-(Ω-aminocaproyl)acridine]amino}uridine (0.21 grams, 0.17 mmol) are added under argon and the mixture shaken mechanically for 19 hours. More nucleoside (0.025 grams) is added and the mixture shaken an additional 5.5 hours. Pentachlorophenol (0.045 grams, 0.17 mmol) is added and the mixture shaken 18 hours. CPG is filtered off and washed successively with dichloromethane, triethylamine, and dichloromethane. CPG is then dried under vacuum, suspended in 15 ml piperidine and shaken 15 minutes. CPG is filtered off, washed thoroughly with dichloromethane and again dried under vacuum. The extent of loading is determined by spectrophotometric assay of dimethoxytrityl cation in 0.3 M p-toluenesulfonic acid at 498 nm. to be approximately 27 μmol/g.
EXAMPLE 38
Preparation of 5'-O-(dimethoxytrityl)-2 '-O-[(hexyl-N,N-dimethyl)amino]uridine.
5'-O-(dimethoxytrityl)-2'-O-(hexylamino)uridine (0.19 grams, 0.29 mmol) is dissolved in 4 ml methanol. Sodium acetate pH 4.0 (2 ml), sodium cyanoborohydride (0.02 grams, 0.3 mmol) and 37% formaldehyde in water (300 μl) are added to the reaction mixture, which is stirred 2 hours, after which it is concentrated in vacuo . The residue is dissolved in dichloromethane (50 mL) and washed with an equal volume saturated NaHCO3. The aqueous layer is washed with dichloromethane and the combined organic extracts washed with an equal volume saturated NaCl. The aqueous layer is washed with dichloromethane and the combined organic layers dried over MgSO4 and concentrated. The residue is chromatographed on a silica gel column, eluting with a gradient of 50% ethyl acetate in hexanes to 100% ethyl acetate. The desired product (0.15 grams, 80%) elutes with 10% Methanol-90% ethyl acetate.
EXAMPLE 39
Oligonucleotides Having 3'-Alkylamino Group
3'-O-Hexyl-(N-phthalimido)-aminouridine-CPG, i.e. the 5'-O-dimethoxytrityl-3'-O-[hexyl-(Ω-N-phthalimidoamino)]-uridine-2'-O-(succinyl-aminopropyl) controlled pore glass from Example 5, was used to synthesize the following oligonucleotides:
Oligomer 49: GAC U*
Oligomer 50: GCC TTT CGC GAC CCA ACA CU
Oligomer 51: GCC TTT CGC GAC CCA ACA CU* wherein "*" denotes the 3'-0 hexylamino-modified nucleoside. Standard commercial phosphoramidites were used with the synthesis cycle times specified by the manufacturer in a 380B
ABI instrument (Applied Biosystems).
Oligomer 49 was used for structural proof of 3'-O-alkylamine-bearing oligonucleotides at the 3 '-terminal end.
It showed the expected three 31P NMR signals (-0.5 ppm, -0.25 ppm, -0,2 ppm) and seven lines in the trace aromatic base region in 1H NMR its spectrum.
Oligomer 51 was used to demonstrate the nuclease resistance offered by this the alkylamino group and also for further conjugation. The oligomer was treated with pyrenebutyric acid-N-hydroxy succinimide ester in 0.2 M NaHCO3 buffer/DMF. The product, Conjugate 1, was purified by HPLC and size exclusion methods. HPLC retention times (eluting with a gradient of 5% CH3CN for 10 minutes then 5%-40% CH3CN for 50 minutes) were as follows:
Retention Time
(min.)
Oligomer 50 25.99
Oligomer 51 25.91
Conjugate 1 49.35
The nuclease stability of Oligomer 51 and the conjugate were tested against Oligomer 50 in HeLa cytoplasmic/nuclear extracts. The cell extract was diluted 1.4 times. The final concentration of oligonucleotide was 20 μM. The half lives of the oligonucleotides were as follows:
t1/2
(hours)
Oligomer 50 1.0
Oligomer 51 3.5
Conjugate 1 3.6
The half life of phosphodiester Oligomer 50 increased 3-4 times by simple modification at the 3'-end with the hexylamino group, by itself, or by further conjugation. EXAMPLE 40
Oligonucleotides Having 2'-O-Alkylamino Group
A. The phosphoramidite from Example 4, 5'-O- (dimethoxytrityl)-2'-O-[hexyl-(Ω-N-phthalimido)amino]-uridine-3'-O-[(2-cyanoethyl)-N,N-diisopropyl]phosphoramidite was made as a 0.2 M solution in anhydrous CH3CN and used to synthesize the following oligonucleotides in an ABI DNA synthesizer, model 380 B. During the modified amidite coupling, the reaction time was increased to 10 minutes. A coupling efficiency of approximately 90% was observed. After deprotection with concentrated ammonium hydroxide (55°C, 16 hours) the oligonucleotides were purified by reverse phase HPLC and desalting column (Sephadex G-25).
Oligomer 52 (SEQ ID NO: 14): GCGTGU*CTGCG
Oligomer 53 : GAU*CT
B. GCGTGTU'CTGCG where U' is 2 '-O-[hexyl-N-(1-pyrenepropyl-carbonyl)amino uridine, Conjugate 2 (Oligomer 52 - pyrene butyrate conjugate).
To 20 O.D. of Oligomer 52 in 200 μL of 0.2 M NaHCO3 buffer, 5 ml of pyrene-butyric acid-N-hydroxy succinimide ester in an Eppendorf tube was added followed by 200 μL of DMF. The tube was shaken overnight. The reaction was purified by size exclusion and HPLC to yield 18 O.D. of product.
C. GCGTGTU"CTGCG where U" is 2'-O-[6-bromoacetamidohex-lyl]-uridine, Conjugate 3 (Oligomer 52 - bromoacetate conjugate).
To 12 O.D. of Oligomer 52 in 100 μL of 0.2 M NaHCO3 buffer, 2 mg bromoacetic acid-NHS ester (N-hydroxy succinimidyl bromoacetate) was added. After leaving the reaction to stand overnight, it was purified by size exclusion and HPLC to yield 7.5 O.D. of product.
D. GCGTGTU^CTGCG where U^ is 2 '-O-[hexyl-N-(polyethylene glycol)-propionoyl]amino uridine,
Conjugate 4 (Oligomer 52 - PEG conjugate).
To 24 O.D. of Oligomer 52 in 200 μL of 0.2 M NaHCO3 buffer, 20 mg of Polyethylene glycol propionic acid-N-hydroxy succinimide ester was added. The reaction was mechanically shaken overnight and purified by Sephadex G-25 size exclusion and chromatography to yield 22 O.D. of product.
HPLC retention times (eluting with a gradient of 5% CH3CN for 10 minutes then 5%-40% CH3CN for 50 minutes in a C- 18 Delta-Pak reverse phase column) were as follows:
Retention Time
(min.)
Oligomer 52 24.05
Conjugate 2 40.80
Conjugate 3 26.04
Conjugate 4 55.58
Changes in Tm due to pyrene conjugation were evaluated against both DNA and RNA. Tm was measured in 100 mM Na+, 10 nM phosphate, 0.1 mM EDTA, pH 7 at 4 μM strand concentration. The results were as follows:
Ta v. DNA (°C) Tm v. RNA (°C)
Oligomer 52 50.9 55.5
Conjugate 2 55.3 55.5
(4.4) (0.0)
The values in parentheses are changes in Tm compared to amino linker in oligomer 52 as a control.
EXAMPLE 41
Oligonucleotide synthesis using 2'-O-hexylamino(pyrenebutyrate)uridine phosphoramidite.
The amidite 5'-O-(dimethoxytrityl)-2'-O-[hexyl-N-(1-pyrene propyl carbonyl)amino]uridine-3'-O-(2-cyanoethyl-N,N-diisopropyl) phosphoramidite (0.2M in anhydrous acetonitrile) was used to synthesize the following oligomers, both for NMR studies:
Oligomer 54: GAU*CT
Oligomer 55: GCC GU*G TCG
(U*=2' -O-modified phosphoramidite)
These oligomers were purified trityl-on reverse-phase HPLC, detritylated in 80% acetic acid for one hour and then repurified by RP-HPLC and desalted by size-exclusion chromatography. NMR analysis showed the presence of pyrene peaks.
EXAMPLE 42
Oligonucleotide synthesis using 2 ' -O-hexylamino(dinitrophenyl)uridine phosphoramidite.
Theamidite 5'-O-(dimethoxytrityl)-2'-O-[hexyl-N-(2,4-dinitrophenyl)amino]uridine-3'-O-(2-cyanoethyl-N,N,-diisopropyl)phosphoramidite (0.18 M in anhydrous acetonitrile) was used to synthesize oligonucleotides, Oligomers 56 to 63. All are analogues of an ICAM antisense sequence. These oligomers were purified trityl-on by RP-HPLC (Waters Delta-Pak C18 column, 300 A, 7.8 mm × 30 cm, linear 50-min gradient of 5-60% acetonitrile in 0.05 M TEAA pH 7.3), detritylated in 80% acetic acid for one hour and then purified by RP-HPLC and desalted by size-exclusion chromatography. Data are summarized below:
Backbone Total Retention
(O.D.) Time
(min)
Oligomer 56 : P=O 40 39.16 GAU*CT
Oligomer 57: P=S 64 39.19 (SEQ ID NO:15)
U*GG GAG CCA TAG CGA GGC#
Oligomer 58: P=S 45 39.21 U*GG GAG CCA TAG CGA GGC
Oligomer 59: P=O 60 37.68
U*GG GAG CCA TAG CGA GGC
Oligomer 60: P=O 69 38.58
U*GG GAG CCA U*AG CGA GGC
Oligomer 61: P=O 86 32.38
TGG GAG CCA U*AG CGA GGC
(SEQ ID NO: 16)
Oligomer 62: P=O 34 35.76
U*CT GAG TAG CAG AGG AGC TC#
(SEQ ID NO: 17)
Oligomer 63 : P=S 72 43.37
U*GG GAG CCA U*AG CGA GGC#
#=Non-nucleoside 6-carbon amino linker (Glen Research) and Bold indicates nucleotides having 2'-O-methyl substitutions EXAMPLE 43
Oligonucleotide synthesis using 2'-O-[hexylamino-(cholesterol)]uridine phosphoramidite
The amidite 5'-O-dimethoxytrityl-2'-O-[hexyl-N-(3-oxycarbonyl-cholesteryl)amino]uridine-3'-O-[2-cyanoethyl-N,N,-diisopropyl]-phosphoramidite (0.2M in anhydrous aceto- nitrile/dichloromethane 2:1 v/v) was used to synthesize Oligomers 67-74. These oligomers are purified trityl-on by reverse-phase HPLC (Waters Delta-Pak C18, 300A, 7.8 mm × 30 cm, linear 55-min gradient of 5-80% acetonitrile in 0.05 M TEAA pH 7.3), detritylated in 80% acetic acid for one hour and then repurified by RP-HPLC and desalted by size-exclusion chromatography. Data are summarized below: Backbone Target Retention
Time (min)
Oligomer 67: P=O NMR 52.73 GAU*CT
Oligomer 68: P=O ICAM 49.64
U*GG GAG CCA TAG CGA GGC
Oligomer 69: P=S ICAM 51.98
U*GC CCA AGC TGG CAT CCG TCA
(SEQ ID NO: 18)
Oligomer 70: P=S CMV 52.57
U*GC GTT TGC TCT TCT TCT TGC G
(SEQ ID NO: 19)
Oligomer 71: P=S mselCAM 53.24 U*GC ATC CCC CAG GCC ACC AT
(SEQ ID NO: 20)
Oligomer 72 : P=S Raf 53.95
U*CC CGC CTG TGA CAT GCA TT
(SEQ ID NO: 21)
Oligomer 73 : P=S PKCa 51.04
GU*T CTC GCT GGT GAG TTT CA
(SEQ ID NO: 22)
Oligomer 74 : P=S ICAM 52.75 F1-UU*GG GAG CCA TAG CGA GGC
(SEQ ID NO: 23)
Fl-U = U 2'-modified with fluorescein (see Example 44).
EXAMPLE 44
Synthesis of oligonucleotides using 2 ' -O-[hexylamino- (fluorescein)] amidite.
The amidite 5'-O-dimethoxytrityl-2'-O-[hexyl-N-(5-thiocarbonyl-3,6-dipivolyl fluorescein)amino]uridine-3'-O- (cyanoethyl-N,N-diisopropyl phosphoramidite) (0.2 M in anhydrous acetonitrile) was used to synthesize Oligomer 74 (above) and Oligomers 75-82 on a 1 × 105 (Oligomer 75) or 1 × 102 (remaining Oligomers) μmol scale. These oligomers are purified trityl-on by reverse phase HPLC (Waters Delta-Pak C18, 300A, 7.8 mm × 30 cm, linear gradient of acetonitrile in 0.05 M TEAA pH 7.3), detritylated in 80% acetic acid for one hour and then repurified by RP-HPLC and desalted by size-exclusion chromatography.
Backbone Target
Oligomer 75:
GAU*CT P=O NMR
Oligomer 76:
U*GG GAG CCA TAG CGA GGC P=O ICAM
Oligomer 77:
U*GC CCA AGC TGG CAT CCG TCA P=S ICAM Oligomer 78 :
U*GC CCA AGC TGG CAT CCG TCA# P=S ICAM
Oligomer 79 :
U*GC GTT TGC TCT TCT TCT TGC G P=S CMV
Oligomer 80:
U*GC ATC CCC CAG GCC ACC AT P=S mselCAM
Oligomer 81: (SEQ ID NO: 26)
U*GC ATC CCC CAG GCC ACC A P=S mselCAM (U-CPG)
(U-CPG)=2'-O-hexylphthalimido U 6
Oligomer 82:
GU*T CTC GCT GGT GAG TTT CA P=S PKC
Where U* is U modified with fluorescein.
EXAMPLE 45
1-Adamantane Acetic Acid Pentafluorophenyl Ester
1-Adamantane acetic acid (5 g, 25.77 mmol) was dissolved in 50 mL of CH2Cl2 and to this suspension pentafluorophenyl (5 g, 27.16 mmol) was added. Dicylohexylcarbodiimide (DCC) was then added (6 g, 29.12 mmol), at which point a highly exothermic reaction set in. The reaction flask was saturated with argon, sealed and then shaken in a wrist action shaker. After 5 hours the solution was filtered in a sintered glass funnel to filter off the dicylohexylurea formed during the reaction. The methylene chloride solution was evaporated and the pale yellow solid product (9g, 97% crude product yield) obtained was used in the next condensation step. EXAMPLE 46
5'-O-Dimethoxytrityl-2'-O-[hexyl-N-(1-adamantaneacetamido)-amino]uridine
5'-O-Dimethoxytrityl-2'-O-(hexylamino)uridine (2 g, 3.15 mmol) was dissolved in 20 mL of methylene chloride. Adamantane acetic acid pentafluorophenyl ester (1.8 g from the previous step, 5 mmol crude product) was added followed by 3 mL of triethylamine. The reaction mixture was shaken for 4 hours in a wrist action shaker. TLC analysis (5% CH3OH in CH2Cl2) showed the product formation as revealed by a moving trityl positive spot. When the amine at the origin was completely consumed (5 hours) the reaction mixture was evaporated and applied to a silica column loaded with chloroform solvent (20cm × 5cm diameter). The column was eluted with chloroform (1 liter) followed by 5% CHCl3 in CH3OH. The material which showed trityl positive spots in TLC was pooled together and evaporated to give 2.5 g of the nucleoside-adamantane conjugate (98% yield). 13C analysis showed .the presence of both uridine and adamantane residues. Rf= 0.21 in 5% CH3OH in CH2Cl2.
EXAMPLE 47
5'-O-Dimethoxytrityl-2'-O-[hexyl-N-(1-adamantane acetamido)-amino]uridine-3' - O -(2-cyanoethyl-N,N'-diisopropyl) Phosphoramidite
5'-O-Dimethoxytrityl-2'-O-[hexyl-N-(1-adamantane acetamido) amino] uridine (2.4 g, 2.96 mmol) was dissolved in 20 mL of CH2Cl2. To this solution 200 mg of diisopropylamino- tetrazolide (1.16 mmol) was added followed by 3.1 mL of 2-cyanoethyl-N,N,N',N'-tetraisopropyl phosphoramidite (9.45 mmol) was added under argon atmosphere. The mixture was stirred under argon overnight after which time TLC (5% CH3OH/CH2Cl2) indicated almost complete conversion of nucleoside to its phosphoramidite. The reaction mixture was washed with saturated NaHCO3 followed by saturated NaCl solution and then dried over anhydrous MgSO4. The solution was evaporated and the foamy residue was purified in a silica column using 5% CH3OH/CHCl3 elution system to give the purified phosphoramidite (2 g, 67% yield) LP NMR: 150.741, 150.49 ppm.
EXAMPLE 48
Oligonucleotide Synthesis with Adamantane Modified Amidite
5'-O-Dimethoxytrityl-2'- O-[hexyl-N-(1-adamantane acetamido) amino] uridine phosphoramidite was dissolved in anhydrous CH3CN (100 mg of amidite for each 1 mL of solvent to give 0.1 M solution of the amidite). For the novel amidite the coupling time was extended by increasing the amidite and delivery time to 7.5 minutes and the waiting time to 6.0, thus a total of 13.5 minutes were used.
The oligonucleotides were deprotected and purified using the procedure described in Example 2. Table I summarizes the different oligonucleotides along with their HPLC retention times.
EXAMPLE 49
Table of Oligonucleotides Synthesized with their HPLC Retention Times - Incorporation of 2 '-O-(CH2)6-NHCO-O-adamantylmethyl Uridine using amidite:
SEQUENCE BB RT TARGET
(min)
U*T P=O a NMR
GAU*CT P=O 29.3 NMR
U*GG GAG CCA TAG CGA GGC P=O a ICAM
TGG GAG CCA U*AG CGA GGC P=O 26.8 ICAM
U*GC ATC CCC CAG GCC ACC P=S 31.3/ mlCAM
AT 32.0
U*GC ATC CCC CAG GCC ACC P=S 31.9 mICAM
AT-F1
U* CAG TGC CTG CGC CGC GCT P=S 31.5/ Ki-ras
CG (SEQ ID NO: 27) 32.0
U* CC GTC ATC GCT CCT CAG P=S 31.6/ H-ras
GG (SEQ ID NO: 28) 32.1
U*CC CGC CTG TGA CAT GCA P=S 31.8/ Raf
TT 32.3
a not determined HPLC conditions: Waters DeltaPak C-18 Delta Pak reverse-phase 15m 300 A column, 3.9x 300 mm size equipped with C-18 guard column; Solvent A: 50 mM TEAA, pH 7.0.; Solvent B: acetonitrile; Gradient: 0-10 min., 5% acetonitrile; 10-60 min., 5% to 60% acetonitrile linear increase.
EXAMPLE 50
cis-11-Eicosenoic Acid Pentafluorophenyl Ester
cis-11-Eicosenoic acid (Aldrich, 2 g, 6.44 mmol) was dissolved in 50 mL of THF and to this suspension 1.2 g of pentafluorophenyl (6.5 mmol) was added followed by 1.33 g of DCC. The suspension was saturated with argon, sealed with a rubber septum and then shaken in a wrist action shaker. After 4 hours a clear pale yellow solution results with creamy white precipitate. The precipitated dicyclohexylurea was filtered off, washed with methylene chloride and the combined organic solution was evaporated to give the desired product as a waxy solid (3.25 g, crude product yield). This solid was used in the next condensation step without any further purification.
EXAMPLE 51
5'-O-Dimethoxytrityl-2'-O-[hexyl-N-(cis-11-eicosenoicamido)-amino]uridine
5' -O-Dimethoxytrityl-2'-O-(hexylamino)u-idine (2 g, 3.15 mmol) was dissolved in 20 mL of methylene chloride. cis-11-Eicosenoic acid pentafluorophenyl ester (2.5 g from the previous step, 5 mmol crude product) was added followed by 3 mL of pyridine. The reaction mixture was shaken for 4 hours in a wrist action shaker. TLC analysis (5% CH3OH in CH2Cl2) showed the product formation as revealed by a trityl positive spot above the origin. When the amine at the origin was completely consumed (5 hours) the reaction mixture was evaporated and applied to a silica column loaded with chloroform solvent (20 cm × 5 cm diameter). The column was eluted with chloroform (1 liter) followed by 5% CHCl3 in CH3OH. The material which showed trityl positive spots in TLC was pooled together and evaporated to give 2.72 g of the nucleoside-eicosenoic acid conjugate (93% yield). 13C analysis showed the presence of both uridine and cis-11-eicosenoic acid residues. Rf= 0.29 in 5% CH3OH in CH2Cl2
EXAMPLE 52
5' -O-Dimethoxtrityl-2'-O-[hexyl-N-(cis-11-eicosenoic amido) amino]uridine-3'-O-(2-cyanoethyl-N,N'-diisopropyl) Phosphoramidite
The eicosenoic acid-uridine nucleoside from the previous step (2.5 g, 2.7 mmol) was dissolved in 20 mL of CH2Cl2. To this solution 200 mg of diisopropylaminotetrazolide (1.16 mmol) was added followed by 2.0 mL of 2-cyanoethyl-N,N,N',N'-tetraisopropyl phosphoramidite (6.1 mmol) was added under argon atmosphere. The mixture was stirred under argon overnight after which time TLC (5% CH3OH/CH2Cl2) indicated almost complete conversion of nucleoside to its phosphoramidite. The reaction mixture was washed with saturated NaHCO3 followed by saturated NaCl solution and then dried over anhydrous MgSO4. The solution was evaporated and the foamy residue was purified in a silica column using 5% CH3OH/CHCl3 elution system to give the purified phosphoramidite (2 g, 67% yield). As the phosphoramidite was contaminated with the H-phosphorate from the phosphitylating reagent, it was repurified in a silica column, by eluting with 8:2 EtOAc: Hexane to give 1.8 g (60% yield) of the phosphoramidite. 31P NMR: 150.74 and 150.56 ppm.
EXAMPLE 53
Oligonucleotide Synthesis with cis-11-eicosenoic acid modified amidite
5'-O-Dimethoxytrityl-2'- O-[hexyl-N-(cis-11-eicosenoic amido) amino] uridine phosphoramidite was dissolved in anhydrous CH3CN (100 mg of amidite for each 1 mL of solvent to give 0.09 M solution of the amidite). For the novel amidite the coupling time was extended by increasing the amidite and delivery time to 7.5 minutes and the waiting time to 6.0, thus a total of 13.5 minutes were used. The oligonucleotides were deprotected and purified using the procedure described in Example 2. Table II summarizes the different oligonucleotides along with their HPLC retention times . EXAMPLE 54
Table of Incorporation of 2 ' -O-(CH2)6-NHCO-Cis-11-Eicosenoic U using amidite:
SEQUENCE BB RT TARGET
(min)
U*T P=O a NMR
GAU*CT P=O a NMR
U*GG GAG CCA TAG CGA GGC P=O a ICAM
TGG GAG CCA U*AG CGA GGC P=O 17.8 ICAM
U*GC ATC CCC CAG GCC ACC P=S 55.5/ mlCAM
AT 56.4
U*GC ATC CCC CAG GCC ACC P=S 56.3/ mlCAM
AT-F1 57.3
U* CAG TGC CTG CGC CGC GCT P=S a Ki-ras
CG
U* CC GTC ATC GCT CCT CAG P=S 57.0/ H-ras
GG 57.8
U*CC CGC CTG TGA CAT GCA P=S 57.1/ Raf
TT 57.9
a not determined
HPLC conditions: Waters DeltaPak C-18 Delta Pak reverse- phasel5m 300 A column, 3.9x 300 mm size equipped with C-18 guard column; Solvent A: 50mM TEAA, pH 7.0.; Solvent B: acetonitrile; Gradient: 0-10 min., 5% acetonitrile; 10-60 min., 5% to 60% acetonitrile linear increase.
EXAMPLE 55
5'-O-Dimethoxytrityl-2'-O-[hexyl-N-(N-biotinyl-6-aminocaproyl)amino]uridine
5'-O-Dimethoxytrityl-2'- O-(hexylamino)uridine (1.05 g, 1.66 mmol) was dissolved in 20 mL of methylene chloride. N-Biotinyl-6-amino caproic acid (0.75 g, Fluka, 1.65 mmol) was added followed by 1 mL of pyridine. The reaction mixture was shaken for 4 hours in a wrist action shaker. The white suspension of the biotin reagent completely dissolved into solution by this time, TLC analysis (5% CH3OH in CH2Cl2) showed the product formation as revealed by an upper trityl positive spot above the origin. When the amine at the origin was completely consumed (5 hours) the reaction mixture was evaporated and applied to a silica column loaded with chloroform solvent (20 cm x 5 cm diameter). The column was eluted with chloroform (1 liter) followed by 5% CHCl3 in CH3OH
(1 liter), then followed by 10% CH3OH in CHCl3. The material, which elutes out with 10% CH3OH, showed trityl positive spots in TLC was pooled together and evaporated to give 1.53 g of the nucleoside-biotin conjugate (98% yield). 13C analysis showed the presence of both uridine and biotin residues. Rf= 0.214 in 10% CH3OH in CH2Cl2.
EXAMPLE 56
5'-O-Dimethoxytrityl-2'-O-[hexyl-N-(N-biotinyl-6-aminocaproyl)amino]uridine 3'-O- (2-cyanoethyl-N,N'-diisopropyl) Phosphoramidite
The biotin-uridine nucleoside from the previous step was dissolved in 20 mL of CH2Cl2. To this solution 100 mg of diisopropylaminotetrazolide (.58 mmol) was added followed by 1.0 mL of 2-cyanoethyl-N,N,N',N'-tetraisopropylphosphoramidite (3.05 mmol) was added under argon atmosphere. The mixture was stirred under argon overnight after which time TLC (5% CH3OH/CH2Cl2) indicates almost complete conversion of nucleoside to its phosphoramidite. The reaction mixture was washed with saturated NaHCO3 followed by saturated NaCl solution and then dried over anhydrous MgSO4. The solution was evaporated and the foamy residue was purified in a silica column using 100% ethyl acetate elution system to give the purified phosphoramidite. EXAMPLE 57
5-O-Dimethoxytrityl-3'-O-[hexyl-N-(N-biotinyl-6-aminocaproyl)-amino]uridine
5'-O-Dimethoxytrityl-3'- O-(hexylamino)uridine (0.53 g, 0.83 mmol) was dissolved in 10 mL of methylene chloride. N-Biotinyl-6-aminocaproic acid (0.75 g, Fluka, 1.65 mmol) was added followed by 0.5 mL of pyridine. The reaction mixture was shaken for 4 hours in a wrist action shaker. The white suspension of the biotin reagent was completely dissolved into solution by this time. TLC analysis (10% CH3OH in CH2Cl2) showed the product formation as revealed by an upper trityl positive spot above the origin. When the amine at the origin was completely consumed (5 hours) the reaction mixture was evaporated and applied to a silica column loaded with chloroform solvent (20 cm × 5 cm diameter). The column was eluted with chloroform (1 liter) followed by 5% CHCl3 in CH3OH (1 liter). The material, which elutes out with 10% CH3OH, showed trityl positive spots in TLC was pooled together and evaporated to give 0.6 g of the nucleoside-biotin conjugate and biotin residues. Rf= 0.21 in 10% CH3OH in CH2Cl2.
EXAMPLE 58
5'-O-Dimethoxytrityl-3'-O-[hexyl-N-(N-biotinyl-6-aminocaproyl)amino]uridine-2'-O-(succinylaminopropyl) Controlled Pore
Glass
Succinylated/capped aminopropyl controlled pore glass was dries under vacuum for 3 hours immediately before use. A portion (0.3 g, 24 μmol) was added to 3 mL anhydrous pyridine in a 50 mL round-bottom flask. DEC (0.12 g, 0.63 mmol), TEA
(25 μL, distilled over CaH2). DMAP (0.005 g, 40 μmol) and 5'-O-(dimethoxytrityl)-3'-O-[hexyl-N-(N-biotinyl-6-aminocaproyl)amino]uridine (0.22 g, 0.22 mmol) were added under argon and the mixture shaken mechanically for 19 hours. More nucleoside (0.025 g) was added and the mixture shaken for an additional 5.5 hours. Pentachlorophenol (0.045 g, 0.168 mmol) was add and the mixture shaken for 18 hours. CPG was filtered off and washed successively with dichloromethane, triethylamine, and dichloromethane. The resulting CPG was then dried under vacuum, suspended in 15 mL piperidine and shaken 30 minutes. CPG was filtered off, washed thoroughly with dichloromethane and again dried under vacuum. The extent of loading (determined by spectrophotometric assay of dimethoxytrityl cation in 0.3 M p-toluenesulfonic acid at 498 nm) was approximately 36 μmol/g. The product solid support was subsequently used to synthesize the oligomers, containing biotin at the 3' nucleotide unit. EXAMPLE 59
Oligonucleotide Synthesis with Biotin Modified Amidite and Control Pore Glass
5'-O-Dimethoxytrityl-3'-O-[hexyl-N-(N-biotinyl-6-amino-caproyl)amino]uridine nucleoside phosphoramidite was dissolved in anhydrous CH3CN (100 mg of amidite for each 1 mL of solvent to give 0.08-0.09 M solution of the amidite). For the novel amidite the coupling time was extended by increasing the amidite and delivery time to 7.5 minutes and the waiting time to 6.0, thus a total of 13.5 minutes were used.
The oligonucleotides were deprotected and purified using the procedure described in Example 2. The controlled pore glass containing biotin was used to synthesize 3 '-biotin containing oligonucleotides.
EXAMPLE 60
1-2-Di-O-hexadecyl-rac-glycerol-succinimidyl-carbonate
1,2-Di-O-hexadecyl-rac-glycerol (2g, 3.69 mmol) was dissolved in 3 mL of CH2Cl2 and to this solution disuccinimidyl carbonate (DSC) (1.42 g, 5.54 mmol) was added. Triethylamine was then added (2 mL, 14.3 mmol), followed by 20 mL of anhydrous acetonitrile. The reaction flask was saturated with argon, sealed and then shaken in a wrist action shaker. After 8 hours the reaction mixture was evaporated. The residue was dissolved in CH2Cl2 (100 mL), washed with saturated NaHCO3 solution followed by saturated NaCl solution and the organic layer was dried over anhydrous MgSO4. The solid residue (3.5 g) was used in the next step to condense with the amine. 13C NMR confirms the complete conversion of 1,2-di-O-hexadecyl-rac- glycerol to the corresponding succinimidyl carbonate. EXAMPLE 61
5'-O-Dimethoxytrityl-2'-O-[hexyl-N-(carbonoyl1,2-di-O-hexadecyl-rac-glycerol)amino]uridine
5'-O-Dimethoxytrityl-2'- O-(hexylamino)uridine (2 g, 3.15 mmol) was dissolved in 20 mL of methylene chloride. 1,2-Di-O-hexadecyl-rac-glycerol succinimidyl carbonate (3.0 g from the previous step, 5 mmol crude product) was added followed by 3 mL of pyridine. The reaction mixture was shaken for 4 hours in a wrist action shaker. TLC analysis (5% CH3OH in CH2Cl2) showed the product formation as revealed by a moving trityl positive spot. When the amine at the origin was completely consumed (5 hours) the reaction mixture was evaporated and applied to a silica column loaded with chloroform solvent (20 cm × 5 cm diameter). The column was eluted with chloroform (1 liter) followed by 5% CHCl3 in CH3OH . The material which showed trityl positive spots in TLC was pooled together and evaporated to give 3.0 g of the nucleoside-lipid conjugate (98% yield). 13C analysis showed the presence of both uridine and lipid residues.
EXAMPLE 62
5'-O-Dimethoxytrityl-2'-O-[hexyl-N-(carbonoyl1,2-di-O-hexadecyl-rac-glycerol-succinimidyl-carbonate]-3'-O-(2-cyanoethyl-N,N'-diisopropyl) Phosphoramidite
The lipid-uridine nucleoside from the previous step was dissolved in 20 mL of CH2Cl2. To this solution 200 mg of diisopropylaminotetrazolide (1.16 mmol) was added followed by 1.55 mL of 2-cyanoethyl-N,N,N',N'-tetraisopropyl phosphoramidite (4.75 mmol) was added under argon atmosphere. The mixture was stirred under argon overnight after which time TLC (5% CH3OH/CH2Cl2) indicated almost complete conversion of nucleoside to its phosphoramidite. The reaction mixture was washed with saturated NaHCO3 followed by saturated NaCl solution and then dried over anhydrous MgSO4. The solution was evaporated and the foamy residue was purified in a silica column using 5% CH3OH/CHCl3 elution system to give the purified phosphoramidite.
EXAMPLE 63
Oligonucleotide Synthesis with Lipid Modified Amidite
5'-O-Dimethoxytrityl-2'- O-[hexyl-N-(carbonoyl-1,2-di-O-hexadecyl-rac-glycerol)amino]uridine phosphoramidite was dissolved in anhydrous CH3CN (100 mg of amidite for each 1 mL of solvent to give 0.08-0.09 M solution of the amidite). For the novel amidite the coupling time was extended by increasing the amidite and delivery time to 7.5 minutes and the waiting time to 6.0, thus a total of 13.5 minutes were used. The oligonucleotides were deprotected and purified using the procedure described in Example 2.
EXAMPLE 64
Oligonucleotide Synthesis
5'-O-Dimethoxytrityl-2'- O-[hexyl-N-(1-pyrene butyroyl) amino]uridine phosphoramidite was dissolved in anhydrous CH3CN
(100 mg of amidite for each 1 mL of solvent to give 0.08-0.09
M solution of the amidite). For the novel amidite the coupling time was extended by increasing the amidite and delivery time to 7.5 minutes and the waiting time to 6.0 minutes, hence using a total of 13.5 minutes.
The oligonucleotides were deprotected and purified using the procedure described in Example 2. The Table below summarizes the different oligonucleotides (ICAM, ras, raf and PKC-a oligonucleotides). Table of Incorporation of 2'-O-(CH2)6-NHCO-butyryl pyrene U using amidite
SEQUENCE BB RT TARGET
(min)
U*T P=O 40.66 NMR
U*GG GAG CCA TAG CGA GGC P=O a ICAM
TGG GAG CCA U*AG CGA GGC P=O a ICAM
U*GC ATC CCC CAG GCC ACC P=S 30.00, mlCAM
AT 30.05
U*GC ATC CCC CAG GCC ACC P=S 30.29, mlCAM
AT-3'-aminolink 31.25
U* CAG TGC CTG CGC CGC GCT P=S 30.47, Ki-ras
CG 31.32
U* CC GTC ATC GCT CCT CAG P=S 30.90, H-ras
GG 31.66
U*CC CGC CTG TGA CAT GCA P=S 31.54/ Raf
TT 32.19
U*GT TCT CGC TGG TGA GTT P=S 30.96/ PKC-a
TCA 31.86
a not determined
HPLC conditions: Waters DeltaPak C-4 Delta Pak reverse-phase15m 300 A column, 3.9x 300 mm size equipped with C-18 guard column; Solvent A: 50mM TEAA, pH 7.0.; Solvent B:
acetonitrile; Gradient: 0-10 min., 5% acetonitrile; 10-60 min., 5% to 60% acetonitrile linear increase.
EXAMPLE 65
Incorporation of 2'-O-(CH2)6-NHCO-cholesterol Uridine at 5'-End of Oligonucleotides Using Amidites
Synthesis:
Oligonucleotides were synthesized on an Expedite Nucleic Acid Synthesis System (Millipore Corp., Bedford, MA) . Two 1-μmol syntheses or a single 15 μmol synthesis was performed for each oligonucleotide. Standard DNA synthesis conditions were used except during coupling of the modified amidite which was accomplished as follows: The novel amidite was dissolved in CH2Cl2/CH3CN 50/50 (0.08-0.1M). For 10 μmol syntheses, a 6-min wait step was added to the coupling cycle, which was repeated once. For 1 μmol phosphodiester syntheses, the coupling step was also extended for 6 min, with periodic addition of fresh amidite. For 1 μmol phosphorothioate syntheses, the coupling step was extended for 13 min, with periodic addition of fresh amidite .
Purification:
After standard cleavage from CPG and deprotection
(ammonium hydroxide at 55 °C for 16-24 hours), oligonucleotides were trityl-on purified by preparative HPLC to remove failure sequences. HPLC conditions: Waters Delta-Pak C4 column, 7.8 mm × 30 cm, 300 A, 15 u; 2.5 ml/min flow rate using a gradient of 5-80% AcCN in 50mM triethylammonium acetate pH 7.0 over 50 min. Following lyophilization, oligonucleotides were detritylated for 45 min in 80% acetic acid and lyophilized again. Oligonucleotides were then further purified by size exclusion on G-25 columns to remove salts and the trityl group.
Analysis :
Except for 8002, oligonucleotides were analyzed by HPLC using a gradient analogous to the one above and a Waters Delta-Pak C4 column (3.9 mm x 30 cm) with a flow rate of 1.5 ml/min over 50 min. 8002 was analyzed using a gradient of 5-60% AcCN. Purified phosphorothioate oligonucleotides appeared as two peaks by HPLC, phosphodiesters as one peak. Oligonucleotides were further analyzed by electrophoresis on 20% polyacrylamide denaturing (7M urea) gels. All were predominantly single bands of the appropriate size compared to standards. Gel analysis of 8012 (loaded without any pretreatment) shows a very high band, presumably the tetrameric form of this oligonucleotide, plus a faint band where one would expect a monomeric 8mer+cholesterol to run.
(The parent compound, 5320, is known to form a G-quartet structure.) Some oligonucleotides were also analyzed by capillary electrophoresis. Selected oligonucleotides have been analyzed by electrospray mass spectrometry.
Results are shown in the following Table were * indicated site of selected modification. SEQUENCE TYPE HPLC RETENTION TARGET
TIME (min)
U*GGGAGCCATAGCGAGGC P=0 54.65 ICAM
U*GCCCAAGCTGGCATCCGTCA P=S 45.77, 46. .44 ICAM
U*GCGTTTGCTCTTCTTCTTGCG P=S 45.35, 46. .03 CMV
U*GCATCCCCCAGGCCACCAT P=S 56.74, 57. .65 mlCAM U*CCCGCCTGTGACATGCATT P=S 46.69, 47. .25 RAF
U*TTAGGATTCGTGCTCATGG P=S 47.71, 48, ,32 HCV
(SEQ ID NO: 29)
U*GTTCTCGCTGGTGAGTTTCA P=S 46.78, 47. .58 PKCα
(SEQ ID NO: 30)
U*GGGAGCCATAGCGAGGC P=S not det'd HIV
U*TGGGGTT P=S 48.46, 49. .04 HIV
Example 66
Incorporation of 2 '-O-(CH2)6-NHCO-cholesterol Uridine at nonterminal positions of oligonucleotides using amidite
Oligonucleotides incorporating 2'-O-(CH2)6-NHCO-cholesterol at nonterminal (not at either the 5' or the 3' terminus of the oligonucleotide) were synthesized at a 1 μmol syntheses scale, analyzed and purified as per the procedures of Example 65.
Results are shown in the following Table were * indicated site of selected modification.
SEQUENCE TYPE HPLC RETENTION TARGET TIME (min)
TGGGAGCCAU*AGCGAGGC P=O 42.21 ICAM
GU*TCTCGCTGGTGAGTTTCA P=S not det'd PKCα
Example 67
Incorporation of 3 '-O-(CH2)6-NHCO-cholesterol Uridine at 3' end of oligonucleotides using modified CPG
Cholesterol-modified CPG was packed into screw-top CPG columns (Glen Research). Oligonucleotides were synthesized on a 1-μmol syntheses scale, analyzed and purified as in
Example 65 except that standard DNA synthesis conditions were used for all couplings.
Results are shown in the following Table were * indicated site of selected modification. SEQUENCE TYPE HPLC RETENTION TARGE'
TIME (min)
GCCTTTCGCGACCCAACACU* P=S 48.37 HCV
GCCTTTCGCGACCCAACACU* P=O 50.18 HCV
TGCATCCCCCAGGCCACCAU* P=O 47.01 mlCAM
(SEQ ID NO: 31)
GTGCTCATGGTGCACGGTCU* P=S 49.97 HCV
(SEQ ID NO: 32)
TGCATCCCCCAGGCCACCAU* P=S =59.5 mlCAM Example 68
Incorporation of 2'-O-(CH2)6-NHCO-cholesterol Uridine at 3 'end of oligonucleotides using modified CPG
Cholesterol-modified CPG was packed into screw-top CPG columns (Glen Research) . Oligonucleotides were synthesized on a l-μmol syntheses scale, analyzed and purified as in Example 65 except that standard DNA synthesis conditions were used for all couplings .
Results are shown in the following Table were * indicated site of selected modification.
SEQUENCE TYPE HPLC RETENTION TARGET TIME (min)
TGCATCCCCCAGGCCACCAU* P=O 47.03 ICAM
Example 69
Double Incorporation of Cholesterol by placement of(2'-O-(CH2)6-NHCO-cholesterol Uridine on 5' end and 3'-O-(CH2)6-NHCO-cholesterol Uridine on 3 ' end
Cholesterol-modified CPG was packed into screw-top CPG columns (Glen Research). Oligonucleotides were synthesized on a 1-μmol syntheses scale, analyzed and purified as in
Example 65 except that the extended coupling step for the cholesterol amidite (see Example 65) was repeated once.
Results are shown in the following Table were * indicated site of selected modification.
SEQUENCE TYPE HPLC RETENTION TARGET TIME (min)
U*GCATCCCCCAGGCCACCAU* P=S 54.31 ICAM
(SEQ ID NO:33)
U*GCATCCCCCAGGCCACCAU* P=O 52.54 ICAM Example 70
Incorporation of Cholesterol and Aminohexyl Modifications into
2'F Chimeric Oligonucleotides
The parent oligonucleotide, complementary to messenger RNA of PKCα, is a chimeric phosphorothioate oligonucleotide having a central deoxyribonucleotide region that is "flanked" on both the 5' and the 3' sides with region that have 2'-deoxy-2'-fluoro nucleotides. These compound are alternately referenced as "gapped" oligonucleotides. The central "gapped" regions are shown in underlines in the Table below with the "flanks" (or alternatively the "wings") shown in unmodified type.
The oligonucleotides were synthesized, analyzed and purified as in Example 65, except for the following: Concentration of all amidites was 0.1 M. Two l-μmol syntheses were performed for each oligonucleotide. The coupling step was extended 6 min, with periodic addition of fresh amidite; this extended coupling step was repeated once for the cholesterol amidite coupling. Trityl-on HPLC purification of Compound ID #9532 was accomplished using a linear gradient of 5-40% AcCN over 50 min. After detritylation and purification by size-exclusion, it was analyzed using a similar analytical-scale HPLC procedure gel and capillary electrophoresis. Purified compound ID #9535 appears as two peaks by HPLC, others as one peak. Compound ID#s 9532 and 9534 contained undeprotected 3'-hexylamine; probably about 20% according to previous results (phthalimide is the protecting group).
U1* = 3'-O-(CH2)6-NH2U
U2* = 3'-O-(CH2)6-NHCO-cholesterol U
U3* = 2'-O-(CH2)6-NHCO-cholesterol U
Results are shown in the following Table were * indicated site of selected modification. SEQUENCE HPLC RETENTION
TIME (min)
UGUUCUCGCTGGTGAGUUUCAU 34.5
(SEQ ID NO: 34)
UGUUCUCGCTGGTGAGUUUCAU1* not determined
UGUUCUCGCTGGTGAGUUUCAU2* 48
U3*GUUCUCGCTGGTGAGUUUCAU2* 46.5, 47.5 U3*GUUCUCGCTGGTGAGUUUCAU 46.5, 47.5
EXAMPLE 71
5' -O-Dimethoxytrityl-3' -O - [hexyl- (omega-N-phtalimido)amino]uridine-2'-O-(2-cyanoethyl-N,N-diisopropyl) Phosphoramidite
The 5'-dimethoxytrityl-3'-O-[hexyl-(omega-N-phthalimido)-amino]uridine (2 g, 2.6 mmol) was dissolved in 20 mL anhydrous CH2Cl2. To this solution diisopropylaminotetrazolide (0.2 g, 1.16 mmol) and 2.0 mL 2-cyanoethyl-N,N,N',N'-tetraisopropyl phosphoramidite (6.3 mmol) were added and stirred overnight. TLC (1:1 EtOAc/hexane) showed complete disappearance of starting material. The reaction mixture was transferred with CH2Cl2 and washed with saturated NaHCO3 (100 mL), followed by saturated NaCl solution. The organic layer was dried over anhydrous Na2SO4 and evaporated to yield 3.8 g of a crude product, which was purified in a silica column (200 g) using 1:1 hexane/EtOAc to give 1.9 g (1.95 mmol, 74% yield) of the desired phosphoramidite.
Sequence (3'→5') Features of Sequence
GAU3*CT P=O, 2' -5' Linkage
GCG TGU3* CTG GG P=O, 2' -5' Linkage (SEQ ID NO: 35)
GCG UGU3* CUG CG P=O, 2' -5' Linkage, Chimera (SEQ ID NO: 36) having 2 ' -OMe flanks EXAMPLE 72
NMR and HPLC Analysis of 5'-3 ' versus 5'-2' Intemucleotide Linkages and 2' substituents versus 3' substituents
The 400MHz Η spectrum of oligomer d(GAU2*CT), where U2= 2'-O-aminohexyluridine showed 8 signals between 7.5 and 9.0 ppm corresponding to the 8 aromatic protons. In addition, the anomeric proton of U* appears as a doublet at 5.9 ppm with Jι'/2 ,= 7.5Hz, indicative of C2'-endo sugar puckering. The corresponding 2' -5' linked isomer shows a similar structure with J1',2'= 3.85 Hz at 5.75 ppm, indicating an RNA type sugar puckering at the novel modification site favorable for hybridization to an mRNA target. The proton spectrum of the oligomer d(GACU3*), where U3*=3'-O- hexylamine, showed the expected 7 aromatic proton signals between 7.5 and 9.0 ppm and the anomeric proton doublet at 5.9 ppm with J1',2'= 4.4 Hz. This suggests more of a C3'-endo puckering for the 3 ' -O-alkylamino compounds compared to their 2' analogs. 31P NMR of these oligonucleotides showed the expected 4 and 3 signals from the intemucleotide phosphate linkages for d(GAU*CT) and d(GACU*), respectively. 3'-5' linked vs. 2'-5' linked have different retention times in RP HPLC and hence different lipophilicities, implying potentially different extent of interactions with cell membranes.
EXAMPLE 73
2'-5' Intemucleotide Linked Oligonucleotide Conjugation Chemistry
The oligonucleotides 9274 and 9518 (20 ODs each) were dried and re-dissolved in 0.2M NaHCO3 buffer (200 μL) in an eppendorf tube. 5 mg of pyrene butyric acid-N-hydroxy succinimide ester was dissolved in 400 μL anhydrous DMF. 200 μL of this solution was added to each of the eppendorf tubes and vortexed and left to stand overnight. The reaction mixtures were passed through a g-25 column to remove the excess reagent, an then purified by Reverse-Phase HPLC. The retention times of the starting material and the conjugates are summarized below: Sequence (3'→5') Retention Time
(min)
GAU3CT 23.85
GCG TGU3* CTG GG 24 . 99
pyrene conjugate 39.00
of 9274
pyrene conjugate 40.05
of 9518
HPLC conditions: Waters DeltaPak C-18 Delta Pak reverse- phase15m 300 Å column, 3.9x 300 mm size equipped with C-18 guard column; Solvent A: 50mM TEAA, pH 7.0.; Solvent B: acetonitrile; Gradient: 0-10 min., 5% acetonitrile; 10-60 min., 5% to 40% acetonitrile linear increase.
EXAMPLE 74
Tm Analysis of 2' -5' v. 3 '-5' Connected Oligonucleotides and their Conjugates
Thermal melts were done as per the method of Procedure B(1) (b) . Oligonucleotide identity is as follows:
Oligonucleotide 31-A is a normal 3' -5' linked phosphodiester oligodeoxyribonucleotide of the sequence d(GGC
TGU* CTG CG) (SEQ ID NO: 37) where the * indicates the attachment site of either a 2'-aminolinker or a 2'-aminolinker plus pyrene.
Oligonucleotide 31-B is a normal 3 '-5' linked phosphodiester oligoribonucleotide of the sequence d(GGC TGU* CTG CG) where the * indicates the attachment site of either a 2'-aminolinker or a 2'-aminolinker plus pyrene. Each of the ribonucleotides of the oligonucleotide, except the one bearing the * substituent, are 2'-O-methyl ribonucleotides.
Oligonucleotide 31-C is has 2' -5' linkage at the * position in addition to either a 3'-aminolinker or a 3'-aminolinker plus pyrene at this site. The remainder of the oligonucleotide is a phosphodiester oligodeoxyribonucleotide of the sequence d(GGC TGU* CTG CG). The base oligonucleotide
(no 2'-aminolinker) was not included in the study. OLIGONUCLEOTIDE MODIFICATION DNA ΔTm RNA ΔTm
TARGET TARGET
31-A none 52.2 54.1
2'-aminolinker 50.9 55.5
plus pyrene 55.3 4.4 55.5 0
31-B none 51.5 72.3
2'-aminolinker 49.8 69.3
plus pyrene 50.3 0.4 67.7 -1.6
31-C none NA
3'-aminolinker 42.7 51.7
plus pyrene 43.1 -.3 46.3 -5.4
The 2' -5' linkages demonstrated a higher melting temperature against an RNA target compared to a DNA target .
EXAMPLE 75
2 ' -O-(Propylphthalimide)adenosine and 3'-O-(Propylphthalimide)adenosine
To a solution of adenosine (20.0 g, 75 mmol) in dry dimethylformamide (550 ml) at 5°C was added sodium hydride (60% oil, 4.5 g, 112 mmol). After one hour, N-(3-bromopropyl)phthalimide (23.6 g, 86 mmol) was added and the temperature was raised to 30°C and held for 16 hours. Ice is added and the solution evaporated in vacuo to a gum. The gum was partitioned between water and ethyl acetate (4 × 300 ml). The organic phase was separated, dried, and evaporated in vacuo and the resultant gum chromatographed on silica gel
(95/5 CH2Cl2/MeOH) to give a white solid (5.7 g) of the 2'-O- (propylphthalimide)adenosine. Those fractions containing the
3'-O-(propylphthalimide)adenosine were rechromatographed on silica gel using the same solvent system.
Crystallization of the 2'-O-(propylphthalimide)adenosine fractions from methanol gave a crystalline solid, m.p. 123-124°C. 1H NMR (400 MHz: DMSO-d6) δ 1.70(m, 2H, CH2), 3.4-3.7 (m, 6H, C5', CH2, OCH2, Phth CH2) , 3.95 (q, 1H, C4.H), 4.30 (q, 1H, C5,H), 4.46 (t, 1H, C2,H), 5.15 (d, 1H, C3.OH) , 5.41 (t, 1H, C5.OH) , 5.95 (d, 1H, C1,H) 7.35 (s, 2H, NH2), 7.8 (brs, 4H, Ar), 8.08 (s, 1H, C2H) and 8.37 (s, 1H, C8H). Anal. Calcd. C2ιH22N606: C, 55.03; H, 4.88; N, 18.49. Found: C, 55.38; H, 4.85; N, 18.46.
Crystallization of the 3'-O-(propylphthalimide)adenosine fractions from H2O afforded ana analytical sample, m.p. 178- 179°C. 1H NMR (400 MHz: DMSO-d6) δ 5.86 (d, 1H, H-l'),
EXAMPLE 76
2 ' -O- (Propylphthalimide) -N6-benzoyladenosine
2' -O- (Propylphthalimide) adenosine was treated with benzoyl chloride in a manner similar to the procedure of Gaffney, et al . , Tetrahedron Lett . 1982, 23 , 2257. Chromatography on silica gel (ethyl acetate-methanol) gives the title compound. Anal. Calcd. C28H26N607: C, 60.21; H, 4.69; N, 15.05. Found: C, 59.94; H, 4.66; N, 14.76.
EXAMPLE 77
2 ' - O -(Propylphthalimide)-5'-O-dimethoxytrityl-N-benzoyladenosine
To a solution of 2'-O-(propylphthalimide)-N6-benzoyladenosine (4.0 g) in pyridine (250 ml) was added 4,4'-dimethoxytrityl chloride (3.3 g). The reaction was stirred for 16 hours. The reaction was added to ice/water/ethyl acetate, the organic layer was separated, dried, and concentrated in vacuo and the resultant gum chromatographed on silica gel (ethyl acetate-methanol triethylamine) to give the title compound. Anal. Calcd. C49H44N6O9: C, 68.36; H, 5.15; N, 9.76. Found: C, 68.16; H, 5.03; N, 9.43.
EXAMPLE 78
N6-Benzoyl-5'-O-dimethoxytrityl-2'-(propylphthalimide)-3 ' -O-(N,N-diisopropyl-β-cyanoethyl)adenosine Phosphoramidite
2'-O-(Propylphthalimide)-5'-O-dimethoxytrityl-N6-benzoyladenosine was treated with (β-cyanoethoxy) chloro-N,N- diisopropyl) aminophosphane in a manner similar to the procedure of Seela, et al . , Biochemistry 1987, 26, 2233. Chromatography on silica gel (EtOAc/hexane) gave the title compound as a white foam. 31P NMR (CD3CN) 150.88, 151.22. EXAMPLE 79
2'-O-(Propylamino)adenosine
A solution of 2'-O-(propylphthalimide)adenosine (8.8 g, 19 mmol), 95% ethanol (400 ml) and hydrazine (10 ml, 32 mmol) was stirred for 16 hrs at room temperature. The reaction mixture was filtered and filtrate concentrated in vacuo. Water (150 ml) was added and acidified with acetic acid to pH 5.0. The aqueous solution was extracted with EtOAc (2 × 30 ml) and the aqueous phase was concentrated in vacuo to afford 7.1 g (95%) of the titled compound as a HOAc salt. 1H NMR (200 MHz, DMSO-d6) δ 1.70 (m, 2H, CH2), 2.76 (m, 2H, CH2NH2), 3.55-3.67 (m, 4H, C5.CH2, OCH2) , 3.00 (q, 1H, C4,H), 4.30 (q, 1H, C3,H), 4.47 (t, 1H, C2.H), 6.0 (d, 1H, C11H),
7.39 (s, 2H, NH2) and 8.16 (s, 1H, C2H). EXAMPLE 80
2'-O-[3-(N-trifluoroacetamido)propyl]adenosine
A solution of 2'-O-(propylamino)adenosine in methanol (50 ml) and triethylamine (15 ml, 108 mmol) was treated with ethyl trifluoroacetate (18 ml, 151 mmol). The reaction was stirred for 16 hrs and then concentrated in vacuo and the resultant gum chromatographed on silica gel (9/1, EtOAc/MeOH) to give the title 3.3 g of the compound (54%). m.p. 200-201°C (CH3CN). 1H NMR (200 MHz, DMSO-d6) δ 1.7 (m, 2H, CH2) , 3.2 (m, 2H, CH2NHCO), 3.37-3.67 (m, 4H, C5.CH2, OCH2), 4.00 (q, 1H, C4,H), 4.35 (q, 1H, C3.H), 4.49 (t, 1H, C2,H), 5.26 (d, 1H, C3,OH), 5.43 (t, 1H, C5,OH), 6.02 (d, 1H, C1,H), 7.38 (s, 2H, NH2), 8.16 (s, 1H, C2H), 8.40 (s, 1H, C8H), 9.34. (s, 1H, NHCO). 19F NMR (200 MHz, DMSO) δ -108.76. Anal. Calcd. for C15H19F3N6O5 : C, 42.86; H, 4.56; N, 19.99. Found: C, 43.10; H, 4.52; N, 20.03.
EXAMPLE 81
N6- (Dibenzoyl) -2' -O- [3- (N-trifluoroacetamido)propyl] adenosine
2 ' -O-- [3- (N-trifluoroacetamido) propyl] adenosine is treated as per Example 76 using a Jones modification wherein tetrabutylammonium fluoride is utilized in place of ammonia hydroxide in the work up. The crude product was purified using silica gel chromatography (EtOAc→EtOAc/MeOH l/l) to give the title compound. 1H NMR (200 MHz, DMSO-d6) δ 1.7 (m, 2H, CH2), 3.2 (m, 2H, CH2NHCO), 3.45-3.68 (m, 4H, C5,CH2, OCH2), 4.03 (q, 1H, C4,H), 4.37 (q, 1H, C3.H), 4.53 (t, 1H, C2,H), 5.18 (d, 1H, C3,OH), 5.34 (d, 1H, C3,OH), 6.17 (d, 1H, C1,H), 7.45-7.83 (m, 1H, Ar), 8.73 (s, 1H, C2H), 8.90 (s, 1H, C8H) , 9.37. (s, 1H, NHCO). 19F NMR (200 MHz, DMSO) δ -108.76. Anal. Calcd. for C28H27F3N6O7 : C, 55.41; H, 4.33; N, 13.37. Found: C, 55.16 H, 4.24; N, 13.09.
EXAMPLE 82
N6-(Dibenzoyl)-5'-O-(dimethoxytrityl)-2'-O-[3-(N-trifluoroacetamido)propyl]adenosine
4,4'-Dimethoxytrityl chloride (3.6 g, 10.0 mmol.) was added to a solution of N6-(dibenzoyl)-2'-O-[3-(N-trifluoroacetamido) propyl) adenosine in pyridine (100 ml) at room temperature and stirred for 16 hrs. The solution was concentrated in vacuo and chromatographed on silica gel (EtOAc/TEA 99/1) to give the title compound. 1H NMR (200 MHz, DMSO-d6) δ 1.74 (m, 2H, CH2), 3.23 (m, 2H, CH2NHCO), 3.60-3.73 (m, 10H, ArOCH3,C5.CH2, OCH2) , 4.09 (m, 1H, C4,H), 4.51 (q, 1H, C3,H), 4.66 (t, 1H, C2,H), 5.34 (d, 1H, C3,OH), 6.17 (d, 1H, CVH), 6.80-7.83 (m, 23H, Ar), 8.64 (s, 1H, C2H), 8.78 (s, 1H, C8H), 9.35. (s, 1H, NHCO). 19F NMR (200 MHz, DMSO) δ -108.76. Anal. Calcd. for C49H45F3N6O9 : C, 68.36; H, 5.15; N, 9,76. Found: C, 68.16 H, 5.03; N, 9.43.
EXAMPLE 83
N6-(Dibenzoyl)-5'-O-(dimethoxytrityl)-2'-O-[3-(N-trifluoroacetamido)propyl]-3'-O-(N,N-diisopropyl-S-cyanoethyl)adenosine Phosphoramidite
A solution of N6-(dibenzoyl)-5'-O-(dimethoxytrityl)-2'-O- [3-(N-trifluoroacetamido)propyl]adenosine in dry CH2Cl2 was treated with bis-N,N-diisopropylamino cyanoethyl phosphite (1.1 eqiv) and N,N-diisopropylaminotetrazolide (catalytic amount) at room temperature for 16 hrs. The reaction was concentrated in vacuo and chromatographed on silica gel (EtOAc/hexane/TEA 6/4/1) to give 0.5 g of the title compound. 31P NMR (200 MHz, CD3CN) 150.87; (200 MHz, CDCL3) 150.55, 150.83. 19F NMR (200 MHz, CD3CN) 107.14, (200 MHz, CDCl3) 102.67.
EXAMPLE 84
2'-O-(Butylphthalimide)adenosine
The title compound is prepared as per example 75, using N-(4-bromobutyl)phthalimide in place of the 1-bromopropane. Chromatography on silica gel (EtOAC-MeOH) gives the title compound as a white solid. M.P. 199-200°C. Anal. Calcd. C22H24N6O6: C, 56.42; H, 5.16; N, 17.94. Found: C, 56.31; H, 5.04; N, 17.95.
The 3' compound can be separated from the mother liquors as per Example 75 above. 1H NMR (200 MHz, DMSO-d6) δ 5.88 (d, 1H, C1,H).
EXAMPLE 85
2'-O-(Butylphthalimide-N6-benzoyladenosine)
Benzoylation of 2'-O-(butylphthalimide)adenosine as per Example 76 gave the title compound. 1H NMR (200 MHz, DMSO-d6) δ 6.18 (d, 1H, C1,H) . Anal. Calcd. C29H2N6O7: C, 60.83; H, 4.93; N, 14.68. Found: C, 60.48; N, 14.41.
EXAMPLE 86
2'-O- (Butylphthalimide) -5' -O-dimethoxytrityl-N6-benzoyladenosine
The title compound was prepared from 2'-O-(butylphthalimide)-N6-benzoyladenosine as per Example 77. 1H NMR (200 MHz, DMSO-d6) δ 6.20 (d, 1H, C1,H) . Anal. Calcd. for C50H46N6O9: C, 68.64; H, 5.29; N, 9.60. Found: C, 68.47; H, 5.12; N, 9.37. EXAMPLE 87
N6-Benzoyl-5' -O- (dimethoxytrityl) -2 ' -O- (butylphthalimide) -3 ' - O-(N,N-diisopropyl-β-cyanoethyl)adenosine Phosphoramidite
The title compound was prepared from 2'- O-(butylphthalimide)-5'-O-dimethoxytrityl-N6-benzoyladenosine as per Example 78. 31P NMR (CD3CN) S 150.88, 151.22.
EXAMPLE 88
2'-O-(Pentylphthalimido)adenosine
The title compound was prepared as per Example 75, using N- (5-bromopentyl) phthalimide. The crude material from the extraction was chromatographed on silica gel using CHCl3/MeOH (95/5) to give a mixture of the 2' and 3' isomers. The 2' isomer was recrystallized from EtOH/MeOH 8/2. The mother liquor was rechromatographed on silica gel to afford the 3' isomer.
2'-O-(Pentylphthalimido)adenosine: M.P. 159-160°C. Anal. Calcd. for C23H24N6O5: C, 57.26; H, 5.43; N, 17.42. Found: C, 57.03; H, 5.46; N, 17.33.
3'-O-(Pentylphthalimido)adenosine: 1H NMR (DMSO-d6) δ 5.87 (d, 1H, H-1').
EXAMPLE 89
2'-O-(Pentylphthalimido)-N6-benzoyladenosine
Benzoylation of 2'-O-(pentylphthalimido) adenosine was achieved as per the procedure of Example 76 to give the title compound. 1H NMR (DMSO-d6) : 6.10 (d, 1H, C17 H) . Anal. Calcd. for C30H30N6O7: C, 61.43; H, 5.16; N, 14.33. Found: C, 61.51; H,
4.97; N, 14.10.
EXAMPLE 90
2'- O -(Pentylphthalimido)-5'-O-(dimethoxytrityl)-N6-benzoyladenosine
The title compound was prepared from 2'- O-(pentylphthalimide)-N6-benzoyladenosine as per the procedure of Example 77. Chromatography on silica gel (ethylacetate, hexane, triethylamine), gave the title compound. Anal. Calcd. for C51H48N6O9 : C , 68 . 91 ; H , 5 . 44 ; N , 9 . 45 . Found : C , 68 . 65 ; H , 5 . 45 ; N, 9 . 61 .
EXAMPLE 91
N6-Benzoyl-5'-O-(dimethoxytrityl)-2'-O-(pentylphthalimido)-3'- (N,N-diisopropyl-β-cyanoethyl) Phosphoramidite
The title compound was prepared from 2'-O-(pentylphthalimide)-5'-O-(dimethoxytrityl)-N6-benzoyladenosine as per the procedure of Example 78 to give the compound as a white foam. EXAMPLE 92
2-Amino-2'-O-(propylphthalimide)adenosine and 2-Amino-3'-O- (propylphthalimide)adenosine
To a solution of 2-aminoadenosine (75 g, 281 mmol) in dry dimethylformamide (2000 ml) at room temperature was added sodium hydride 60% (13.0 g, 325 mmol). After one hour N-(3-bromopropane)phthalimide (86.6 g, 3.23 mmol) was added and the temperature was raised to 40°C and held for 16 hrs. A further aliquot of sodium hydride 60% (6.2 g, 155 mmol) and N-(3-bromopropyl)phthalimide (40 g, 150 mmol) was added and heating was continued for an additional 16 hrs. The reaction mixture was cooled, quenched with MeOH and concentrated in vacuo . The resultant gum was chromatographed on silica gel (CHCl3/MeOH 9/1) to give 53.3 g of the 2' isomer (42%). Those fractions containing the 3' isomer were crystallized from EtOAc/MeOH to yield 20 g of the 3' isomer (16%).
2-Amino-2'- O-(propylphthalimide)adenosine: 1H NMR (200 MHz, DMSO-d6) δ 1.82 (m, 2H, CH2), 3.35-3.63 (m, 4H, OCH2,C5,H2), 3.91 (m, 1H, C4.H), 4.26 (m, 1H, c3.H), 4.39 (m, 1H, C2,H), 5.10 (d, 1H, C3.OH), 5.44 (t, 1H, C5.OH), 5.77 (s, 2H, NH2) , 5.81 (d, 1H, C1,H), 6.79 (bs, 2H, NH2) , 7.85 (bs, 4H, Ar) and 7.97 (s, 1H, C8H). Anal. Calcd. for C21H23N7O6 : C, 53.72;, H, 4.94; N, 20.88. Found: C, 53.70; H, 4.48; N, 20.56.
2-Amino-3'-O-(propylphthalimide)adenosine: m.p. 222-224°C, 1H NMR (DMSO-d6) δ 5.69 (d, 1H, H-1')' EXAMPLE 93
2'-O-(Propylphthalimide)guanosine
2-Amino-2'- O-(propylphthalimide)adenosine (38.6 g, 82 mmol) was dissolved in dimethylsulfoxide (DMSO, 1000 ml). Sodium phosphate (0.1 M, 63 ml) and Tris buffer (0.5 M, 1200 ml) were added with stirring. The solution was adjusted to pH 7.0 with phosphoric acid. Adenosine deaminase (Sigma, 1.7 g) was added and the temperature raised to 35°C. The solution was stirred for 4 days with an additional aliquot of adenosine deaminase (0.2 g) added every 24 hrs. The solution was maintained at pH 7.0 with the addition of phosphoric acid. The reaction was cooled, filtered and concentrated in vacuo. The resultant gum was crystallized from MeOH to give 31.6 of the title compound (82%). 1H NMR (200 MHz, DMSO-d6) δ 1.82 (m, 2H, CH2), 3.45 (m, 4H, OCH2, C5,H2) , 3.85 (m, 1H, C4.H), 4.26 (m, 2H, C3.H,C2.H), 5.09 (M, 2H, C3.OH, C5,OH) , 5.80 (d, 1H, Ci.H) , 6.47 (s, 2H, NH2), 7.84 (s, 4H, Ar) , 7.97 (s, 1H, C8H) AND 10.65 (s, 1H, ArNH). Anal. Calcd. for C21H21N6O7 : C, 53.72;, H, 4.94; N, 20.88. Found: C, 54.02; H, 4.73; N, 20.53.
EXAMPLE 94
2'-O-(Propylamino)guanosine
2'-O-(Propylphthalimide)guanosine was treated as per the procedure of Example 79 in water/methanol as the solvent to give the title compound in 91% yield. 1H NMR (200 MHz, DMSO-d6) δ 1.80 (m, 2H, CH2), 3.35-3.70 (m, 4H, OCH2,C5,H2), 3.85 (m, 1H, C4.H) , 4.27 (m, 2H, C3,H,C2.H), 5.10 (m, 2H, C3.OH, C5.OH), 5.78 (d, 1H, C1,H), 6.49 (s, 2H, NH2) and 7.97 (s, 1H, C8H).
EXAMPLE 95
2'-O-[3-(N-trifluoroacetamido)propyl]guanosine
2'-O-(Propylamino)guanosine was treated as per the procedure of Example 80 to give the title compound. EXAMPLE 96
N2-(Dibenzoyl)-2'-O-[3-(N-trifluoroacetamido)propyl]guanosine
2'-O-[3-(N-trifluoroacetamido)propyl]guanosine was treated as per the procedure of Example 81 to give the title compound.
EXAMPLE 97
N2-(Dibenzoyl)-5' -O-(dimethoxytrityl)-2'-O- [3-(N-trifluoroacetamido)propyl]guanosine
N2-(Dibenzoyl)-2'-O-[3-(N-trifluoroacetamido)propyl]-guanosine was treated as per the procedure of Example 82 to give the title compound.
EXAMPLE 98
N2- (Dibenzoyl) -5' -O- (dimethoxytrityl) -2' -O- [3- (N-trifluoroacetamido)propyl] -3'-O- (N,N-diisopropyl-β-cyanoethyl)guanosine Phosphoramidite
N2- (Dibenzoyl) -5'-O- (dimethoxytrityl) -2'-O- [3- (N-trifluoroacetamido)propyl]guanosine was treated as per the procedure of Example 83 to give the title compound. 31P NMR (CDCl3) 150.49, 150.91. 19F NMR (CDC13) 102.71, 102.75.
EXAMPLE 99
2' -O- (Propylphthalimide)uridine and 3' -O- (Propylphthalimide)uridine
A solution of uridine-tin complex (prepared as per Example 3) (48.2 g, 115 mmol) in dry DMF (150 ml) and N-(3-bromopropyl)phthalimide (46 g, 172 mmol) was heated at 130°C for 6 hrs. The crude product was chromatographed directly on silica gel CHCl3/MeOH 95/5. The isomer ration of the purified mixture was 2'/3' 81/19. The 2' isomer was recovered by crystallization from MeOH. The filtrate was rechromatographed on silica gel using CHCl3→CHCl3/MeOH (95/5) gave the 3' isomer as a foam.
2'-O-(Propylphthalimide)uridine: Analytical sample recrystallized from MeOH, m.p. 165.5-166.5°C, 1H NMR (200 MHz, DMSO-d6) δ 1.87 (m, 2H, CH2), 3.49-3.65 (m, 4H, C2,H), 3.80- 3.90 (m, 2H, C3,H1C4,H) , 4.09 (m, IH, C2,H) , 5.07 (d, 1h, C3.OH) , 5.16 (m, 1H, C5.OH) , 5.64 (d, IH, CH=) , 7.84 (d, 1H, C1,H) , 7.92 (bs, 4H, Ar) , 7.95 (d, IH, CH=) and 11.33 (s, 1H, ArNH) . Anal. C20H21N3H8, Calcd. C, 55.69; H, 4.91;, N, 9.74. Found, C, 55.75; H, 5.12; N, 10.01.
3'-O-(Propylphthalimide)uridine: 1H NMR (DMSO-d6) δ 5.74 (d, 1H, H-1') .
EXAMPLE 100
2'-O-(Propylamino)uridine
The title compound was prepared as per the procedure of Example 79 (90% yield). 1H NMR (200 MHz, DMSO-d6) δ 1.80 (m, 2H, CH2) , 3.57-3.66 (m, 4H, OCH2,C5,H2), 3.88 (m, 2H, C3,H,C4,H), 4.15 (m, 1H, C2,H) , 5.64 (d, 1H, CH=), 5.82 (d, 1H, d-H), 7.02 (bs, 2H, NH2) and 8.00 (d, 1H, C8H). EXAMPLE 101
2'-O-[3-(N-trifluoroacetamido)propyl]uridine
2'-O-(Propylamino)uridine was treated as per the procedure of Example 80 to give the title compound. 1H NMR (200 MHz, DMSO-d6) δ 1.75 (m, 2H, CH2), 3.22-3.35 (m, 2H, CH2NH) , 3.38-3.67 (m, 4H, OCH2,C5.H2), 5.16 (m, 2H, C3.OH, C5,OH) , 5.67 (d, 1H, CH=), 7.95 (d, 1H, CH=) , 9.34 (bs, 1H, NHCO) and 11.36 (s, 1H, ArNH). 19F NMR (200 MHz, DMSO) 108.76. Anal. Calcd. for C14H18F3N3O7 : C, 42.31; H, 4.56; N, 10.60. Found: 42.56; H, 4.61; N, 10.25. EXAMPLE 102
5'-O-(dimethoxytrityl)-2'-O-[3-(N-trifluoroacetamido)propyl]-uridine
2'-O-[3-(N-trifluoroacetamido)propyl]uridine was treated as per the procedure of Example 82 to give the title compound. 1H NMR (200 MHz, DMSO-d6) δ 1.95 (m, 2H, CH2), 3.42-3.80 (m, 12H, ArOCH3,OCH2,C5.H2), 4.03 (m, 2H, C2.H), 4.45 (m, 1H, C3,OH) , 5.30 (d, 1H, CH=) , 5.91 (s, 1H, CVH) , 6.83-7.43 (m, 13H, ArH), 7.90 (bs, 1H, NHCO), 8.10 (d, 1H, CH=) and 10.3 (s, 1H, ArNH). 19F NMR (200 MHz, DMSO) 102.75. EXAMPLE 103
5'-O-(Dimethoxytrityl)-2'-O-[3-(N-trifluoroacetamido)propyl]- 3 ' -O-(N,N-diisopropyl-β-cyanoethyl)uridine Phosphoramidite 5'-O-(Dimethoxytrityl)-2'- O-[3-(N-trifluoroacetamido)-propyl]uridine was treated as per the procedure of Example 83 to give the title compound. 31P NMR (200 MHz, CD3CN) 154.87, 155.62. 19F NMR (200 MHz, CD3CN) 107.19.
EXAMPLE 104
2'-O-(Propylphthalimide)cytidine and 3'-O-(Propylphthalimide)-cytidine
The title compounds were prepared as per the procedure of Example 75.
2'-O-(propylphthalimide)cytidine: 1H NMR (200 MHz, DMSO-d6) δ 5.82 (d, 1H, d-H).
3'-O-(propylphthalimide)cytidine: 1H NMR (200 MHz, DMSO-d6) δ 5.72 (d, 1H, C1,H).
EXAMPLE 105
2 ' -O-(Propylamino)cytidine
2'-O-(Propylphthalimide)cytidine was treated as per the procedure of Example 79 to give the title compound. 1H NMR (200 MHz, DMSO-d6) δ 5.82 (d, 1H, d-H).
EXAMPLE 106
2 '-O-[3-(N-trifluoroacetamido)propyl]cytidine
2'-O-(Propylamino)cytidine was treated as per the procedure of Example 80 to give the title compound. 19F NMR (DMSO-d6) 108.73.
EXAMPLE 107
N4-(Benzoyl)-2 ' -O-[3-(N-trifluoroacetamido)propyl]cytidine 2'-O-[3-(N-trifluoroacetamido)propyl]cytidine was treated as per the procedure of Example 81 to give the title compound. 19F NMR (DMSO-d6) 108.79. EXAMPLE 108
N4-(Benzoyl)-5'-O-(dimethoxytrityl)-2 '-O-[3-(N-trifluoroacetamido)propyl]cytidine
N4-(Benzoyl)-2'- O-[3-(N-trifluoroacetamido)propyl]-cytidine was treated as per the procedure of Example 82 to give the title compound.
EXAMPLE 109
N4-(Benzoyl)-5'-O-(dimethoxytrityl)-2 ' -O-[3-(N-trifluoroacetamido)propyl]-3'-O-(N,N-diisopropyl-/S-cyanoethyl)cytidine Phosphoramidite N4-(Benzoyl)-5'-O-(dimethoxytrityl)-2'-O- [3-(N-trifluoroacetamido)propyl]cytidine was treated as per the procedure of Example 83 to give the title compound. 31P NMR (CDCl3) 150.03, 151.36. 19F NMR (CDCl3) 102.76. EXAMPLE 110
2'-O-[3-(Imidizo-1-yl)propyl]adenosine
The title 2'- O-substituted compound was prepared as per the procedure of Example 75 using 1-(4-bromopropyl)imidazole. 1H NMR (200 MHz, DMSO-d6) δ 6.02 (d, 1H, d.H).
The corresponding 3'-O- substituted compound can be separated from the mother liquors as per Example 75. 1H NMR (200 MHz, DMSO-d6) δ 5.91 (d, 1H, d,H).
EXAMPLE 111
2 ' -O-[4-(Imidizo-1-yl)butyl)]adenosine and 3'-O-[4-(Imidizo-1-yl)butyl]adenosine
A solution of adenosine (6.97 g, 26 mmol) in dry DMF (250 ml) was treated with NaH 60% (3.9 g, 97 mmol) for 15 minutes. N-(4-Bromobutyl)imidazoline acetate salt (9.4 g, 2.1 equiv. HOAc, 29 mmol) was added and the reaction mixture stirred at room temperature for 2 days. The reaction was quenched (MeOH) and concentrated in vacuo to a semi-solid. The solid was dissolved in water (250 ml) and extracted with EtOAc (2 × 100 ml). The aqueous phase was concentrated in vacuo and chromatographed on silica gel using EtOAc/MeOH (6/4) to give a mixture of 2' and 3' isomers (70/30, 62%). Crystallization of this solid from EtOAc/MeOH 8/2 gave the 2' isomer. Concentration of the mother liquors and subsequent crystallization from MeOH afforded the 3' isomer in 12% yield.
2'-O-[4-(Imidizo-1-yl)butyl]adenosine: 1H NMR (200 MHz, DMSO-d6) δ 6.01 (d, 1H, C1,H).
3'-O-[4-(Imidizo-1-yl)butyl]adenosine: m.p. 183-184°C.1H NMR (DMSO-d6) δ 5.89 (d, 1H, H-1').
EXAMPLE 112
2'-O-[4-(Imidizo-1-yl)butyl]-N6-benzoyladenosine
The title compound was prepared 2'-O-[4-(imidizo-1-yl)-butyl]adenosine as per Example 76.
EXAMPLE 113
2 '-O-[4-(Imidizo-1-yl)butyl]-5'-O-dimethoxytrityl-N6-benzoyladenosine
The title compound was prepared from N6-benzoyl-2'-O-[4- (imidizo-1-yl)butyl]adenosine as per Example 77.
EXAMPLE 114
N6-Benzoyl-5'-O-(dimethoxytrityl)-2'-O-[4-(imidizo-1-yl)-(butyl]-3 ' -O-(N,N-diisopropyl-β-cyanoethyl)adenosine Phosphoramidite
The title compound was prepared from 2'- O-[4-(imidizo-1-yl)butyl]-5'-O-dimethoxytrityl-N6-benzoyladenosine as per Example 78. 31P NMR (CDCl3) 150.48, 151.06.
EXAMPLE 115
2-Amino-2'-O-[4-(imidizo-1-yl)butyl]adenosine and 2-Amino-3'-O-[4-(imidizo-1-yl)butyl]adenosine
The title compounds are prepared as per Example 111 with the substitution of 2-aminoadenosine for adenosine. The isomer ratio of 2'/3' was 74/26.
2-Amino-2'- O-[4-(imidizo-1-yl)butyl]guanosine: 1H NMR (200 MHz, DMSO-d6) δ 5.84 (d, 1H, d.H).
2-Amino-3'-O-[4-(imidizo-1-yl)butyl]guanosine: 1H NMR (200 MHz, DMSO-d6) δ 5.68 (d, 1H, d.H). EXAMPLE 116
2 ' -O-[4-(Imidazo-1-yl)butyl]guanosine
In the manner described in Example 93, 2-amino-2'- O-[4- (imidazo-1-yl)butyl]adenosine in sodium phosphate (0.1 M) and Tris buffer (0.5 M) at pH 7.0 is deaminated with adenosine deaminase (Sigma) at 35°C to give the title compound.
EXAMPLE 117
N2-(Dibenzoyl)-2'-O-[4-(imidazo-1-yl)butyl]guanosine
2'- O-[4-(Imidazo-1-yl)butyl]guanosine was treated as per the procedure of Example 81 to give the title compound.
EXAMPLE 118
N2-(Dibenzoyl)-5'-O-(dimethoxytrityl)-2'-O-[4-(imidazo-1-yl)butyl]guanosine
N2-(Dibenzoyl)-2'-O-[4-(imidizo-1-yl)butyl]guanosine was treated as per the procedure of Example 82 to give the title compound.
EXAMPLE 119
N2-(Dibenzoyl)- 5 ' -O-(dimethoxytrityl)-2'-O-[4-(imidazo-1-yl)butyl]-3'-O-(N,N-diisopropyl-β-cyanoethyl)guanosine Phosphoramidite
N2-(Dibenzoyl)-5'-O-(dimethoxytrityl)-2'-O-[4-(imidazo-1-yl)butyl]guanosine was treated as per the procedure of Example 83 to give the title compound. 31P NMR (CDCl3) 150.67, 150.80 EXAMPLE 120
2 ' -O-[4-(Imidizo-1-yl)butyl]cytidine and 3'-O-[4-(imidizo-1-yl)-butyl]cytidine
The title compounds were prepared as per the procedure of Example 111 with the substitution of cytidine for adenosine. The crude product was chromatographed on silica gel using EtOAc/MeOH/HOAc. The isomer ratio of 2'/3' was 60/40.
2'-O-[4-(Imidizo-1-yl)butyl]cytidine: 1H NMR (200 MHz, DMSO-d6) δ 5.88 (d, 1H, d.H). 3'- O-[4-(Imidizo-1-yl)butyl]cytidine: 1H NMR (DMSO-d6) δ 5.78 (d, 1H, H'1')
EXAMPLE 121
2 '-O-[4-(Imidizo-1-yl)butyl]-N4-benzoylcytidine
The title compound was prepared 2'- O-[4-(imidizo-1-yl)-butyl]cytidine as per Example 76.
EXAMPLE 122
2'-O-[4-(Imidizo-1-yl)butyl]-5'-O-dimethoxytrityl-N4-benzoylcytidine
The title compound was prepared from N4-benzoyl-2'-O-[4- (imidizo-1-yl)butyl]cytidine as per Example 77.
EXAMPLE 123
N4-Benzoyl-5'-O-(dimethoxytrityl)-2 ' -O-[4-(imidizo-1-yl)- (butyl]-3'-O-(N,N-diisopropyl-β-cyanoethyl) cytidinePhosphoramidite
The title compound was prepared from 2'-O-[4-(imidizo-1-yl)butyl]-5'-O-dimethoxytrityl-N4-benzoylcytidine as per Example 78. 31P NMR (CDCl3) 150.39, 150.92.
EXAMPLE 124
3-Benzyloxymethyl-5-methyluridine
A solution of 5-methyluridine (51.6, 200 mmol) in DMF
(100 ml) was treated with sodium hydride (60% oil, 9.9 g, 248 mmol). After 1 hr at room temperature, benzylchloromethyl ether (34.4 g, 220 mmol) was added dropwise and the reaction mixture heated to 35°C for 4 hrs. The reaction mixture was cooled, quenched with MeOH (5 ml), filtered and concentrated in vacuo . The resultant gum was partitioned between
EtOAc/sat. NaCl, separated, dried and the organic phase concentrated whereupon the title compound crystallized. 1H NMR (DMSO-d6) δ 5.83 (d, 1H, C1,-H). EXAMPLE 125
3-Benzyloxymethyl-5-methyl-2'-O-(4-chlorobutyl)uridine
A solution of 3 -benzyloxymethyl-5-methyluridine (25.9 g, 68 mmol) was treated with NaH (60% oil, 7.9 g, 200 mmol) for 1 hr at room temp. 1-Bromo-4-chlorobutane (19.7 g, 115 mmol) was added slowly and the reaction stirred at room temp, for 16 hrs. The reaction was then quenched (MeOH), concentrated in vacuo and the residue chromatographed on silica gel CHCl3/MeOH 95/5 to give the title compound in 41% yield. 1H NMR (DMSO-d6) δ 5.87 (d, 1H, d.H).
EXAMPLE 126
3-Benzyloxymethyl-5-methyl-2'-O-[4-(imidazo-1-yl)butyl]uridine
To a solution of imidazole (6.8 g, 100 mmol) in DMF (150 ml) was added NaH (60% in oil, 4 g, 100 mmol). After 4 hrs, this suspension was added to a suspension of 3-benzyloxymethyl-5-methyl-2'-O-(4-chlorobutyl)uridine (8.7 g, 18 mmol), Nal (2.6 g) and DMF (200 ml). The reaction was stirred 16 hrs at room temp., quenched with MeOH, concentrated in vacuo and the residue chromatographed on silica gel CHCl3/MeOH 85/15→50/50 to give the title compound in 31% yield. 1H NMR (DMSO-d6) δ 5.87 (d, 1H, d.H).
EXAMPLE 127
2 ' -O-[4-(Imidazo-1-yl)butyl]-5-methyluridine
A solution of 3-benzyloxymethyl-5-methyl-2'- O-[4- (imidazo-1-yl)butyl]uridine (5.4 g, 10 mmol) in MeOH (200 ml) was hydrogenated with 20% palladium hydroxide (9.0 g) at 1 atmosphere H2 for 16 hrs. The reaction was filtered through celite and the mother liquor concentrated to afford the product in 83% yield. 1H NMR (DMSO-d6) δ 5.86 (d, 1H, d.H). EXAMPLE 128
5 ' - O -(Dimethoxytrityl)- 2 ' -O-[4-(imidazo-1-yl)butyl]-5-methyluridine
5-Methyl-2'-O-[4-(imidazo-1-yl)butyl]uridine was treated as per the procedure of Example 77 to give the title compound in 91% yield. 1H NMR (DMSO-d6) δ 5.86 (d, 1H, d.H).
EXAMPLE 129
5'-O-(Dimethoxytrityl)-2 ' -O-[4-(imidazo-1-yl)butyl]-3'-O-(N,N-diisopropyl-β-cyanoethyl)-5-methyluridine Phosphoramidite 5'- O-(Dimethoxytrityl)-5-methyl-2'-O-[4-(imidazo-1-yl)butyl]uridine was treated as per the procedure of Example 78 to give the title compound in 83% yield. 1H NMR (DMSO-d6) δ 5.85 (d, 1H, d.H). 31P NMR (DMSO-d6) 153.99, 154.45.
Example 130
Effect Of Derivatization On Melting Temperature
Melting temperatures (Tm) for a variety of modified oligonucleotides according to the invention were determined according the method set forth in Procedure B(1) (b). The resulting data is shown in Tables 5-8, wherein all listed oligonucleotides contain 2'-deoxy sugars and phosphodiester backbones unless otherwise indicated.
Table 5 shows changes in Tm that result by modifying the 2 '-position of adenosine nucleotides to include a variety of substituent groups. For example, the first entry shows that the introduction of 2'-O-aminopropyl adenosine substituents at two adenosine nucleotides resulted in a heteroduplex having a Tm that is 1.13°C greater than the heteroduplex formed by an unmodified oligonucleotide having the same sequence.
Table 6 shows changes in Tm that result by modifying one or more 2'- and 3 '-positions of the indicated parent oligonucleotides to include linkers and pyrene conjugates. These modifications were made to terminal and internal (i.e., non-terminal) positions within the oligonucleotide. The notation "PS" indicates the presence of a phosphorothioate backbone, and the notation "2'-5' linkage" indicates 2'-5' intersugar linkages. As can be seen from the first entry, the introduction of a 2'-aminopentoxy linker to a single, internal adenosine nucleotide of the parent oligonucleotide resulted in a Tm decrease of 3.1°C whereas the introduction of a 2'-pyrenyl-aminopentoxy conjugate resulted in a Tm increase of 3.3°C.
Tables 7a-c show changes in Tm that result by modifying one or more positions of the indicated parent oligonucleotides to include linkers and cholate or cholesterol conjugates. As can be seen from the first entry, the introduction of an aminolink linker at the 3'-position of a single terminal nucleotide of the parent phosphorothioate oligonucleotide resulted in a Tm increase of 1.3°C and the addition of a cholate group to the linker resulted in a further Tm increase of 1.1°C.
Table 8 shows changes in Tm that result by modifying one or more 3'-positions of the indicated parent oligonucleotides to include linkers and PEG conjugates. The entries under the heading "PEG vs Unmodified" represent preliminary findings. As can be seen, the first entry indicates that introduction of an aminolink linker at the 3'-position of a single terminal nucleotide of the parent phosphodiester oligonucleotide resulted in a Tm increase of 0.9°C and that the addition of a PEG 550 group to the linker did not change the Tm of the resulting product.
Figure imgf000096_0001
Figure imgf000097_0001
Figure imgf000098_0001
Figure imgf000099_0001
Figure imgf000100_0001
Figure imgf000101_0001
SEQUENCE LISTING
(1) GENERAL INFORMATION:
(i) APPLICANTS: ISIS Pharmaceuticals, Inc., et al.
(ii) TITLE OF INVENTION: AMINE-DERIVATIZED NUCLEOSIDES AND
OLIGONUCLEOSIDES
(iii) NUMBER OF SEQUENCES: 41
(iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz and Norris
(B) STREET: One Liberty Place - 46th Floor
(C) CITY: Philadelphia
(D) STATE: PA
(E) COUNTRY : U.S.A.
(F) ZIP: 19103
(v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: WordPerfect 5.1
(vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER: N/A
(B) FILING DATE: Herewith
(C) CLASSIFICATION:
(vϋ) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: 08/117,363
(B) FILING DATE: 9/3/94
(vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: 07/854,634
(B) FILING DATE: 7/1/92
(viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Lucci, Joseph
(B) REGISTRATION NUMBER: 33,307
(C) REFERENCE/DOCKET NUMBER: ISIS-1691
(ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: 215-568-3100
(B) TELEFAX: 215-568-3439
(2) INFORMATION FOR SEQ ID NO:1:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 base pairs
(B) TYPE: nucleic acid (C) STRANDEDNESS : single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:
GGCTGACTGC G 11
(2) INFORMATION FOR SEQ ID NO: 2:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:
CTGTCTCCAT CCTCTTCACT 20
(2) INFORMATION FOR SEQ ID NO: 3:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:
TTGCTTCCAT CTTCCTCGTC 20
(2) INFORMATION FOR SEQ ID NO:4:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:
TGGGAGCCAT AGCGAGGC 18
(2) INFORMATION FOR SEQ ID NO: 5:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY:, linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5: CTGTCTCCAT CCTCTTCACT 20
(2) INFORMATION FOR SEQ ID NO:6:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:
TCCAGGTGTC CGCATC 16
(2) INFORMATION FOR SEQ ID NO : 7 :
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:
GGACCGGAAG GTACGAG 17
(2) INFORMATION FOR SEQ ID NO: 8:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:
CCTGGCCTTC CATGCTC 17
(2) INFORMATION FOR SEQ ID NO: 9:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:
CCUGGCCUUC CAUGCUC 17
(2) INFORMATION FOR SEQ ID NO: 10: (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:
CCCAGGCUCA GA 12
(2) INFORMATION FOR SEQ ID NO: 11:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:
GAGCUCCCAG GC 12
(2) INFORMATION FOR SEQ ID NO: 12:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:
CAUGCUGCAG CC 12
(2) INFORMATION FOR SEQ ID NO:13:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:
GCCTTTCGCG ACCCAACACU 20
(2) INFORMATION FOR SEQ ID NO: 14:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single (D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:
GCGTGUCTGC G 10
(2) INFORMATION FOR SEQ ID NO: 15:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:
UGGGAGCCAT AGCGAGGC 18
(2) INFORMATION FOR SEQ ID NO: 16:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS : single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:
TGGGAGCCAU AGCGAGGC 18
(2) INFORMATION FOR SEQ ID NO: 17:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:
UCTGAGTAGC AGAGGAGCTC 20
(2) INFORMATION FOR SEQ ID NO: 18:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:
UGCCCAAGCT GGCATCCGTC A 21 (2) INFORMATION FOR SEQ ID NO: 19:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:
UGCGTTTGCT CTTCTTCTTG CG 22
(2) INFORMATION FOR SEQ ID NO: 20:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:
UGCATCCCCC AGGCCACCAT 20
(2) INFORMATION FOR SEQ ID NO: 21:
(i) SEQUENCE CHARACTERISTICS :
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:
UCCCGCCTGT GACATGCATT 20
(2) INFORMATION FOR SEQ ID NO: 22:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:
GUTCTCGCTG GTGAGTTTCA 20
(2) INFORMATION FOR SEQ ID NO:23:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs (B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:
UUGGGAGCCA TAGCGAGGC 19
(2) INFORMATION FOR SEQ ID NO: 24:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:
CCAAGCCUCA GA 12
(2) INFORMATION FOR SEQ ID NO: 25:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:
CCAGGCUCAG AT 12
(2) INFORMATION FOR SEQ ID NO: 26:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:
UGCATCCCCC AGGCCACCA 19
(2) INFORMATION FOR SEQ ID NO: 27:
(i) SEQUENCE CHARACTERISTICS :
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:
UCAGTGCCTG CGCCGCGCTC G 21
(2) INFORMATION FOR SEQ ID NO: 28:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:
UCCGTCATCG CTCCTCAGGG 20
(2) INFORMATION FOR SEQ ID NO: 29:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:
UTTAGGATTC GTGCTCATGG 20
(2) INFORMATION FOR SEQ ID NO: 30:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:
UGTTCTCGCT GGTGAGTTTC A 21
(2) INFORMATION FOR SEQ ID NO: 31:
(i) SEQUENCE CHARACTERISTICS :
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 31:
TGCATCCCCC AGGCCACCAU 20 (2) INFORMATION FOR SEQ ID NO: 32:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:
GTGCTCATGG TGCACGGTCU 20
(2) INFORMATION FOR SEQ ID NO: 33:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:
UGCATCCCCC AGGCCACCAU 20
(2) INFORMATION FOR SEQ ID NO: 34:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:
UGUUCUCGCT GGTGAGUUUC AU 22
(2) INFORMATION FOR SEQ ID NO: 35:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:
GCGTGUCTGG G 11
(2) INFORMATION FOR SEQ ID NO:36:
(i) SEQUENCE CHARACTERISTITS:
(A) LENGTH: 11 base pairs (B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:
GCGUGUCUGC G 11
(2) INFORMATION FOR SEQ ID NO: 37:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:
GGCTGUCTGC G 11
(2) INFORMATION FOR SEQ ID NO: 38:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:
GAGCTCCCAG GC 12
(2) INFORMATION FOR SEQ ID NO: 39:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 39:
CGACTATGCA AGTAC 15
(2) INFORMATION FOR SEQ ID NO: 40:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 40:
CGACTATGCA AAAAC 15
(2) INFORMATION FOR SEQ ID NO: 41:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 41:
ACCGAGGATCATGTCGTACGC 21

Claims

WHAT IS CLAIMED IS:
1. A compound comprising a plurality of linked nucleosides, wherein:
each nucleoside includes a ribofuranosyl sugar portion and a base portion; and
at least one of said nucleosides bears at a 2'-O-position, a 3'-O-position, or a 5'-O-position a substituent having formula:
-RA-N(R1a)(R1b)
where:
RA is alkyl having from 1 to about 10 carbon atoms or (CH2-CH2-Q)x;
R1a and R1b, independently, are H, R2, or an amine protecting group, have formula C(X)-R2, C(X)-RA-R2, C(X)- Q-RA-R2, C(X)-Q-R2, or, together, complete a cycloalkyl or cycloaryl moiety having two to six carbon atoms and one or two nitrogen atoms; and
R2 is a steroid molecule, a reporter molecule, a lipophilic molecule, a reporter enzyme, a peptide, a protein, or has formula -Q-(CH2CH2-Q-)x-R3;
X is O or S;
each Q is, independently, is NH, O, or S; x is 1 to about 200;
R3 is H, RA, C(O)OH, C(O)ORA, C(O)R4, RA-N3, or RA-NH2; R4 is Cl, Br, I, SO2R5 or has structure:
Figure imgf000113_0001
;
m is 2 to 7; and
R5 alkyl having 1 to about 10 carbon atoms.
2. The compound of claim 1 wherein more than one of said nucleosides bear said substituent at a 2'-O-position, a 3'-O-position, or a 5'-O-position.
3. The compound of claim 1 wherein RA is (CH2)n where n is an integer from 1 to about 10.
4. The compound of claim 3 wherein n is 6.
5. The compound of claim 1 wherein said R1a and R1b, together, are phthalimido.
6. The compound of claim 1 wherein R1a is H and R1b is C(O)-(CH2)n-R2 where n is an integer from 1 to about 10.
7. The compound of claim 1 wherein R1a is H and R1b is R2.
8. The compound of claim 1 wherein R1a is H and R1b is C(O)-O-R2.
9. The compound of claim 1 wherein R1a and R1b both are alkyl.
10. The compound of claim 1 wherein R1a is H and R1b is C(O)-(CH2)n-R2 where n is an integer from 1 to about 10.
11. The compound of claim 10 wherein R2 has formula -(CH2)5-NH-.
12. The compound of claim 1 wherein R1a is H and R1b is C(S)-NH-R2.
13. The compound of claim 1 wherein R2 includes pyrene, fluorescein, dinitrophenyl, cholesterol, acridine.
14. The compound of claim 1 wherein R1a is H and R1b is C(O)-R2.
15. The compound of claim 14 wherein R2 has formula -O-(CH2CH2-O-)x-R3.
16. The compound of claim 1 wherein a 3 '-position of at least one of said nucleosides is linked to a 5 '-position of an adjacent nucleoside.
17. The compound of claim 1 wherein a 2'-position of at least one of said nucleosides is linked to a 5'-position of an adjacent nucleoside.
18. A compound comprising a plurality of linked nucleosides, wherein:
each nucleoside includes a ribofuranosyl sugar portion and a base portion; and
at least one of said nucleosides bears at a 2'-O-position, a 3'-O-position, or a 5' -O-position a substituent having formula:
-RA-N(R1a)(R1b)
where:
RA is alkyl having from 1 to about 7 carbon atoms; and
R1a and R1b are H.
19. The compound of claim 18 wherein RA is propyl.
20. A compound comprising a plurality of linked nucleosides, wherein:
each nucleoside includes a ribofuranosyl sugar portion and a base portion; and
at least one of said nucleosides bears at a 2'-O-position, a 3'-O-position, or a 5'-O-position a substituent having formula:
-RA-N(R1a)(R1b)
where:
RA is alkyl having from 1 to about 7 carbon atoms; and
R1a and R1b, together, complete a cycloaryl moiety having two to six carbon atoms and one or two nitrogen atoms .
21. The compound of claim 20 wherein RA is butyl and R1a and R1b, together, are imidazole.
22. A nucleoside comprising a ribofuranosyl sugar portion and a base portion, wherein said nucleoside bears at a 2'-O-position, a 3'-O-position, or a 5'-O-position a substituent having formula:
-RA-N(R1a)(R1b)
where :
RA is alkyl having from 1 to about 10 carbon atoms;
R1a and R1b, independently, are H, R2, or an amine protecting group or have formula C(X)-R2, C(X)-RA-R2, C(X)-Q-RA-R2, C(X)-Q-R2; and
R2 is a steroid molecule, a reporter molecule, a lipophilic molecule, a reporter enzyme, a peptide, a protein, or has formula -Q-(CH2CH2-Q-)x-R3;
X is O or S;
each Q is, independently, is NH, 0, or S;
x is 1 to about 200;
R3 is H, RA, C(O)OH, C(O)ORA, C(O)R4, RA-N3, or RA- NH2; and
R4 is Cl, Br, I, SO2R5 or has structure:
Figure imgf000116_0001
;
m m is 2 to 7; and
R5 alkyl having 1 to about 10 carbon atoms.
23. The compound of claim 22 wherein RA is (CH2)n where n is an integer from 1 to about 10.
24. The compound of claim 22 wherein n is 6.
25. The compound of claim 22 wherein said R1a and R1b, together, are phthalimido.
26. The compound of claim 22 wherein R1a is H and R1b is C(O)-(CH2)n-R2 where n is an integer from 1 to about 10.
27. The compound of claim 22 wherein R1a is H and R1b is R2.
28. The compound of claim 22 wherein R1a is H and R1b is C(O)-O-R2.
29. The compound of claim 22 wherein R1a and R1b both are alkyl.
30. The compound of claim 22 wherein R1a is H and R1b is C(O)-(CH2)n-R2 where n is an integer from 1 to about 10.
31. The compound of claim 30 wherein R2 has formula -(CH2)5-NH-.
32. The compound of claim 22 wherein R1a is H and R1b is C(S)-NH-R2.
33. The compound of claim 22 wherein R2 includes pyrene, fluorescein, dinitrophenyl, cholesterol, acridine.
34. The compound of claim 22 wherein R1a is H and R1b is C(O)-R2.
35. The compound of claim 34 wherein R2 has formula -O-(CH2CH2-O-)x-R3.
36. A method for modulating the production of a protein by an organism comprising contacting an organism with a compound of claim 1.
37. A method for modulating the production of a protein by an organism comprising contacting an organism with a compound of claim 22.
38. A method of treating an animal having a disease characterized by undesired production of protein comprising contacting said animal with a compound of claim 1.
39. A method of treating an animal having a disease characterized by undesired production of protein comprising contacting said animal with a compound of claim 22.
40. A method for detecting the presence or absence of an RNA in a biological sample suspected of containing said RNA comprising contacting said sample with a compound of claim 1.
41. A method for detecting the presence or absence of an RNA in a biological sample suspected of containing said RNA comprising contacting said sample with a compound of claim 22.
PCT/US1994/010131 1990-01-11 1994-09-02 Amine-derivatized nucleosides and oligonucleosides WO1995006659A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
EP94928048A EP0728139B1 (en) 1993-09-03 1994-09-02 Amine-derivatized nucleosides and oligonucleosides
CA002170869A CA2170869C (en) 1993-09-03 1994-09-02 Amine-derivatized nucleosides and oligonucleosides
JP50832695A JP3484197B2 (en) 1993-09-03 1994-09-02 Amine derivatized nucleosides and oligonucleosides
DE69433036T DE69433036T2 (en) 1993-09-03 1994-09-02 AMINODERIVATIZED NUCLEOSIDES AND OLIGONUCLEOSIDES
AU77233/94A AU679566B2 (en) 1993-09-03 1994-09-02 Amine-derivatized nucleosides and oligonucleosides
AT94928048T ATE247128T1 (en) 1993-09-03 1994-09-02 AMINODERIVATIZED NUCLEOSIDES AND OLIGONUCLEOSIDES
US08/602,862 US7037646B1 (en) 1990-01-11 1994-09-02 Amine-derivatized nucleosides and oligonucleosides
US09/435,806 US6653458B1 (en) 1993-09-03 1999-11-08 Modified oligonucleotides

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85463492A 1992-07-01 1992-07-01
US08/117,363 1993-09-03
US08/117,363 US6783931B1 (en) 1990-01-11 1993-09-03 Amine-derivatized nucleosides and oligonucleosides

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US08/117,363 Continuation-In-Part US6783931B1 (en) 1990-01-11 1993-09-03 Amine-derivatized nucleosides and oligonucleosides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US08/602,862 Continuation-In-Part US7037646B1 (en) 1990-01-11 1994-09-02 Amine-derivatized nucleosides and oligonucleosides

Publications (1)

Publication Number Publication Date
WO1995006659A1 true WO1995006659A1 (en) 1995-03-09

Family

ID=26815203

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/010131 WO1995006659A1 (en) 1990-01-11 1994-09-02 Amine-derivatized nucleosides and oligonucleosides

Country Status (1)

Country Link
WO (1) WO1995006659A1 (en)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0724447A4 (en) * 1991-10-24 1996-01-22 Isis Pharmaceuticals Inc Derivatized oligonucleotides having improved uptake and other properties
US5594117A (en) * 1994-08-25 1997-01-14 Chiron Corporation Polynucleotide reagents containing modified deoxyribose moieties and associated methods of synthesis and use
EP0831854A1 (en) * 1995-06-06 1998-04-01 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
US5744460A (en) * 1996-03-07 1998-04-28 Novartis Corporation Combination for treatment of proliferative diseases
US5859228A (en) * 1995-05-04 1999-01-12 Nexstar Pharmaceuticals, Inc. Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
US6001991A (en) * 1996-10-04 1999-12-14 Isis Pharmaceuticals Inc. Antisense oligonucleotide modulation of MDR P-glycoprotein gene expression
US6011020A (en) * 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
EP0983291A1 (en) * 1996-09-13 2000-03-08 Isis Pharmaceuticals, Inc. Carbamate-derivatized nucleosides and oligonucleosides
US6051698A (en) * 1997-06-06 2000-04-18 Janjic; Nebojsa Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
US6147204A (en) * 1990-06-11 2000-11-14 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US6168778B1 (en) 1990-06-11 2001-01-02 Nexstar Pharmaceuticals, Inc. Vascular endothelial growth factor (VEGF) Nucleic Acid Ligand Complexes
WO2001008707A2 (en) * 1999-07-28 2001-02-08 Aventis Pharma Deutschland Gmbh Conjugates and methods for the production thereof, and their use for transporting molecules via biological membranes
US6229002B1 (en) 1995-06-07 2001-05-08 Nexstar Pharmaceuticlas, Inc. Platelet derived growth factor (PDGF) nucleic acid ligand complexes
US6426335B1 (en) 1997-10-17 2002-07-30 Gilead Sciences, Inc. Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
US6465188B1 (en) 1990-06-11 2002-10-15 Gilead Sciences, Inc. Nucleic acid ligand complexes
US6670468B1 (en) 1996-06-06 2003-12-30 Novartis Ag 2′-substituted nucleosides and oligonucleotide derivatives
US6753423B1 (en) 1990-01-11 2004-06-22 Isis Pharmaceuticals, Inc. Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals
US8071737B2 (en) 1995-05-04 2011-12-06 Glead Sciences, Inc. Nucleic acid ligand complexes
US8853376B2 (en) 2002-11-21 2014-10-07 Archemix Llc Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4910300A (en) * 1985-12-11 1990-03-20 Chiron Corporation Method for making nucleic acid probes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4910300A (en) * 1985-12-11 1990-03-20 Chiron Corporation Method for making nucleic acid probes

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SCIENCE, Vol. 238, issued 04 December 1987, COREY et al., "Generation of a Hybrid Sequence-Specific Single Stranded Deoxyribonuclease", pages 1401-1403. *
See also references of EP0728139A4 *

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6753423B1 (en) 1990-01-11 2004-06-22 Isis Pharmaceuticals, Inc. Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals
US6168778B1 (en) 1990-06-11 2001-01-02 Nexstar Pharmaceuticals, Inc. Vascular endothelial growth factor (VEGF) Nucleic Acid Ligand Complexes
US6147204A (en) * 1990-06-11 2000-11-14 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US6465188B1 (en) 1990-06-11 2002-10-15 Gilead Sciences, Inc. Nucleic acid ligand complexes
US6011020A (en) * 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
EP0724447A1 (en) * 1991-10-24 1996-08-07 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
EP0724447A4 (en) * 1991-10-24 1996-01-22 Isis Pharmaceuticals Inc Derivatized oligonucleotides having improved uptake and other properties
US5597909A (en) * 1994-08-25 1997-01-28 Chiron Corporation Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use
US5594117A (en) * 1994-08-25 1997-01-14 Chiron Corporation Polynucleotide reagents containing modified deoxyribose moieties and associated methods of synthesis and use
US5859228A (en) * 1995-05-04 1999-01-12 Nexstar Pharmaceuticals, Inc. Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
US8071737B2 (en) 1995-05-04 2011-12-06 Glead Sciences, Inc. Nucleic acid ligand complexes
EP0831854A1 (en) * 1995-06-06 1998-04-01 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
EP0831854A4 (en) * 1995-06-06 2001-01-24 Isis Pharmaceuticals Inc Oligonucleotides having phosphorothioate linkages of high chiral purity
US6229002B1 (en) 1995-06-07 2001-05-08 Nexstar Pharmaceuticlas, Inc. Platelet derived growth factor (PDGF) nucleic acid ligand complexes
US7879993B2 (en) 1995-06-07 2011-02-01 Gilead Sciences, Inc. Platelet derived growth factor (PDGF) nucleic acid ligand complexes
US6582918B2 (en) 1995-06-07 2003-06-24 Gilead Sciences, Inc. Platelet derived growth factor (PDGF) nucleic acid ligand complexes
US5744460A (en) * 1996-03-07 1998-04-28 Novartis Corporation Combination for treatment of proliferative diseases
US6670468B1 (en) 1996-06-06 2003-12-30 Novartis Ag 2′-substituted nucleosides and oligonucleotide derivatives
EP0983291A4 (en) * 1996-09-13 2001-04-04 Isis Pharmaceuticals Inc Carbamate-derivatized nucleosides and oligonucleosides
EP0983291A1 (en) * 1996-09-13 2000-03-08 Isis Pharmaceuticals, Inc. Carbamate-derivatized nucleosides and oligonucleosides
US6001991A (en) * 1996-10-04 1999-12-14 Isis Pharmaceuticals Inc. Antisense oligonucleotide modulation of MDR P-glycoprotein gene expression
US6962784B2 (en) 1996-10-25 2005-11-08 Gilead Sciences, Inc. Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
US6051698A (en) * 1997-06-06 2000-04-18 Janjic; Nebojsa Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
US6426335B1 (en) 1997-10-17 2002-07-30 Gilead Sciences, Inc. Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
US7939654B2 (en) 1997-12-16 2011-05-10 Gilead Sciences, Inc. Platelet derived growth factor (PDGF) nucleic acid ligand complexes
JP2003505517A (en) * 1999-07-28 2003-02-12 アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Conjugates and methods for their preparation and their use for transporting molecules across biological membranes
KR100721696B1 (en) * 1999-07-28 2007-05-28 사노피-아벤티스 도이칠란트 게엠베하 Conjugates for transporting molecules via biological membranes and methods for the production thereof
HRP20020074B1 (en) * 1999-07-28 2011-01-31 Sanofi-Aventis Deutschland Gmbh Conjugates and methods for the production thereof, and their use for transporting molecules via biological membranes
WO2001008707A2 (en) * 1999-07-28 2001-02-08 Aventis Pharma Deutschland Gmbh Conjugates and methods for the production thereof, and their use for transporting molecules via biological membranes
JP4791665B2 (en) * 1999-07-28 2011-10-12 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Conjugates and methods for their production and their use to transport molecules across biological membranes
WO2001008707A3 (en) * 1999-07-28 2001-11-08 Aventis Pharma Gmbh Conjugates and methods for the production thereof, and their use for transporting molecules via biological membranes
US8420396B2 (en) 1999-07-28 2013-04-16 Sanofi-Aventis Deutschland Gmbh Conjugates and processes for their preparation and their use for transporting molecules across biological membranes
US8853376B2 (en) 2002-11-21 2014-10-07 Archemix Llc Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics

Similar Documents

Publication Publication Date Title
EP0728139B1 (en) Amine-derivatized nucleosides and oligonucleosides
US7037646B1 (en) Amine-derivatized nucleosides and oligonucleosides
US6783931B1 (en) Amine-derivatized nucleosides and oligonucleosides
US6111085A (en) Carbamate-derivatized nucleosides and oligonucleosides
EP0716604B1 (en) Thiol-derivatized nucleosides and oligonucleosides
US6753423B1 (en) Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals
WO1995006659A1 (en) Amine-derivatized nucleosides and oligonucleosides
EP0724447B1 (en) Derivatized oligonucleotides having improved uptake
US6153737A (en) Derivatized oligonucleotides having improved uptake and other properties
EP0882061B1 (en) Sugar-modified gapped oligonucleotides
US6172209B1 (en) Aminooxy-modified oligonucleotides and methods for making same
AU2003213150A2 (en) Method of using modified oligonucleotides for hepatic delivery
JP2001097994A (en) Improved method for synthesizing 2'-o-substituted pyrimidine nucleoside and its oligomer compound
JP2001512457A (en) Aminooxy-modified oligonucleotide
US6114513A (en) Thiol-derivatized oligonucleotides
US5852182A (en) Thiol-derivatized oligonucleosides
US6653458B1 (en) Modified oligonucleotides
Pandolfi et al. Evaluation of different types of end-capping modifications on the stability of oligonucleotides toward 3′-and 5′-exonucleases
US20040142899A1 (en) Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals
WO2000004189A1 (en) Modified oligonucleotides

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA US US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE MW SD AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 08602862

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2170869

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1994928048

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1994928048

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1994928048

Country of ref document: EP